US 20120115926A1 ( 19 ) United States ( 12 ) Patent Applicati0n Publicati0n mm Pub. N0. : US 2012 / 0115926 A1 Geary et al. ( 43 ) Pub. Date : May 10 , 2012 ( 54 ) ANTISENSE MODULATION OF ( 60 ) Pr0Visi0na1app1icati0n N0. 60 / 600 , 785 , ﬁ1ed 011 Aug. APOLIPOPROTEIN B EXPRESSION 10 , 2004 , pr0Visi0na1 app1icati0n N0. 60 / 612 , 831 , ﬁ1ed 0n Sep. 23 , 2004. ( 75 ) 1nVent0rs : Richard S. Geary , Car1sbad , CA ( US ) ; Zhengr0ng Yu , Car1sbad , CA _ . _ . ( US ) ; R0sanne M. Cr00ke , Publ1cat10n Class1ﬁcat10n Car1Sbad , CA ( US ) ( 51 ) Int. Cl. ( 73 ) Assignee : Genzyme C0rp0rati0n , jgg ; / 10 / g088 gggggg Cambridge , MA ( US ) ° ( 21 ) App1. NO. : 13 / 214 , 135 ( 52 ) U. S. C1. . 514 / 44 A ; 514 / 44 R ( 22 ) Fi1ed : Aug. 19 , 2011 ( 57 ) ABSTRACT Related U ' S ' Applicati0n Data Meth0ds f0r the rapid and 10ng - term 10wering 0f 1ipid1eVe1s ( 63 ) C0ntinuati0n of app1iCati0n N0. 11 / 573 , 537a ﬁ1ed 011 in human subjects and f0r the treatment 0f C0nditi0ns ass0Ci - . Aug. 27 , 2009 , mm aband0ned , ﬁ1ed as app1iCati0n N0. PCT / US2005 / 028342 0n Aug. 10 , 2005. ated With e1eVated LDL - ch01ester01 and e1eVated ap01ip0pr0 - tein B are pr0Vided. Patent Applicati0n Publicati0n. Pement Change mm Baseline. - 1U0. . . . May 10 , 2012. Flgure 1. . “ameﬂ , . u%~u ; .‘w - . 4 m. . . . . : , . r ; mm 11. . - r ' _. 1 ' EE. m§ : ' L - "“!1“ : . ‘I m ' m J w L ' D “Ia I L . ' r. . i . _ m - " - . ' r""" v ' " "i o I. US 2012 / 0115926 A1. . . OOO O 8 O O 0 O D 00 0 0 0 ° 0 O l 1 l 14 2 14. Tmugh AUC , ( ugme ) . US 2012 / 0115926 A1. ANTISENSE MODULATION 0F APOLIPOPROTEIN B EXPRESSION. CROSS REFERENCE TO RELATED APPL1CAT1ONS. [ 0001 ] This app1icati0n c1aims pri0rity under 35 U. S. C. §1 19 ( e ) t0 U. S. Pr0Visi0na1App1icati0n N0. 60 / 600 , 785 ﬁ1ed 0n Aug. 10 , 2004 , and a1s0 claims pri0rity under 35 U. S. C. §1 19 ( e ) t0 U. S. Pr0Visi0nal App1icati0n N0. 60 / 612 , 831 ﬁ1ed 0n Sep. 23 , 2004 , each 0f Which is hereby inc0rp0rated by reference in its entirety. BACKGROUND OF THE 1NVENT1ON. [ 0002 ] 1. Fie1d 0f the 1nVenti0n. [ 0003 ] The present inVenti0n pr0Vides c0mp0siti0ns and meth0ds f0r lowering LDL - ch0lester0l and treatment 0f c0n - diti0ns ass0ciated With e1eVated ch01ester01 1eVe1s. M0re spe - ciﬁca11y , the inVenti0n re1ates t0 c0mp0siti0ns and meth0ds f0r inhibiting ap01ip0pr0tein B eXpressi0n in the 1iVer. [ 0004 ] 2. Descripti0n 0f the Re1ated Art. [ 0005 ] C0r0nary heart disease ( CHD ) has been the 1eading cause 0f death in the United States f0r 0Ver a century , and c0mplicati0ns fr0m ather0sc1er0sis are the m0st c0mm0n causes 0f death in Western sOcieties ( Kn0pp , New Eng / . J. Medicine , 1999 , 341 , 498 - 511 ; DaVis and Hui , Arteri0sc / er. Thmmb. Vasc. Bi0 / . , 2001 , 21 , 887 - 898 ; B0n0W , Circu / ati0n , 2002 , 106 , 3140 - 3141 ) . E1eVated 10W density 1ip0pr0tein - ch01ester01 ( LDL - ch01ester01 ) is Wide1y rec0gnized as a risk fact0r f0r CHD. HOWeVer , despite pharmac010gic interVen - ti0n , many indiVidua1s are unab1e t0 10Wer LDL - ch01ester01 1eVe1s. [ 0006 ] The guide1ines f0r 1ipid 10Wering therapy Were estab1ished by the Adu1t Treatment Pane1 111 0f the Nati0na1 Ch01ester01 Educati0n Pr0gram ( N CEP ) in 2001. M0diﬁca - ti0ns t0 these guidelines Were rec0mmended by the C00rdinating C0mmittee 0f the NCEP in 2004 , and inc1uded m0re aggressiVe treatment g0a1s ( Grundy et a1. , Circu / atim , 2004 , 1 10 , 227 - 239 ) . These guide1ines deﬁne 3 categ0ries 0f risk f0r maj0r 00r0nary eVents and pr0Vide desirab1e LDL - ch01ester0l target leVels. Th0 se at highest risk are patients With CHD 0r CHD risk equiVa1ent and sh0u1d maintain LDL - ch01ester01 be10W 100 mg / dL. The m0 st recent NCEP guide1ines rec0m - mend that patients at Very high risk f0r CHD use drug therapy t0 acbieVe LDL - ch01ester01 leVels 0f less than 70 mg / dL. CHD equiValent is deﬁned as subjects With diabetes , periphera1Vascu1ar disease , abd0mina1a0rtic aneurysm , sympt0m - atic car0tid artery disease , and th0se With mu1tip1e risk fact0rs that 00nfer a 10 year risk f0r CHD greater than 20%. F0r the sec0nd categ0ry , th0se patients at m0derate1y high risk f0r CHD With multiple ( 2 0r m0re ) risk fact0rs in Wh0m the 10 year risk f0r CHD is 20% , the g0a1 is LDL - ch01ester01 0f1ess than 130 mg / dL. The m0 st recent rec0mmendati0ns inc1ude a therapeutic 0pti0n t0 10Wer LDL - ch01ester01 1eVe1s t0 1ess than 100 mg / dL in the m0derate1y high - risk categ0ry. The third categ0ry includes indiViduals With 0 - l risk fact0rs and the target LDL - ch01ester01 is 1ess than 160 mg / dL. The risk fact0rs inc1ude age , cigarette sm0king , hypertensi0n , 10W HDL - ch01ester0l , and fami1y hist0ry 0f CHD. Drug therapy sh0uld be initiated When serum LDL - ch0lester01 remains ab0Ve 130 , l60 and 190 mg / dL in the 3 risk gr0ups , respectiVe1y , despite therapeutic 1ifesty1e changes ( Grundy et a1. , CirCu / ati0n , 2004 , 110 , 227 - 239 ) . May 10 , 2012. [ 0007 ] LOW density lip0pr0teins are 0ne 0f ﬁVe br0ad c1asses 0f 1ip0pr0teins , Which inc1ude the f0110Wing : chy10 - micr0ns , resp0nsib1e f0r the transp0rt dietary 1ipids fr0m intestine t0 tissues ; Very 10W density 1ip0pr0teins ( VLDL ) ; intermediate density 1ip0pr0teins ( 1DL ) ; 10W density 1ip0pr0 - teins ( LDL ) ; a11 0f Which transp0rt triacy1g1ycer01s and ch0 - 1ester01 fr0m the 1iVer t0 tissues ; and high density 1ip0pr0teins ( HDL ) , Which transp0rt end0gen0us ch01ester01 fr0m tissues t0 the 1iVer. Lip0pr0tein particles underg0 00ntinu0us meta - b01ic pr0cessing and haVe Variable pr0perties and c0mp0si - ti0ns. The pr0tein c0mp0nents 0f 1ip0pr0teins are kn0Wn as ap01ip0pr0teins. At 1east nine ap01ip0pr0teins , 0ne 0f Which is ap01ip0pr0tein B , are distributed in signiﬁcant am0unts am0ng the Vari0us human 1ip0pr0teins. [ 0008 ] Ap0lip0pr0tein B ( a1s0 kn0Wn as Ap0B , ap01ip0 - pr0tein B - 100 ; Ap0B - 100 , ap0lip0pr0tein B - 48 ; Ap0B - 48 and Ag ( X ) antigen ) , is a 1arge g1yc0pr0tein inV01Ved in the assemb1y and secreti0n 0f 1ipids and in the transp0rt and recept0r - mediated uptake and de1iVery 0f distinct c1asses 0f 1ip0pr0teins. Ap01ip0pr0tein B perf0rms a Variety 0f func - ti0ns , inc1uding the abs0rpti0n and pr0cessing 0f dietary 1ipids , as Wel1 as the regu1ati0n 0f circu1ating 1ip0pr0tein1eVe1s ( DaVids0n and She1ness , Annu. Rev. Nutx , 2000 , 20 , 169 - 193 ) . [ 0009 ] TWO f0rms 0f ap01ip0pr0tein B exist in mamma1s. Ap0B - 100 represents the fu1l - 1ength pr0tein c0ntaining 4536 amin0 acid residues , synthesized primari1y in the human 1iVer ( DaVids0n and She1ness , Annu. Rev. Nqu , 2000 , 20 , 169 - 193 ) . A truncated f0rm kn0Wn as ap0B - 48 is c01inear With the amin0teImina12152 residues and is synthesized in the sma11 intestine 0f all mammals ( DaVids0n and Shelness , Annu. Rev. Nutr. , 2000 , 20 , 169 - 193 ) . 1n humans , ap0B - 48 circu1ates in ass0ciati0n With chy10micr0ns and chy10micr0n remnants and these particles are c1eared by a distinct recept0r kn0Wn as the LDL - recept0r - re1ated pr0tein ( DaVids0n and She1ness , Annu. Rev. Nutic , 2000 , 20 , 169 - 193 ) . Ap0B - 48 can be VieWed as an adaptati0n by Which dietary 1ipid is de1iVered fr0m the sma11 intestine t0 the 1iVer , Whi1e ap0B - 100 participates in the transp0rt and de1iVery 0f ch01ester01 ( DaVids0n and She1ness , Amm. Rev. Nutx , 2000 , 20 , 169 - 193 ) . Ap0B - 100 is the maj0r pr0tein c0mp0nent 0f LDL and c0ntains the d0main required f0r interacti0n 0f this 1ip0pr0tein species With the LDL recep - t0r. 1n additi0n , ap0B - 100 c0ntains an unpaired cysteine residue Which mediates an interacti0n With ap01ip0pr0tein ( a ) and generates 1ip0pr0tein ( a ) 0r Lp ( a ) , an0ther distinct 1ip0pr0tein With ather0genic p0tential ( DaVids0n and Shelness , Annu. Rev. Nutr. , 2000 , 20 , 169 - 193 ) . E1eVated p1asma 1eVe1s 0f the ap0B - 100 - c0ntaining 1ip0pr0tein Lp ( a ) are ass0ciated With increased risk f0r ather0sc1er0sis and its manifestati0ns , Which may include hyperch0lester01emia ( Seed et a1. , N. Eng / . J Med. , 1990 , 322 , 1494 - 1499 ) , my0cardial infarcti0n ( Sandkamp et a1. , C / in. Chem. , 1990 , 36 , 20 - 23 ) , and thr0m - b0sis ( NOWak - G0tt1 et a1. , Pediatries , 1997 , 99 , E11 ) . [ 0010 ] Ap01ip0pr0tein B is inV01Ved ch01ester01 h0me0stasis and its 0Verpr0ducti0n has been ass0ciated With Vari0us diseases , including fami1ia1 hyperch0lester0lemia , fami1ia1 defectiVe ap0B - 100 and familial 00mbined hyperch0lester - 01emia ( Kane and HaVe1 , The Metab0 / iC and M0leeu / ar Bases 0f [ nherited Diseases , 2001 , 8th editi0n , 2717 - 2751 ) . Perturbati0ns in the metab0lism 0f ap0B - 100 that c01resp0nd With an increased risk 0f CHD are a1s0 0bserVed in diabetes and 0besity ( Grundy , Am. J. Cardi0 / . , 1998 , 81 , 18B - 25B ; Chan et a1. , Diabetes , 2002 , 51 , 2377 - 2386 ; Chan et a1. , Metab0 / ism , 2002 , 51 , 1041 - 1046 ) . Furtherm0re , genetic studies in m0use. US 2012 / 0115926 A1. m0dels haVe dem0nstrated a c0rrelati0n betWeen eleVated ap01ip0pr0tein B , e1eVated ch01ester01 1eVe1s and ather0sc1e - r0sis ( Kim and Y0ung , J Lipid Res. , 1998 , 39 , 703 - 723 ; Nishina et al. , J. Lipid Res. , 1990 , 31 , 859 - 869 ) . [ 001 1 ] In studies 0f patients With familia1 hyp0beta1ip0pr0 - teinemia ( FHBL ) , these patients exhibit 10Wered serum ap0 - 1ip0pr0tein B 1eVe1s , 10Wered serum LDL - ch01ester01 1eVe1s and a reduced incidence 0f c0r0nary artery disease ( Sch0n - feld et a1 , J. Lipid Res. , 2003 , 44 , 878 - 883 ) . Murine studies haVe dem0nstrated that mice haVing heter0zyg0us deﬁciencies in ap01ip0pr0tein B exhibit reduced serum LDL - ch01ester01 and ap01ip0pr0tein B 1eVe1s , and , ﬁ1rtherm0re , are pr0 - . tected fr0m diet - induced hyperch01ester01emia. ( Farese et a1 . , Pr0c. Nat / . Acad Sci. U. S. A. , 1995 , 92 , 1774 - 1778 ) . SUMMARY OF THE 1NVENT1ON. [ 0012 ] S0me emb0diments 0f the present inVenti0n are described in the numbered paragraphs be10W : . [ 0013 ] 1 . A meth0d 0f reducing serum ch0lester01 leVels in a human subject , c0mprising administering t0 said subject a p1ura1ity 0f d0ses 0f an 01ig0nuc1e0tide targeted t0 ap01ip0 - pr0tein B , Wherein said administering resu1ts in a p1asma tr0ugh AUC fr0m ab0ut 2 pg - hr / mL t0 ab0ut 20 pg - hr / mL f0r the 01ig0nucle0tide in said human subject. [ 0014 ] 2. The meth0d 0f Paragraph 1 , Wherein said administering resu1ts in a p1asma tr0ugh AUC fr0m ab0ut 2 ug - hr / mL t0 ab0ut 10 ug ' br / mL. [ 0015 ] 3. The meth0d 0f Paragraph 1 , Wherein said administering resu1ts in a plasma tr0ugh AUC fr0m ab0ut 4 ug - br / mL t0 ab0ut 6 pg - hr / mL. [ 0016 ] 4. The meth0d 0f Paragraph 1 , Wherein said administering resu1ts in a p1asma tr0ugh AUC 0f ab0ut 5 ug - hr / mL. [ 0017 ] 5. The meth0d 0f Paragraphs 1 , 2 , 3 0r 4 , Wherein said p1asma tr0ugh AUC is achieVed fr0m ab0ut 3 t0 ab0ut 33 days subsequent t0 the administrati0n 0f a d0se 0f said plu - ra1ity 0f d0ses 0f the 01ig0nuc1e0tide. [ 0018 ] 6. The meth0d 0f Paragraph 1 , Wherein said serum ch01ester01 1eVe1s are reduced in said human subject by at 1east ab0ut ten percent. [ 0019 ] 7. The meth0d 0f Paragraph 1 , Wherein said serum ch0lester0l leVels are reduced in said human subject by at 1east ab0ut thirty percent. [ 0020 ] 8. The meth0d 0f Paragraph 1 , Wherein said serum ch01ester01 1eVe1s are serum 10W density 1ip0pr0tein ( LDL ) ch01ester01 1eVe1s. [ 0021 ] 9. The meth0d 0f Paragraph 1 , Wherein said serum ch0lester0l leVels are serum Very 10W density lip0pr0tein ( VLDL ) ch01ester01 1eVe1s. [ 0022 ] 10. The meth0d 0f Paragraph 1 , Wherein said 01ig0 - . nuc1e0tide c0mprises the nuc1e0base sequence “GCCTCAGTCTGCTTCGCACC” ( SEQ 1D NO : 2 ) . [ 0023 ] 1 1 . The meth0d 0f Paragraph 1 , Wherein at 1east 0ne d0se 0f said p1ura1ity 0f d0ses is administered ab0ut 0nce a Week. [ 0024 ] 12. The meth0d 0f Paragraph 1 , Wherein at 1east 0ne d0se 0f said p1ura1ity 0f d0ses is administered ab0ut 0nce a m0nth. [ 0025 ] 13. The meth0d 0f Paragraph 1 , Wherein said human subject suffers fr0m hyperch01ester01emia. [ 0026 ] 14. The meth0d 0f Paragraph l , Wherein each d0se 0f said p1ura1ity 0f d0ses c0mprises fr0m ab0ut 50 mg t0 ab0ut 400 mg 0f the 01ig0nuc1e0tide. May 10 , 2012. [ 0027 ] 15. The meth0d 0f Paragraph 1 , Wherein each d0se 0f said p1ura1ity 0f d0ses c0mprises ab0ut 20O mg 0f the 01ig0nuc1e0tide. [ 0028 ] 16. A meth0d 0f reducing serum ch0lester0l leVels in a human subject , 00mprising administering t0 said subject a p1ura1ity 0f d0ses 0f an 01ig0nuc1e0tide targeted t0 ap01ip0 - pr0tein B , Wherein said administering resu1ts in a p1asma tr0ugh c0ncentrati0n fr0m ab0ut 5 ng / mL t0 ab0ut 40 ng / mL 0f the 01ig0nuc1e0tide in said human subject. [ 0029 ] 17. The meth0d 0f Paragraph 16 , Wherein said administering resu1ts in a p1asma tr0ugh c0ncentrati0n fr0m ab0ut 5 ng / mL t0 ab0ut 20 ng / mL. [ 003 0 ] 18. The meth0d 0f Paragraphs 16 0r 17 , Wherein said p1asma tr0ugh c0ncentrati0n is achieVed ab0ut 7 days subsequent t0 the administrati0n 0f a d0se 0f said plurality 0f d0ses 0f the 01ig0nuc1e0tide. [ 0031 ] 19. The meth0d 0f Paragraph 16 , Wherein said serum ch01ester01 1eVe1s are reduced in said human subject by at least ab0ut ten percent. [ 0032 ] 20. The meth0d 0f Paragraph 16 , Wherein said serum ch01ester01 leVe1s are reduced in said human subject by at 1east ab0ut thirty percent. [ 0033 ] 21. The meth0d 0f Paragraph 16 , Wherein said serum ch01ester01 leVels are serum 10W density lip0pr0tein ( LDL ) ch01ester011eVe1s. [ 0034 ] 22. The meth0d 0f Paragraph 16 , Wherein said serum ch01ester0l leVels are serum Very 10W density 1ip0pr0 - tein ( VLDL ) ch01ester01 1eVels. [ 0035 ] 23. The meth0d 0f Paragraph 16 , Wherein said 01i - g0nuc1e0tide c0mprises the nuc1e0base sequence “GCCTCAGTCTGCTTCGCACC” ( SEQ 1D NO : 2 ) . [ 0036 ] 24. The meth0d 0f Paragraph 16 , Wherein at 1east 011e d0se 0f said p1ura1ity 0f d0 ses is administered ab0ut 011ce a Week. [ 0037 ] 25. The meth0d 0f Paragraph 16 , Wherein at least 0ne d0se 0f said p1ura1ity 0f d0 ses is administered ab0ut 0nce a m0nth. [ 0038 ] 26. The meth0d 0f Paragraph 16 , Wherein said human subject suffers fr0m hyperch01ester01emia. [ 0039 ] 27. The meth0d 0f Paragraph l6 , Wherein each d0 se 0f said plurality 0f d0ses c0mprises fr0m ab0ut 50 mg t0 ab0ut 400 mg 0f the 01ig0nuc1e0tide. [ 0040 ] 28. The meth0d 0f Paragraph l6 , Wherein each d0 se 0f said p1ura1ity 0f d0ses c0mprises ab0ut 200 mg 0f the 01ig0nuc1e0tide. [ 0041 ] 29. A meth0d 0f reducing serum LDL - ch0lester0l in a human subject , c0mprising administering t0 the human subject a d0se 0f an 01ig0nuc1e0tide c0mprising the nuc1e0 - base sequence “GCCTCAGTCTGCTTCGCACC” ( SEQ 1D NO : 2 ) , sufﬁcient t0 achieVe a plasma tr0ugh AUC 0f at 1east ab0ut 2 pg - hr / mL. [ 0042 ] 30. The meth0d 0f Paragraph 29 , Wherein said d0 se is sufﬁcient t0 achieVe a plasma tr0ugh AUC in the range 0f ab0ut 2 pg - hr / mL t0 ab0ut 20 ug - hr / mL. [ 0043 ] 31 . The meth0d 0f Paragraphs 29 0r 30 , Wherein said p1asma tr0ughAUC is achieVed fr0m ab0ut 3 t0 ab0ut 33 days subsequent t0 the administrati0n 0f said d0se 0f the 01ig0 - nuc1e0tide. [ 0044 ] 32. The meth0d 0f Paragraph 31 , Wherein said d0 se is administered ab0ut 0nce a Week , ab0ut 0nce a m0nth 0r ab0ut 0nce eVery three m0nths. [ 0045 ] 33 . A meth0d 0f reducing serum LDL - ch01ester01 in a human subject , c0mprising administering t0 the human subject a d0se 0f an 01ig0nuc1e0tide c0mprising the nuc1e0 - . US 2012 / 0115926 A1. base sequence “GCCTCAGTCTGCTTCGCACC” ( SEQ 1D NO : 2 ) , sufﬁcient t0 achieVe a p1asma tr0ugh c0ncentrati0n 0f at 1east ab0ut 5 ng / mL. [ 0046 ] 34. The meth0d 0f Paragraph 33 , Wherein said d0se is sufﬁcient t0 achieVe a p1asma tr0ugh c0ncentrati0n in the range 0f ab0ut 5 ng / mL t0 ab0ut 40 ng / mL. [ 0047 ] 35. The meth0d 0f Paragraphs 33 0r 34 , Wherein said p1asma tr0ugh c0ncentrati0n is achieVed ab0ut 7 days subsequent t0 the administrati0n 0f said d0se 0f the 01ig0nucle - 0tide. [ 0048 ] 36. The meth0d 0f Paragraph 33 , Wherein said d0se is administered ab0ut 0nce a Week , ab0ut 0nce a m0nth 0r ab0ut 0nce eVery three m0nths. [ 0049 ] 37. A meth0d 0f reducing serum LDL - ch01ester01 in a human subject , c0mprising administering t0 the human subject a d0se 0f an 01ig0nuc1e0tide c0mprising the nucle0 - base sequence “GCCTCAGTCTGCTTCGCACC” ( SEQ 1D NO : 2 ) , sufﬁcient t0 achieVe an estimated 1iVer c0ncentrati0n 0f at 1east ab0ut 10 ug / g. [ 0050 ] 38. The meth0d 0f Paragraph 37 , Wherein said d0se is sufﬁcient t0 achieVe an estimated 1iVer 00ncentrati0n in the range 0f ab0ut 10 ug / g t0 ab0ut 150 ug / g. [ 0051 ] 39. The meth0d 0f Paragraph 37 , Wherein said d0se is administered ab0ut 0nce a Week , ab0ut 0nce a m0nth 0r ab0ut 0nce eVery three m0nths. [ 0052 ] 40. A meth0d 0f reducing serum LDL - ch01ester01 in a human subject c0mprising administering t0 said human subject an 01ig0nuc1e0tide 00mprising the nucle0base sequence “GCCTCAGTCTGCTTCGCACC” ( SEQ 1D NO : 2 ) , Wherein said 01ig0nuc1e0tide is administered during a 10ading peri0d and a maintenance peri0d. [ 0053 ] 41. The meth0d 0f Paragraph 40 , Wherein said 01i - g0nuc1e0tide is 2O t0 30 nucle0bases in 1ength. [ 0054 ] 42. The meth0d 0f Paragraph 40 , Wherein the 10ading peri0d c0mprises administering the 01ig0nuc1e0tide t0 the human subject 0nce a day f0r up t0 10 days. [ 0055 ] 43. The meth0d 0f Paragraph 42 , Wherein the 01ig0 - nuc1e0tide during the 10ading peri0d is administered intraVe - n0us1y 0r subcutane0us1y. [ 0056 ] 44. The meth0d 0f Paragraph 40 , Wherein the maintenance peri0d c0mprises administering the 01ig0nuc1e0tide at least 0nce ab0ut eVery 3 m0nths. [ 0057 ] 45. The meth0d 0f Paragraph 44 , Wherein the 01ig0 - nuc1e0tide during the maintenance peri0d is administered 0nce ab0ut eVery m0nth. [ 0058 ] 46. The meth0d 0f Paragraph 44 , Wherein the 01ig0 - nuc1e0tide is administered 0nce ab0ut eVery 2 Weeks. [ 0059 ] 47. The meth0d 0f Paragraph 44 , Wherein the 01ig0 - nucle0tide is administered 0nce ab0ut eVery 7 days. [ 0060 ] 48. The meth0d 0f Paragraph 44 , Wherein the 01ig0 - nuc1e0tide during the maintenance peri0d is administered subcutane0us1y. [ 0061 ] 49. The meth0d 0f Paragraph 42 0r 44 , Wherein a d0se fr0m ab0ut 0.1 mg / kg / day t0 ab0ut 5 mg / kg / day is administered. [ 0062 ] 50. The meth0d 0f Paragraph 49 , Wherein the d0se is fr0m ab0ut 0.1 mg / kg / day t0 ab0ut 1.2 mg / kg / day. [ 0063 ] 51. The meth0d 0f Paragraph 42 0r 44 , Where the d0se is fr0m ab0ut 50 mg per Week t0 ab0ut 600 mg per Week. [ 0064 ] 52. The meth0d 0f Paragraph 51 , Wherein the d0se is ab0ut 50 mg per Week. [ 0065 ] 53. The meth0d 0f Paragraph 51 , Wherein the d0se is ab0ut 100 mg per Week. May 10 , 2012. [ 0066 ] 54. The meth0d 0f Paragraph 5 l , Wherein the d0 se is ab0ut 200 mg per Week. [ 0067 ] 5 5. The meth0d 0f Paragraph 51 , Wherein the d0 se is ab0ut 400 mg per Week. [ 0068 ] 56. The meth0d 0f Paragraph 40 , Wherein said 01i - g0nuc1e0tide c0mprises 181S 301012. [ 0069 ] 57. The meth0d 0f Paragraph 40 , Wherein said meth0d resu1ts in a reducti0n in serum VLDL - ch01ester01 , serum trig1ycerides , serum 1ip0pr0tein ( a ) 0r any c0mbinati0n 0f VLDL - ch0lester01 , serum trig1ycerides and serum 1ip0pr0 - tein ( a ) . [ 0070 ] 58. The meth0d 0f Paragraph 40 , Wherein said human subject exhibits at 1east 0ne indicati0n se1ected fr0m the gr0up c0nsisting 0f an eleVated serum t0tal ch0lester01 1eVe1 , an e1eVated serum LDL - ch01ester0l 1eVel , an e1eVated t0ta1 ch01ester01 : HDL rati0 and an e1eVated LDL : HDL rati0. [ 0071 ] 59. The meth0d 0f Paragraph 40 , Wherein said human subject has suffered fr0m 0r suffers fr0m h0m0zyg0us fami1ial hyperch01ester0lemia 0r heter0Zyg0us fami1ia1 hyperch0lester01emia. [ 0072 ] 60. The meth0d 0f Paragraph 40 , Wherein said human subject has suffered fr0m , suffers fr0m 0r is at an increased risk f0r n0nfami1ia1 hyperch01ester01emia. [ 0073 ] 61 . The meth0d 0f Paragraph 40 , Wherein the human subject has serum LDL - ch01ester01 1eVe1s ab0Ve ab0ut 70 mg / dL pri0r t0 administering said 01ig0nuc1e0tide. [ 0074 ] 62. The meth0d 0f Paragraph 40 , Wherein the human subject has serum LDL - ch01ester01 1eVe1s ab0Ve ab0ut 100 mg / dL pri0r t0 administering said 01ig0nuc1e0tide. [ 0075 ] 63. The meth0d 0f Paragraph 40 , Wherein the human subject has serum LDL - ch01ester01 1eVe1s ab0Ve ab0ut 130 mg / dL pri0r t0 administering said 01ig0nucle0tide. [ 0076 ] 64. The meth0d 0f Paragraph 61 , 62 , 0r 63 , Wherein administering said 01ig0nuc1e0tide reduces serum LDL - ch0 - lester0l leVels in the human subject t0 less than ab0ut 70 mg / dL. [ 0077 ] 65. The meth0d 0f Paragraph 62 0r 63 , Wherein administering said 01ig0nucle0tide reduces serum LDL - ch0 - 1ester01 1eVe1s in the human subject t0 1ess than ab0ut 100 mg / dL. [ 0078 ] 66. The meth0d 0f Paragraph 63 , Wherein administering said 01ig0nuc1e0tide reduces serum LDL ch01ester01 1eVe1s in the human subject t0 1ess than ab0ut 130 mg / dL. [ 0079 ] 67. A meth0d 0f reducing serum ch0lester01 1eVe1s in a human subject , c0mprising se1ecting a human subject preVi0us1y unsuccessfu11y treated by a statin ; and administering t0 said human subject an 01ig0nuc1e0tide 00mprising the nuc1e0base sequence “GCCTCAGTCTGCTTCGCACC” ( SEQ 1D NO : 2 ) . [ 0080 ] 68. The meth0d 0f Paragraph 67 , Wherein said serum ch0lester0l leVels 00mprise serum LDL - ch0lester0l 1eVe1s. [ 0081 ] 69. The meth0d 0f Paragraph 67 , Wherein the human subject is int0lerant t0 a statin. [ 0082 ] 70. The meth0d 0f Paragraph 67 , Wherein the subject has experienced adVerse effects resulting fr0m treatment With said statin. [ 0083 ] 71. The meth0d 0f Paragraph 70 , Wherein the subject has experienced my0pathy , fatigue , Central NerV0us System ( CNS ) effects resu1ting fr0m treatment With said statin 0r any c0mbinati0n 0f my0pathy , fatigue , and CNS effects resu1ting fr0m treatment With said statin. [ 0084 ] 72. The meth0d 0f Paragraph 67 , Wherein the human subject has insufﬁcient LDL - recept0r actiVity. US 2012 / 0115926 A1. [ 0085 ] 73. The meth0d 0f Paragraph 67 , Wherein said 01i - g0nuc1e0tide c0mprises ISIS 301012. [ 0086 ] 74. A meth0d 0f using an 01ig0nuc1e0tide c0mprising the nuc1e0base sequence “GCCTCAGTCTGCTTCGCACC” ( SEQ ID NO : 2 ) in a treatment f0r reducing serum LDL - ch0lester01 in a human subject , said meth0d c0mprising inf0rming said human subject that the administrati0n 0f said 01ig0nuc1e0tide resu1ts in a p1asma tr0ugh AUC 0f at 1east ab0ut 2 ng - hr / mL. [ 0087 ] 75. The meth0d 0f Paragraph 74 , Wherein said human subject is inf0Imed that the administrati0n 0f said 01ig0nuc1e0tide resu1ts in a p1asma tr0ugh AUC in the range 0f ab0ut 2 ug - hr / mL t0 ab0ut 20 ug - br / mL. [ 0088 ] 76. The meth0d 0f Paragraphs 74 0r 75 , Wherein said p1asma tr0ugh AUC is achieVed fr0m ab0ut 3 t0 ab0ut 33 days subsequent t0 the administrati0n 0f said d0se 0f the 01ig0 - nuc1e0tide. [ 0089 ] 77. The meth0d 0f Paragraph 74 , Wherein inf0rming said human subject c0mprises pr0Viding printed matter that adVises that the administrati0n 0f said 01ig0nuc1e0tide results in a plasma tr0ugh AUC 0f at 1east ab0ut 2 ug - hr / mL. [ 0090 ] 78. The meth0d 0f Paragraph 77 , Wherein said printed matter is a 1abe1. [ 0091 ] 79. A meth0d 0f using an 01ig0nuc1e0tide c0mprising the nuc1e0base sequence “GCCTCAGTCTGCTTCGCACC” ( SEQ ID NO : 2 ) in a treatment f0r reducing serum LDL - ch01ester01 in a human subject , said meth0d c0mprising inf0rming said human subject that the administrati0n 0f said 01ig0nuc1e0tide resu1ts in a p1asma tr0ugh c0ncentrati0n 0f at 1east ab0ut 5 ng / mL. [ 0092 ] 80. The meth0d 0f Paragraph 79 , Wherein said human subject is inf0Imed that the administrati0n 0f said 01ig0nuc1e0tide resu1ts in a p1asma tr0ugh c0ncentrati0n in the range 0f ab0ut 5 ng / mL t0 ab0ut 40 ng / mL. [ 0093 ] 81 . The meth0d 0f Paragraphs 79 0r 80 , Wherein said p1asma tr0ugh 00ncentrati0n is achieVed ab0ut 7 days subsequent t0 the administrati0n 0f said d0se 0f the 01ig0nuc1e - 0tide. [ 0094 ] 82. The meth0d 0f Paragraph 79 , Wherein inf0rming said human subject c0mprises pr0Viding printed matter that adVises that the administrati0n 0f said 01ig0nuc1e0tide results in a p1asma tr0ugh c0ncentrati0n 0f at 1east ab0ut 5 ng / mL. [ 0095 ] 83. The meth0d 0f Paragraph 82 , Wherein said printed matter is a label. [ 0096 ] 84. A meth0d 0f using an 01ig0nuc1e0tide c0mprising the nuc1e0base sequence “GCCTCAGTCTGCTTCGCACC” ( SEQ ID NO : 2 ) in a treatment f0r reducing serum LDL - ch01ester01 in a human subject , said meth0d c0mprising inf0rming said human subject that the administrati0n 0f said 01ig0nuc1e0tide resu1ts in an estimated 1iVer c0ncentrati0n 0f said 01ig0nuc1e0tide 0f at 1east ab0ut 10 ug / g. [ 0097 ] 85. The meth0d 0f Paragraph 84 , Wherein said human subject is inf0rmed that the administrati0n 0f said 01ig0nuc1e0tide results in an estimated liVer c0ncentrati0n 0f said 01ig0nucle0tide in the range 0f ab0ut lO ug / g t0 ab0ut 150 ug / g. [ 0098 ] 86. The meth0d 0f Paragraph 84 , Wherein inf0rming said human subject c0mprises pr0Viding printed matter that adVises that the administrati0n 0f said 01ig0nuc1e0tide resu1ts in an estimated 1iVer c0ncentrati0n 0f said 01ig0nuc1e0tide 0f at least ab0ut 10 ug / g. [ 0099 ] 87. The meth0d 0f Paragraph 86 , Wherein said printed matter is a 1abe1. May 10 , 2012. [ 0100 ] 88. A pharmaceutical 00mp0siti0n c0mprising 0ne 0r m0re d0ses 0f an 01ig0nuc1e0tide that is 14 t0 3O nuc1e0 - bases in 1ength and Which hybridiZes t0 a nuc1eic acid sequence enc0ding ap01ip0pr0tein B , Wherein each 0f said 0ne 0r m0re d0 ses ranges fr0m ab0ut 50 mg t0 ab0ut 400 mg , and Wherein intraVen0us administrati0n t0 a human subject 0f said 01ig0nuc1e0tide at ab0ut 0.7 mg / kg 0f b0dy Weight t0 ab0ut 5.9 mg / kg 0f b0dy Weight is sufﬁcient t0 acbieVe a p1asma AUCO_48 fr0m ab0ut 11 ng - hr / mL t0 ab0ut 148 ng - br / mL. [ 0101 ] 89. The pharmaceutical 00mp0siti0n 0f Paragraph 88 , Wherein intraVen0us admini strati0n t0 a human subject 0f said 01ig0nucle0tide at ab0ut 0.7 mg / kg 0f b0dy Weight is sufﬁcient t0 achieVe a p1asma AUC0_48 0f 11 ug - hr / mL : 3 ug - br / mL. [ 0102 ] 90. The pharmaceutica1 c0mp0siti0n 0f Paragraph 88 , Wherein intraVen0us admini strati0n t0 a human subject 0f said 01ig0nuc1e0tide at ab0ut 1 mg / kg 0f b0dy Weight is sufﬁcient t0 achieVe a p1asma AUCO_48 0f 24 ug - hr / mLi3 ug - br / mL. [ 0103 ] 91. The pharmaceutica1 00mp0siti0n 0f Paragraph 88 , Wherein intraVen0us admini strati0n t0 a human subject 0f said 01ig0nuc1e0tide at ab0ut 2.7 mg / kg 0f b0dy Weight is sufﬁcient t0 achieVe a p1asma AUCO_48 0f 68 ug - hr / mL : 14 ug - br / mL. [ 0104 ] 92. The pharmaceutica1 c0mp0siti0n 0f Paragraph 88 , Wherein intraVen0us admini strati0n t0 a human subject 0f said 01ig0nucle0tide at ab0ut 5.9 mg / kg 0f b0dy Weight is sufﬁcient t0 achieVe a p1asma AUC0_48 0f 148 g - hr / mL : 14 ug - br / mL. [ 0105 ] 93. The pharmaceutica1 00mp0siti0n 0f any 0f Paragraphs 88 t0 92 , Wherein said 01ig0nuc1e0tide hybridizes t0 a regi0n 0f said nucleic acid sequence enc0ding ap0lip0pr0tein B that c0mprises nuc1e0tides 2920 t0 3420 0f SEQ ID NO : 1. [ 0106 ] 94. The pharmaceutica1 c0mp0siti0n 0f any 0f Paragraphs 88 t0 92 , Wherein said 01ig0nuc1e0tide hybridizes t0 a regi0n 0f said nuc1eic acid sequence enc0ding ap01ip0pr0tein B that 00mprises nuc1e0tides 3230 t0 3288 0f SEQ ID NO : 1. [ 0107 ] 95. The pharmaceutica1 c0mp0siti0n 0f any 0f Paragraphs 88 t0 92 , Wherein said 01ig0nuc1e0tide c0mprises the nuc1e0base sequence “GCCTCAGTCTGCTTCGCACC” ( SEQ ID NO : 2 ) . [ 0108 ] 96. The pharmaceutica1 c0mp0siti0n 0f Paragraph 95 , Wherein said 01ig0nuc1e0tide 00mprises ISIS 301012. [ 0109 ] 97. A pharmaceutica1 c0mp0siti0n c0mprising 0ne 0r m0re d0ses 0f an 01ig0nuc1e0tide that is 14 t0 30 nuc1e0 - bases in 1ength and Which hybridizes t0 a nuc1eic acid sequence enc0ding ap01ip0pr0tein B , Wherein each 0f said 0ne 0r m0re d0 ses ranges fr0m ab0ut 50 mg t0 ab0ut 400 mg , and Wherein subcutane0us administrati0n t0 a human subject 0f said 01ig0nuc1e0tide at ab0ut 0.7 mg / kg 0f b0dy Weight t0 ab0ut 5.9 mg / kg 0f b0dy Weight , subsequent t0 the administrati0n 0f 0ne 0r m0re 10ading d0 ses , is sufﬁcient t0 achieVe a plasma AUC fr0m ab0ut 19 ug - hr / mL t0 ab0ut 160 ug - hr / mL. [ 0110 ] 98. The pharmaceutical 00mp0siti0n 0f Paragraph 97 , Wherein subcutane0us administrati0n t0 a human subject 0f said 01ig0nucle0tide at ab0ut 0.7 mg / kg 0f b0dy Weight is sufﬁcient t0 achieVe a p1asma AUC 0f 19 ug°br / mL : 9 ug - hr / mL. [ 0111 ] 99. The pharmaceutical 00mp0siti0n 0f Paragraph 97 , Wherein subcutane0us administrati0n t0 a human subject 0f said 01ig0nuc1e0tide at ab0ut 1 mg / kg 0f b0dy Weight is sufﬁcient t0 achieVe a p1asma AUC 0f 28 ug°br / mL : 5 ug - hr / mL. US 2012 / 0115926 A1. [ 0112 ] 100. The pharmaceutical c0mp0siti0n 0f Paragraph 97 , Wherein subcutane0us administrati0n t0 a human subject 0f said 01ig0nuc1e0tide at ab0ut 2.7 mg / kg 0f b0dy Weight is sufﬁcient t0 achieVe a p1asma AUC 0f 63 ng - hr / mL : 13 ug - br / mL. [ 0113 ] 101. The pharmaceutica1 c0mp0siti0n 0f Paragraph 97 , Wherein subcutane0us administrati0n t0 a human subject 0f said 01ig0nucle0tide at ab0ut 5.9 mg / kg 0f b0dy Weight is sufﬁcient tO achieVe a p1asma AUC 0f 16O ug - hr / mL. [ 0114 ] 102. The pharmaceutica1 c0mp0siti0n 0f any 0f Paragraphs 97 t0 101 , Wherein said 01ig0nuc1e0tide hybridizes t0 a regi0n 0f said nuc1eic acid sequence enc0ding ap0 - 1ip0pr0tein B that c0mprises nuc1e0tides 292O t0 3420 0f SEQ ID NO : 1. [ 0115 ] 103. The pharmaceutica1 c0mp0siti0n 0f any 0f Paragraphs 97 t0 101 , Wherein said 01ig0nuc1e0tide hybridizes t0 a regi0n 0f said nucleic acid sequence enc0ding ap0 - 1ip0pr0tein B that 00mprises nucle0tides 3230 t0 3288 0f SEQ ID NO : 1. [ 0116 ] 104. The pharmaceutica1 c0mp0siti0n 0f any 0f Paragraphs 97 t0 101 , Wherein said 01ig0nuc1e0tide c0m - prises the nuc1e0base sequence “GCCTCAGTCTGCTTCGCACC” ( SEQ ID NO : 2 ) . [ 0117 ] 105. The pharmaceutica1 c0mp0siti0n 0f Paragraph 104 , Wherein said 01ig0nuc1e0tide c0mprises ISIS 301012. [ 0118 ] 106. A pharmaceutica1 c0mp0siti0n c0mprising 0ne 0r m0re d0ses 0f an 01ig0nuc1e0tide that is 14 t0 3O nucle0 - bases in 1ength and Wbich hybridizes t0 a nuc1eic acid sequence enc0ding ap01ip0pr0tein B , Wherein each 0f said 0ne 0r m0re d0ses ranges fr0m ab0ut 50 mg t0 ab0ut 400 mg , and Wherein subcutane0us administrati0n t0 a human subject 0f said 01ig0nuc1e0tide at ab0ut 0.7 mg / kg 0f b0dy Weight t0 ab0ut 5.9 mg / kg 0f b0dy Weight , subsequent t0 the administrati0n 0f 0ne 0r m0re 10ading d0 ses , is sufﬁcient t0 achieVe a p1asma tr0ugh c0ncentrati0n fr0m ab0ut 2 ng / mL t0 ab0ut 40 ng / mL. [ 0119 ] 107. The pharmaceutica1 c0mp0siti0n 0f Paragraph 106 , Wherein said 01ig0nucle0tide hybridizes t0 a regi0n 0f said nuc1eic acid sequence enc0ding ap01ip0pr0tein B that c0mprises nuc1e0tides 2920 t0 3420 0f SEQ ID NO : 1. [ 0120 ] 108. The pharmaceutical c0mp0siti0n 0f Paragraph 106 , Wherein said 01ig0nuc1e0tide hybridizes t0 a regi0n 0f said nuc1eic acid sequence enc0ding ap01ip0pr0tein B that c0mprises nuc1e0tides 3230 t0 3288 0f SEQ ID NO : 1. [ 0121 ] 109. The pharmaceutica1 c0mp0siti0n 0f Paragraph 106 , Wherein said 01ig0nuc1e0tide 00mprises the nuc1e0base sequence “GCCTCAGTCTGCTTCGCACC” ( SEQ ID NO : 2 ) . [ 0122 ] 1 10. A pharmaceutica1 c0mp0siti0n c0mprising 0ne 0r m0re d0ses 0f an 01ig0nuc1e0tide that is 14 t0 30 nuc1e0 - bases in 1ength and Wbich hybridizes t0 a nuc1eic acid sequence enc0ding ap0lip0pr0tein B , Wherein each 0f said 0ne 0r m0re d0ses ranges fr0m ab0ut 50 mg t0 ab0ut 400 mg , and Wherein subcutane0us administrati0n t0 a human subject 0f said 01ig0nuc1e0tide at ab0ut 0.7 mg / kg 0f b0dy Weight t0 ab0ut 5.9 mg / kg 0f b0dy Weight , subsequent t0 the administrati0n 0f 0ne 0r m0re loading d0 ses , is sufﬁcient t0 achieVe a bi0aVai1abi1ity 0f at 1east ab0ut 54%. [ 0123 ] 111. The pharmaceutica1 c0mp0siti0n 0f Paragraph 110 , Wherein said 01ig0nuc1e0tide hybridiZes t0 a regi0n 0f said nuc1eic acid sequence enc0ding ap01ip0pr0tein B that c0mprises nuc1e0tides 2920 t0 3420 0f SEQ ID NO : 1. [ 0124 ] 112. The pharmaceutica1 c0mp0siti0n 0f Paragraph 110 , Wherein said 01ig0nuc1e0tide hybridizes t0 a regi0n 0f. May 10 , 2012. said nucleic acid sequence enc0ding ap0lip0pr0tein B that c0mprises nuc1e0tides 3230 t0 3288 0f SEQ ID NO : 1. [ 0125 ] 1 13. The pharmaceutica1 c0mp0siti0n 0f Paragraph 110 , Wherein said 01ig0nuc1e0tide 00mprises the nucle0base sequence “GCCTCAGTCTGCTTCGCACC” ( SEQ ID NO : 2 ) . [ 0126 ] 1 14. A pharmaceutica1 c0mp0siti0n c0mprising 0ne 0r m0re d0ses 0f an 01ig0nuc1e0tide that is 14 t0 3O nuc1e0 - bases in 1ength and Which hybridiZes t0 a nuc1eic acid sequence enc0ding ap01ip0pr0tein B , Wherein each 0f said 0ne 0r m0re d0 ses ranges fr0m ab0ut 50 mg t0 ab0ut 400 mg , and Wherein subcutane0us administrati0n t0 a human subject 0f said 01ig0nuc1e0tide at ab0ut 0.7 mg / kg 0f b0dy Weight t0 ab0ut 5.9 mg / kg 0f b0dy Weight , subsequent t0 the administrati0n 0f 0ne 0r m0re 10ading d0 ses , is sufﬁcient t0 achieVe a termina1 e1iminati0n t1 , 2 fr0m ab0ut 23 t0 ab0ut 47 days. [ 0127 ] 1 15. The pharmaceutical c0mp0siti0n 0f Paragraph 1 14 , Wherein subcutane0us administrati0n t0 a human subject 0f said 01ig0nuc1e0tide at ab0ut 0.7 mg / kg 0f b0dy Weight is sufﬁcient t0 achieVe a terminal e1iminati0n tl / 2 0f ab0ut 23 daysﬂ day. [ 0128 ] 1 16. The pharmaceutical c0mp0siti0n 0f Paragraph 1 14 , Wherein subcutane0us administrati0n t0 a human subject 0f said 01ig0nuc1e0tide at ab0ut 1 mg / kg 0f b0dy Weight is sufﬁcient t0 achieVe a termina1 e1iminati0n tl / 2 0f ab0ut 27 days : 12 days. [ 0129 ] 1 17. The pharmaceutical c0mp0siti0n 0f Paragraph 1 14 , Wherein subcutane0us administrati0n t0 a human subject 0f said 01ig0nuc1e0tide at ab0ut 2.7 mg / kg 0f b0dy Weight is sufﬁcient t0 achieVe a termina1 e1iminati0n tl / 2 0f ab0ut 31 daysﬂl days. [ 0130 ] 1 18. The pharmaceutical c0mp0siti0n 0f Paragraph 1 14 , Wherein subcutane0us administrati0n t0 a human subject 0f said 01ig0nuc1e0tide at ab0ut 5.9 mg / kg 0f b0dy Weight is sufﬁcient t0 achieVe a termina1 e1iminati0n tl / 2 0f ab0ut 47 days. [ 0131 ] 119. The pharmaceutical c0mp0siti0n 0f any 0f Paragraphs 114 t0 118 , Wherein said 01ig0nuc1e0tide hybridizes t0 a regi0n 0f said nuc1eic acid sequence enc0ding ap0 - 1ip0pr0tein B that 00mprises nuc1e0tides 2920 t0 3420 0f SEQ ID NO : 1. [ 0132 ] 120. The pharmaceutica1 c0mp0siti0n 0f any 0f Paragraphs 114 t0 118 , Wherein said 01ig0nuc1e0tide hybridizes t0 a regi0n 0f said nuc1eic acid sequence enc0ding ap0 - 1ip0pr0tein B that 00mprises nuc1e0tides 323O t0 3288 0f SEQ ID NO : 1. [ 0133 ] 121. The pharmaceutica1 00mp0siti0n 0f any 0f Paragraphs 114 t0 118 , Wherein said 01ig0nucle0tide c0m - prises the nucle0base sequence “GCCTCAGTCTGCTTCGCACC” ( SEQ ID NO : 2 ) . [ 0134 ] 122. The phamiaceutical c0mp0siti0n 0f Paragraph 121 , Wherein said 01ig0nucle0tide 00mprises ISIS 301012. [ 0135 ] 123. A p1ura1ity 0f d0ses 0f an 01ig0nuc1e0tide targeted t0 ap01ip0pr0tein B f0r reducing serum ch0lester01 leVels Wherein administrati0n 0f said plurality 0f d0ses said 01ig0nuc1e0tide resu1ts in a p1asma tr0ugh AUC f0r said 01i - g0nuc1e0tide fr0m ab0ut 2 ug - hr / mL t0 ab0ut 2O ug - br / mL. [ 0136 ] 124. The plurality 0f d0ses 0f Paragraph 123 , Wherein said administrati0n resu1ts in a p1asma tr0ugh AUC fr0m ab0ut 2 ug - br / mL t0 ab0ut 10 ug - br / mL. [ 0137 ] 125. The p1ura1ity 0f d0ses 0f Paragraph 123 , Wherein said administrati0n resu1ts in a p1asma tr0ugh AUC fr0m ab0ut 4 ug - br / mL t0 ab0ut 6 ug - br / mL. US 2012 / 0115926 A1. [ 0138 ] 126. The plurality 0f d0ses 0f Paragraph 123 , Wherein said administrati0n resu1ts in a p1asma tr0ugh AUC 0f ab0ut 5 ug - hr / mL. [ 0139 ] 127. The p1ura1ity 0f d0ses 0f Paragraphs 123 , 124 , 125 0r 126 , Wherein said p1asma tr0ughAUC is acbieVed fr0m ab0ut 3 t0 ab0ut 33 days subsequent t0 the administrati0n 0f a d0se 0f said plura1ity 0f d0ses 0f the 01ig0nuc1e0tide. [ 0140 ] 128. The p1ura1ity 0f d0ses 0f Paragraph 123 , Wherein said serum ch0lester0l leVels are reduced by least ten percent. [ 0141 ] 129. The p1ura1ity 0f d0ses 0f Paragraph 123 , Wherein said serum ch0lester01 leVels is are reduced by 1east thirty percent. [ 0142 ] 130. The p1ura1ity 0f d0ses 0f Paragraph 123 , Wherein said serum ch0lester0l leVe1s are serum LDL - ch01ester01 1eVels. [ 0143 ] 131. The plura1ity 0f d0ses 0f Paragraph 123 , Wherein said serum ch0lester01 leVels are serum VLDL - ch0 - 1ester01 1eVe1s. [ 0144 ] 132. The plura1ity 0f d0ses 0f Paragraph 123 , Wherein said 01ig0nucle0tide 00mprises the nucle0base sequence “GCCTCAGTCTGCTTCGCACC” ( SEQ ID NO : 2 ) . [ 0145 ] 133. The p1ura1ity 0f d0ses 0f Paragraph 127 , Wherein administrati0n is ab0ut 0nce a Week. [ 0146 ] 134. The plura1ity 0f d0ses 0f Paragraph 127 , Wherein administrati0n is ab0ut 0nce a m0nth. [ 0147 ] 135. The p1ura1ity 0f d0ses 0f Paragraph 127 , Wherein each 0f said p1ura1ity 0f d0ses c0mprises fr0m ab0ut 50 mg t0 ab0ut 400 mg 0f said 01ig0nuc1e0tide. [ 0148 ] 136. The p1ura1ity 0f d0ses 0f Paragraph 127 , Wherein each 0f said p1ura1ity 0f d0ses c0mprises ab0ut 200 mg 0f said 01ig0nuc1e0tide. [ 0149 ] 137. A p1ura1ity 0f d0ses 0f an 01ig0nuc1e0tide targeted t0 ap01ip0pr0tein B f0r reducing serum ch01ester01 1eVe1s Wherein administrati0n 0f said p1ura1ity 0f d0ses said 01ig0nuc1e0tide resu1ts in a p1asma tr0ugh c0ncentrati0n fr0m ab0ut 5 ng / mL t0 ab0ut 40 ng / mL. [ 0150 ] 138. The p1ura1ity 0f d0ses 0f Paragraph 137 , Wherein admini strati0n resu1ts in a p1asma tr0ugh 00ncentra - ti0n fr0m ab0ut 5 ng / mL t0 ab0ut 20 ng / mL. [ 0151 ] 139. The p1ura1ity 0f d0ses 0f Paragraphs 137 0r 138 , Wherein said p1asma tr0ugh c0ncentrati0n is achieVed ab0ut 7 days sub sequent t0 the admini strati0n 0f a d0se 0f said p1ura1ity 0f d0ses 0f the 01ig0nuc1e0tide. [ 0152 ] 140. The p1ura1ity 0f d0ses 0f Paragraph 137 , Wherein said serum ch01ester01 1eVe1s are reduced by 1east ten percent. [ 0153 ] 141. The plura1ity 0f d0ses 0f Paragraph 137 , Wherein said serum ch01ester01 1eVe1s are reduced by 1east thirty percent. [ 0154 ] 142. The p1ura1ity 0f d0ses 0f Paragraph 137 , Wherein said serum ch01ester01 1eVe1s are serum LDL - ch01ester01 1eVels. [ 0155 ] 143. The plura1ity 0f d0ses 0f Paragraph 137 , Wherein said serum ch01ester01 1eVe1s are serum VLDL - ch0 - 1ester01 1eVe1s. [ 0156 ] 144. The p1ura1ity 0f d0ses 0f Paragraph 137 , Wherein said 01ig0nucle0tide 00mprises the nucle0base sequence “GCCTCAGTCTGCTTCGCACC” ( SEQ ID NO : 2 ) . [ 0157 ] 145. The p1ura1ity 0f d0ses 0f Paragraph 137 , Wherein administrati0n is ab0ut 0nce a Week. May 10 , 2012. [ 0158 ] 146. The plurality 0f d0ses 0f Paragraph 137 , Wherein admini strati0n is ab0ut 0nce a m0nth. [ 0159 ] 147. The p1ura1ity 0f d0ses 0f Paragraph 137 , Wherein each 0f said p1urality 0f d0 ses c0mprises fr0m ab0ut 50 mg t0 ab0ut 400 mg 0f said 01ig0nucle0tide. [ 0160 ] 148. The p1ura1ity 0f d0ses 0f Paragraph 137 , Wherein each 0f said p1ura1ity 0f d0ses c0mprises ab0ut 20O mg 0f said 01ig0nuc1e0tide. [ 0161 ] 149. Use 0f a p1ura1ity 0f d0ses 0f an 01ig0nucle - 0tide targeted t0 ap01ip0pr0tein B f0r the preparati0n 0f a medicament f0r reducing serum ch01ester01 1eVe1s , Wherein administrati0n 0f said medicament resu1ts in a p1asma tr0ugh AUC f0r said 01ig0nuc1e0tide fr0m ab0ut 2 ug - hr / mL t0 ab0ut 10 ug - hr / mL. [ 0162 ] 150. The use 0f Paragraph 149 , Wherein admini stra - ti0n 0f said medicament resu1ts in a p1asma tr0ughAUC fr0m ab0ut 2 ug - br / mL t0 ab0ut 10 ug - br / mL. [ 0163 ] 151. The use 0f Paragraph 149 , Wherein admini stra - ti0n 0f said medicament results in a p1asma tr0ughAUC fr0m ab0ut 4 ng - br / mL t0 ab0ut 6 ug - hr / mL. [ 0164 ] 152. The use 0f Paragraph 149 , Wherein admini stra - ti0n 0f said medicament resu1ts in a p1asma tr0ugh AUC 0f ab0ut 5 ng - hr / mL. [ 0165 ] 153. The use 0f Paragraphs 149 , 150 , 151 0r 152 , Wherein said p1asma tr0ugh AUC is achieVed fr0m ab0ut 3 t0 ab0ut 33 days subsequent t0 the administrati0n 0f a d0se 0f said medicament. [ 0166 ] 154. The use 0f Paragraph 149 , Wherein said serum ch01ester01 1eVe1s are reduced by least ab0ut ten percent. [ 0167 ] 155. The use 0f Paragraph 149 , Wherein said serum ch01ester01 1eVe1s are reduced by 1east ab0ut thirty percent. [ 0168 ] 156. The use 0f Paragraph 149 , Wherein said serum ch01ester011eVe1s are serum LDL - ch01ester01 1eVe1s. [ 0169 ] 157. The use 0f Paragraph 149 , Wherein said serum ch0lester0l leVels are serum VLDL - ch0lester0l leVels. [ 0170 ] 158. The use 0f Paragraph 149 , Wherein said 01ig0 - nuc1e0tide c0mprises the nuc1e0base sequence “GCCTCAGTCTGCTTCGCACC” ( SEQ ID NO : 2 ) . [ 0171 ] 159. The use 0f Paragraph 149 , Wherein said administrati0n is ab0ut 0nce a Week. [ 0172 ] 160. The use 0f Paragraph 149 , Wherein said administrati0n is ab0ut 0nce a m0nth. [ 0173 ] 161. The use 0f Paragraph 149 , Wherein each 0f said p1ura1ity 0f d0ses c0mprises fr0m ab0ut 50 mg t0 ab0ut 400 mg 0f said 01ig0nuc1e0tide. [ 0174 ] 162. The use 0f Paragraph 149 , Wherein each 0f said p1ura1ity 0f d0 ses 00mprises ab0ut 200 mg 0f said 01ig0nuc1e - 0tide. [ 0175 ] 163. Use 0f a p1ura1ity 0f d0ses 0f an 01ig0nuc1e - 0tide targeted t0 ap01ip0pr0tein B f0r the preparati0n 0f a medicament f0r reducing serum ch0lester0l leVels , Wherein administrati0n 0f said medicament resu1ts in a p1asma tr0ugh c0ncentrati0n 0f said 01ig0nuc1e0tide fr0m ab0ut 5 ng / mL t0 ab0ut 40 ng / mL. [ 0176 ] 164. The use 0f Paragraph 163 , Wherein admini stra - ti0n 0f said medicament resu1ts in a p1asma tr0ugh c0ncentrati0n fr0m ab0ut 5 ng / mL t0 ab0ut 20 ng / mL. [ 0177 ] 165. The use 0f Paragraphs 163 0r 164 , Wherein said p1asma tr0ugh c0ncentrati0n is acbieVed ab0ut 7 days subsequent t0 the administrati0n 0f a d0se 0f said medicament. [ 0178 ] 166. The use 0f Paragraph 163 , Wherein said serum ch01ester01 1eVe1s are reduced by 1east ab0ut ten percent. [ 0179 ] 167. The use 0f Paragraph 163 , Wherein said serum ch01ester01 1eVe1s are reduced by 1east ab0ut thirty percent. US 2012 / 0115926 A1. [ 0180 ] 168. The use of Paragraph 163 , Wherein said serum cho1estero1 1eVe1s are serum LDL - cho1estero1 1eVe1s. [ 0181 ] 169. The use of Paragraph 163 , Wherein said serum cho1estero1 1eVe1s are serum VLDL - cho1estero1 1eVe1s. [ 0182 ] 170. The use of Paragraph 163 , Wherein said oligonuc1eotide comprises the nucleobase sequence “GCCTCAGTCTGCTTCGCACC” ( SEQ ID NO : 2 ) . [ 0183 ] 171. The use of Paragraph 163 , Wherein administration is about once a Week. [ 0184 ] 172. The use of Paragraph 163 , Wherein admini stration is about once a month. [ 0185 ] 173. The use of Paragraph 163 , Wherein each of said p1ura1ity of doses comprises from about 50 mg to about 400 mg of said oligonuc1eotide. [ 0186 ] 174. The use of Paragraph 163 , Wherein each of said p1ura1ity of doses comprises about 200 mg of said oligonucleotide. [ 0187 ] 175. Use of an oligonuc1eotide comprising the nuc1eobase sequence “GCCTCAGTCTGCTTCGCACC” ( SEQ ID NO : 2 ) for the preparation of a medicament for reducing serum LDL - cholestero1 , Wherein administration of said medicament is suﬁicient to achieVe a p1asma troughAUC for said oligonuc1eotide of at 1east about 2 pg ' hr / mL. [ 0188 ] 176. The use of Paragraph 175 , Wherein said administration of said medicament is sufﬁcient to achieVe a p1asma trough AUC in the range of about 2 ng - hr / mL to about 20 ug - hr / mL. [ 0189 ] 177. The use of Paragraphs 175 or 176 , Wherein said p1asma trough AUC is achieVed from about 3 to about 33 days subsequent to the administration of said medicament. [ 0190 ] 178. The use of Paragraph 175 , Wherein the administration of said medicament occurs about once a Week , about once a month or about once eVery three months. [ 0191 ] 179. Use of an oligonuc1eotide comprising the nuc1eobase sequence “GCCTCAGTCTGCTTCGCACC” ( SEQ ID NO : 2 ) for the preparation of a medicament for reducing serum LDL - cho1estero1 , Wherein administration of said medicament is sufﬁcient to acbieVe a plasma trough concentration for said oligonuc1eotide of at 1east about 5 ng / mL. [ 0192 ] 180. The use of Paragraph 179 , Wherein said administration of said medicament is sufﬁcient to achieVe a p1asma trough concentration in the range of about 5 ng / mL to about 4O ng / mL. [ 0193 ] 181. The use of Paragraphs 179 or 180 , Wherein said p1asma trough concentration is achieVed about 7 days subsequent to the administration of said medicament. [ 0194 ] 182. The use of Paragraph 179 , Wherein the administration of said medicament occurs about once a Week , about once a month or about once eVery three months. [ 0195 ] 183. Use of an oligonuc1eotide comprising the nuc1eobase sequence “GCCTCAGTCTGCTTCGCACC” ( SEQ ID NO : 2 ) for the preparation of a medicament for reducing serum LDL - cholestero1 , Wherein administration of said medicament is sufﬁcient to achieVe an estimated liVer concentration of at 1east about 10 ug / g. [ 0196 ] 184. The use of Paragraph 183 , Wherein said administration of said medicament is sufﬁcient to achieVe an estimated 1iVer concentration in the range of about 10 ug / g to about 150 ug / g. [ 0197 ] 185. The use of Paragraph 183 , Wherein the administration of said medicament occurs about once a Week , about once a month or about once eVery three months. May 10 , 2012. [ 0198 ] 186. Use of an oligonucleotide comprising the nuc1eobase sequence “GCCTCAGTCTGCTTCGCACC” ( SEQ ID NO : 2 ) for the preparation of a medicament for reducing serum LDL - cholestero1 , Wherein said medicament is administered during a 10ading period and a maintenance period. [ 0199 ] 187. The use of Paragraph 186 , Wherein said oligonuc1eotide is 20 to 30 nuc1eobases in 1ength. [ 0200 ] 188. The use of Paragraph 186 , Wherein the loading period comprises administering the medicament once a day for up to 10 days. [ 0201 ] 189. The use of Paragraph 188 , Wherein said medicament is administered intraVenously or subcutaneous1y. [ 0202 ] 190. The use of Paragraph 186 , Wherein the maintenance period comprises administering the medicament at 1east once about eVery 3 months. [ 0203 ] 191. The use of Paragraph 190 , Wherein the medicament is administered once about eVery month. [ 0204 ] 192. The use of Paragraph 190 , Wherein the medicament is administered once about eVery 2 Weeks. [ 0205 ] 193. The use of Paragraph 190 , Wherein the medicament is administered once about eVery 7 days. [ 0206 ] 194. The use of Paragraph 190 , Wherein said medicament is administered intraVenous1y or subcutaneous1y. [ 0207 ] 195. The use of Paragraphs 188 or 190 , Wherein the oligonuc1eotide present in the medicament is administered in a dose from about 0.1 mg / kg / day to about 5 mg / kg / day. [ 0208 ] 196. The use of Paragraphs 195 , Wherein the oligonuc1eotide present in the medicament is administered in a dose from about 0.1 mg / kg / day to about 1.2 mg / kg / day. [ 0209 ] 197. The use of Paragraphs 188 or 190 , Wherein the oligonuc1eotide present in the medicament is administered in a dose from about 50 mg per Week to about 600 mg per Week. [ 0210 ] 198. The use of Paragraph 197 , Wherein the oligonuc1eotide present in the medicament is administered in a dose of about 50 mg per Week. [ 0211 ] 199. The use of Paragraph 197 , Wherein the dose is about 100 mg per Week. [ 0212 ] 200. The use of Paragraph 197 , Wherein the dose is about 200 mg per Week. [ 0213 ] 201. The use of Paragraph 197 , Wherein the dose is about 400 mg per Week. [ 0214 ] 202. The use of Paragraph 186 , Wherein the oligonuc1eotide comprises ISIS 301012. [ 0215 ] 203. The use of Paragraph 186 , Wherein admini stration of the medicament results in a reduction in serum VLDLcho1estero1 , serum trig1ycerides , serum 1ipoprotein ( a ) or any combination of serum VLDL - cho1estero1 , serum trig1ycerides and serum 1ipoprotein ( a ) . [ 0216 ] 204. The use of Paragraph 186 , Wherein the medicament is administered to a human subject that exhibits at 1east one indication se1ected from the group consisting of an e1eVated serum tota1 cho1estero1 1eVe1 , an e1eVated serum LDL - cholestero1 leVel , an eleVated tota1 cho1estero1 : HDL ratio and an e1eVated LDL : HDL ratio. [ 0217 ] 205. The use of Paragraph 186 , Wherein the medicament is administered to a human subject Who has suffered from or suffers from homozygous fami1ia1 hypercho1esterolemia , or heterozygous fami1ia1hypercholesterolemia. [ 0218 ] 206. The use of Paragraph 186 , Wherein the medicament is administered to a human subject Who has suffered from , suffers from or is at an increased risk for nonfami1ia1 hypercho1estero1emia. US 2012 / 0115926 A1. [ 0219 ] 207. The use of Paragraph 186 , Wherein the medicament is administered to a human subject Who has serumLDL cho1estero1 1eVe1s aboVe about 7O mg / dL prior to administration. [ 0220 ] 208. The use of Paragraph 186 , Wherein the medicament is administered to a human subject Who has serumLDL cho1estero1 1eVe1s aboVe about IO0 mg / dL prior to administration. [ 0221 ] 209. The use of Paragraph 186 , Wherein the medicament is administered to a human subject Who has serumLDL cho1estero1 1eVe1s aboVe about I30 mg / dL prior to administration. [ 0222 ] 210. The use of Paragraphs 207 , 208 or 209 , Wherein the administering said medicament reduces the serum - LDL cho1esterol 1eVe1s to 1ess than about 70 mg / dL. [ 0223 ] 211. The use of Paragraphs 208 or 209 , Wherein the administering said medicament reduces the serum - LDL cho - 1estero1 1eVe1s to 1ess than about 100 mg / dL. [ 0224 ] 212. The use of Paragraph 209 , Wherein the administering said medicament reduces the serum LDL - cho1estero1 1eVe1s to 1ess than about 130 mg / dL. [ 0225 ] 213. The method of Paragraphs 29 , 33 , 37 , 74 , 79 , or 84 , Wherein said oligonuc1eotide comprises ISIS 301012. [ 0226 ] 214. The pharmaceutica1 composition of Paragraphs 109 or 113 , Wherein said oligonuc1eotide comprises ISIS 301012. [ 0227 ] 215. The p1ura1ity of doses of Paragraphs 132 or 144 , Wherein said oligonuc1eotide comprises ISIS 301012. [ 0228 ] 216. The use ofParagraphs 158 , 170 , 175 , 179 , 183 , 186 , Wherein said oligonuc1eotide comprises ISIS 301012. [ 0229 ] In addition to the foregoing embodiments , the present inVention re1ates to methods of reducing serum cho - 1estero1 by administering an oligonuc1eotide targeted to apo - 1ipoprotein B , such as the antisense oligonuc1eotide ISIS 301012 and a second 1ipid - 1oWering agent at a dose 10Wer than that Which Wou1d be required to achieVe a therapeutic or prophy1actic effect if the second agent Was administered a1one. For examp1e , second 1ipid - 1oWering agents can be se1ected from the group consisting of bi1e acid sequestrants ( e. g. , cho1estyramine , co1estipo1 , and co1eseVe1am hydroch1o - ride ) , ﬁbrates ( e. g. , cloﬁbrate , gemﬁbrozil , fenoﬁbrate , bezaﬁbrate , and ciproﬁbrate ) , niacin , statins ( e. g. , 10Vastatin , preVastatin , atorVastatin , simVastatin , and ﬁuVastatin ) , and cho1estero1 absorption inhibitors ( e. g. , ezetimibe ) . BRIEF DESCRIPTION OF THE DRAWINGS. [ 0230 ] FIG. 1 is a line graph shoWing the percent change from baseline of apolipoprotein B ( ApoB - 100 ) , serum LDLcho1estero1 ( LDL ) and serum tota1 cho1esterol in re1ating to p1asmatroughAUC1eVe1s in human subjects approximate1y 3. days fol1oWing the end of the mu1tiple dose treatment period ( MD25 ) described in Examp1e 3. DETAILED DESCRIPTION OF THE INVENTION. [ 0231 ] One embodiment of the inVention relates to compositions and methods for loWering serum LDL - cholesterol leV - e1s in a human suffering from , or at risk for , hypercho1esterolemia by administering to the human an oligonuc1eotide targeted to apo1ipoprotein B. As used herein “targeting” or “targeted to” refers to an oligonucleotide capable of hybridizing With a selected nucleic acid molecu1e or region of a nuc1eic acid mo1ecu1e. Such hybridization of an oligonuc1e - otide With its target nuc1eic acid modu1ates ( inhibits or stimu - . May 10 , 2012. lates ) the normal function of the nucleic acid through a mechanism general1y referred to as “antisense.” In one embodiment , the oligonuc1eotide comprises the nuc1eobase sequence “GCCTCAGTCTGCTTCGCACC” ( SEQ ID NO : 2 ) . In other embodiments , the oligonucleotide is ISIS 301012. It Was discoVered that the oligonuc1eotide ISIS 301012 Was effectiVe at reducing the leVe1 of serum apolipoprotein B and serum LDL - cholesterol in humans for an extended period after administration. For examp1e , treatment of humans With ISIS 301012 1ed to 10Wered LDL - cho1estero1 and apo1ipoprotein B 1eVe1s for seVeral Weeks fol1oWing cessation of treatment. For this reason , ISIS 3OIO12 proVides an extended durationa1 effect on hypercho1estero1emia , and thereby is a useﬁil for the treatment for this disease. [ 0232 ] An additiona1 embodiment of the inVention re1ates to administering an oligonucleotide targeted to apo1ipoprotein B to a human subject so that the p1asma trough AUC is betWeen about 2 to 2O ug - br / mL , 2 to 10 ug - hr / mL , or 2 to 7 ug - br / mL. In one embodiment , the oligonuc1eotide is administered so that the p1asma trough AUC is about 4 to 6 ug - hr / mL. In yet another embodiment , the oligonuc1eotide is administered so that the p1asma trough AUC is about 5 ng - hr / mL. In stil1 other embodiments , the oligonuc1eotide is administered so that the p1asma trough AUC is about 2 ug - hr / mL , about 3 ug - hr / mL , about 4 ug - br / mL , about 5 ug - hr / mL , about 6 ug - hr / mL , about 7 ug - hr / mL , about 8 ug - hr / mL , about 9 ug - hr / mL , about 10 ug - hr / mL , about 11 ug - hr / mL , about 12 ug°br / mL , about 13 ug - br / mL , about 14 pg - hr / mL , about 15 ug - br / mL , about 16 ug - br / mL , about 17 pg - hr / mL , about 18 ug - hr / mL , about 19 ng - hr / mL or about 20 ug - hr / mL. In one embodiment , the subject is treated by Week1y 200 mg maintenance doses of the oligonuc1eotide , and the oligonuc1eotide is ISIS 301012. In other embodiments , the subject is treated on1y once per month With a concentration of the oligonuc1e - otide that is selected to result in the desired plasma trough AUC. A1ternatiVe1y , the subject can be treated on1y once eVery tWo , or eVen eVery tbree months With a concentration of the. oligonuc1eotide that is selected to resu1t in the desired p1asma trough AUC. [ 0233 ] Another embodiment of the inVention re1ates to the use of ISIS 301012 as a treatment for a human Who suffers from , or is at an increased risk for , hypercho1estero1emia , Wherein the ISIS 301012 oligonuc1eotide is administered during a 10ading period and a maintenance period. The doses during the loading period are typical1y bigher , or more frequent , than during the maintenance period , and both the amount and frequency of do sing are se1ected such that 1iVer tissue 1eVe1s of ISIS 301012 approach tissue 1eVe1s that proVide therapeutic beneﬁts. Oligonuc1eotide p1asma trough concentrations are in equi1ibrium With tissue drug concentrations and thus are used as a representation of liVer tissue concentrations. For examp1e , a 2OO mg dose of ISIS 301012 administered intraVenous1y 3 times during a 1 Week 10ading period achieVed a p1asma trough concentration of approximate1y 18 ng / mL. Reductions in serum LDL - cholestero1 , serum total cholesterol , and serum apolipoprotein B Were obserVed. The doses during the maintenance period are typi - ca11y 10Wer or 1ess frequent than during the 10ading period , and are administered once per Week , once eVery 2 Weeks , once per month or once eVery 3 months. This dose may be equal to or 1ess than the dose administered during the loading period. For examp1e , a 200 mg dose of ISIS 301012 may be administered once per Week during the maintenance period. US 2012 / 0115926 A1. [ 023 4 ] As used herein , an oligonucleotide may proVide a therapeutic beneﬁt to a human subject When a reduction of at 1east 5% , 10% , 15% , 20% , 30% , 40% , 50% , 60% , 70% , 80% or 90% of serum apo1ipoprotein B or serum LDL - cho1estero1 1eVe1s is found. HoWeVer , any reduction in serum apo1ipoprotein B or LDL - cho1estero1 1eVe1s may be therapeutica11y ben - eﬁcia1 to a subject , so the aforementioned percentage reductions are i11ustratiVe , and not 1imiting , on embodiments of the inVention. An oligonucleotide may proVide a therapeutic ben - eﬁt to a human subject When serum LDL - cholestero1 leVel is 10Wered to about 70 mg / dL or 1es s , to about 10O mg / dL or 1ess , or to about 13O mg / dL or 1ess. [ 0235 ] As used herein , “suffering from hypercho1esterolemia” refers to a human subject Who has LDL - cho1estero1 or tota1 cho1estero1 1eVe1s higher than the recommended LDLcho1estero1 or tota1 cho1estero1 1eVe1s as estab1ished by the Nationa1 Cholestero1 Education Panel. As used herein , “at risk for hypercho1esterolemia” refers to a human subject Who exhibits one or more risk factors for coronary heart disease , such as , for examp1e , those risk factors deﬁned by the Nationa1 Cho1estero1 Education Panel As used herein , “in need thereof is interchangeab1e With “suffering from hypercho1estero1emia” or “at risk for hypercho1estero1emia”. “Subject” and “human subject” are herein used interchangeab1y. [ 023 6 ] Another embodiment of the inVention relates to loWering the leVe1 of apo1ipoprotein B - containing 1ipoproteins in a human subject. As used herein , “apo1ipoprotein B - containing 1ipoprotein” refers to any 1ipoprotein that has apo1ipoprotein B as its protein component , and is understood to inc1ude LDL , VLDL , IDL , and lipoprotein ( a ) . LDL , VLDL , IDL and 1ipoprotein ( a ) each contain one mo1ecu1e of apo1ipoprotein B , thus a serum apo1ipoprotein B measurement reﬂects the tota1 number of these 1ipoproteins . As is knoWn in the art , each of the aforementioned 1ipoproteins is atherogenic. Thus , 10W - ering one or more apo1ipoprotein B - containing 1ipoproteins in serum may proVide a therapeutic beneﬁt to a human subject. Sma11 LDL particles are considered to be particu1ar1y atherogenic re1atiVe to 1arge LDL partic1es , thus 10Wering sma11 LDL partic1es can proVide a therapeutic beneﬁt to a human subject. Fo1loWing treatment With ISIS 30l012 , 1eVels of serum small LDL particles , serum VLDL - cholesterol , or serum 1ipoprotein ( a ) Were found to be reduced in humans. [ 0237 ] Another embodiment of the inVention relates to loWering additional lipid parameters in a subject. FolloWing treatment With ISIS 301012 , serum trig1ycerides , LDL : HDL ratio , or tota1 cho1estero1 : HDL ratio Were found to be reduced in humans. Reduction of tota1 cho1estero1 : HDL ratio or LDL : HDL ratio is a clinica1ly desirable improVement in cho1estero1 ratio. Similarly , it is clinically desirable to reduce serum trig1ycerides humans Who exhibit e1eVated1ipid1eVe1s. [ 0238 ] Other embodiments of the inVention encompass methods of reducing serum LDL - cholesterol in a human by administering a dose of an oligonuc1eotide that inhibits expression of apo1ipoprotein B. In this embodiment , the oligonuc1eotide is administered in a dose that proVides a predetermined trough concentration in the humans p1asma , Wherein the predetermined plasma trough concentration resu1ts in a 10Wered serum LDL - cho1estero1 1eVe1. In one embodiment , the p1asma trough concentration ranges from about 5 ng / mL to about 40 ng / mL. In one embodiment , the oligonuc1eotide is SEQ ID NO : 2. Preferab1y , the loWered serum LDL - cho1esterol leVel proVides , a therapeutic beneﬁt to the human. This embodiment encompasses reducing additiona1 1ipid parameters , such as serum tota1 cho1estero1 , serum. May 10 , 2012. small LDL particles , serum triglycerides , serum lipoprotein ( a ) , and serum VLDL - cho1estero1. [ 0239 ] In another embodiment , the oligonuc1eotide is administered in a dose that proVides a predetermined concentration in the humans p1asma , Wherein the predetermined p1asma trough concentration is measured as a p1asma trough “area under the curVe” ( AUC ) , as detai1ed more comp1ete1y be1oW , and Wherein the predetermined p1asma trough AUC resu1ts in a 10Wered serum LDL - cho1estero1 1eVe1. Such p1asma trough AUC range from about 2 ug - br / mL to about 2O ug - br / mL. In one embodiment , the oligonuc1eotide is SEQ ID NO : 2. This embodiment encompasses reducing additiona1 1ipid parameters , such as serum sma1l LDL partic1es , serum tota1 cho1estero1 , serum trig1ycerides , serum 1ipoprotein ( a ) , and serum VLDL - cho1estero1. [ 0240 ] Stil1 other embodiments of the present inVention re1ate to a p1ura1ity of doses or one or more pharmaceutica1 compositions comprising a p1ura1ity of doses of an oligonuc1eotide targeted to apo1ipoprotein B for reducing serum cho1estero1 1eVe1s. In certain embodiments , the serum cho1estero1 is serum LDL - cho1esterol or serum VLDL - cholestero1. Administration of such p1ura1ity of doses to a subject , such as a human , resu1ts in a p1asma trough AUC for the oligonuc1e - otide of from about 2 ug - br / mL to about 20 ug - hr / mL , about 2 ug - hr / mL to about 10 ug - br / mL , and about 4 ug - hr / mL , to about 6 pg - hr / mL. In other embodiments , the p1asma trough AUC is about 5 ug - hr / mL. In sti11 other embodiments , the administration of the p1ura1ity of doses resu1ts in a p1asma trough AUC for the oligonuc1eotide of about 2 ug - hr / mL , about 3 ug - hr / mL , about 4 ug - br / mL , about 5 ug - hr / mL , about 6 ug - hr / mL , about 7 ug - hr / mL , about 8 ug - hr / mL , about 9 pg - hr / mL , about 10 ug - hr / mL , about 11 ug - hr / mL , about 12 ug°br / mL , about 13 ug - br / mL , about 14 pg - hr / mL , about 15 ug°br / mL , about 16 ug - br / mL , about 17 pg - hr / mL , about 18 ug - br / mL , about 19 ug - hr / mL or about 20 ng - hr / mL. In any of the foregoing embodiments , the p1asma trough AUC is achieVed from about 3 to about 33 days after administration of at 1east one dose of the p1ura1ity of doses of the oligonuc1e - otide. In some embodiments , the serum cho1estero1 is serum LDL - cholesterol In some preferred embodiments , the oligonucleotide used in the plurality of doses is SEQ ID NO : 2. [ 0241 ] In certain other embodiments , administration of a p1ura1ity of doses an oligonuc1eotide targeted to apo1ipoprotein B results in a plasma trough concentration of about 5 ng / mL to about 40 ng / mL , Whereas in other embodiments the p1asma trough concentration is about 5 ng / mL to about 20 ng / mL. In sti11 other embodiments the p1asma trough concentration is about 5 ng / mL , about 6 ng / mL , about 7 ng / mL , about 8 ng / mL , about 9 ng / mL , about lO ng / mL , about 11 ng / mL , about 12 ng / mL , about 13 ng / mL , about 14 ng / mL , about IS ng / mL , about 16 ng / mL , 17 ng / mL , about 18 ng / mL , about 19 ng / mL , about 20 ng / mL , about 21 ng / mL , about 22 ng / mL , about 23 ng / mL , about 24 ng / mL , about 25 ng / mL , about 26 ng / mL , about 27 ng / mL , about 28 ng / mL , 29 ng / mL , about 30 ng / mL , about 31 ng / mL , about 32 ng / mL , about 33 ng / mL , about 34 ng / mL , about 35 ng / mL , about 36 ng / mL , about 37 ng / mL , about 38 ng / mL , about 39 ng / mL or about 40 ng / mL. In such embodiments , the plasma trough concentration is achieVed about 7 days after administration of at least one dose of the p1ura1ity of doses of the oligonuc1eotide. In some preferred embodiments , the oligonuc1eotide used in the p1ura1ity of doses is SEQ ID NO : 2. [ 0242 ] Embodiments described herein a1so re1ate the use of a p1ura1ity of doses of an oligonuc1eotide targeted to apo1ipo - . US 2012 / 0115926 A1. protein B for the preparation of a medicament for reducing serum cho1estero1 1eVe1s. Administration such medicament to a subject , such as a human , resu1ts in a p1asma trough AUC for the oligonucleotide of from about 2 ug - hr / mL to about 20 ug - hr / mL , about 2 ug - br / mL to about 10 ug - br / mL , and about 4 ug - br / mL to about 6 ug - hr / mL. In other embodiments , the p1asma trough AUC is about 5 ug - br / mL. In sti11 other embodiments , the administration of medicament resu1ts in a p1asma trough AUC for the oligonuc1eotide of about 2 ug - br / mL , about 3 ug - hr / mL , about 4 ug - hr / mL , about 5 ug - hr / mL , about 6 ug ' hr / mL , about 7 ug - br / mL , about 8 ug - br / mL , about 9 ug - hr / mL , about 10 ug - hr / mL , about 11 ug - hr / mL , about 12 ug - br / mL , about 13 ug - br / mL , about 14 ug - br / mL , about 15 ug - hr / mL , about 16 ug - br / mL , about 17 ug - br / mL , about 18 ug - hr / mL , about 19 ug - br / mL or about 20 ug - hr / mL. In any of the foregoing embodiments , the p1asma trough AUC is achieVed from about 3 to about 33 days after administration of the medicament containing the oligonuc1eotide. In some preferred embodiments , the oligonucleotide used in the preparation of the medicament is SEQ ID NO : 2. [ 0243 ] In certain other embodiments , administration of a p1ura1ity of doses an oligonuc1eotide targeted to apo1ipoprotein B resu1ts in a p1asma trough concentration of about 5 ng / mL to about 40 ng / mL , Whereas in other embodiments the p1asma trough concentration is about 5 ng / mL to about 20 ng / mL. In sti11 other embodiments the p1asma trough concentration is about 5 ng / mL , about 6 ng / mL , about 7 ng / mL , about 8 ng / mL , about 9 ng / mL , about 10 ng / mL , about 11 ng / mL , about 12 ng / mL , about 13 ng / mL , about 14 ng / mL , about 15 ng / mL , about 16 ng / mL , 17 ng / mL , about 18 ng / mL , about 19 ng / mL , about 20 ng / mL , about 21 ng / mL , about 22 ng / mL , about 23 ng / mL , about 24 ng / mL , about 25 ng / mL , about 26 ng / mL , about 27 ng / mL , about 28 ng / mL , 29 ng / mL , about 30 ng / mL , about 31 ng / mL , about 32 ng / mL , about 33 ng / mL , about 34 ng / mL , about 35 ng / mL , about 36 ng / mL , about 37 ng / mL , about 38 ng / mL , about 39 ng / mL or about 40 ng / mL. In such embodiments , the p1asma trough concentration is achieVed about 7 days after administration of the medicament containing the oligonuc1eotide. In some preferred embodiments , the oligonucleotide used in the preparation of the medicament is SEQ ID NO : 2. [ 0244 ] Sti11 other embodiments of the present inVention re1ate to the use of the oligonuc1eotide of SEQ ID NO : 2 for the preparation of a medicament for reducing serum LDLcho1estero1 , Wherein administration of the medicament is suf - ﬁcient to achieVe one or a combination of the folloWing pharmacokinetic properties : a p1asma trough AUC of at 1east about 2 ug - br / mL , a p1asma trough concentration of at 1east about 5 ng / mL or an estimated 1iVer concentration of at 1east about 10 ug / g of 1iVer. [ 0245 ] Additional embodiments described herein relate to the use of an oligonucleotide comprising SEQ ID NO : 2 for the preparation of a medicament for reducing serum LDLcho1estero1 , Wherein the medicament is administered during a 10ading period and a maintenance period. For examp1e , in the 10ading period , the medicament can be administered at about 1 dose per day for up to about 10 days. The medicament may be administered either intraVenous1y or subcutaneous1y. In some embodiments , the maintenance period comprises administering the medicament at least once about eVery 3 months. HoWeVer , during the maintenance , the medicament may be administered more frequently. For examp1e , the medicament can be administered once about eVery 1 month , once about eVery tWo Weeks or once about eVery Week. Mainte - . May 10 , 2012. nance doses of the medicament may be administered intraVenous1y or subcutaneous1y. In some embodiments the 10ading doses and / or the maintenance doses of the medicament are administered at a rate of about 0.1 mg / kg / day to about 5 mg / kg / day. In certain embodiments , administration occurs at the rate of from about 0.1 mg / kg / day to about 1.2 mg / kg / day. In other embodiments , the medicament is administered in a dose from about 50 mg to about 6OO mg per Week. [ 0246 ] In any of the foregoing embodiments , the oligonuc1eotide comprising SEQ ID NO : 2 can be ISIS 301012. ISIS 301012 is targeted to human apo1ipoprotein B mRNA , and is a chimeric oligonuc1eotide ( “gapmer” ) 20 nuc1eotides in 1ength , composed of a centra1 “gap” region consisting of ten 2 ' - deoxynucleotides , Which is ﬁanked on both sides ( 5 ' and 3 ' directions ) by ﬁVe - nuc1eotide “Wings”. The Wings are composed of 2 ' - O - methoxyethy1 ( 2 ' - MOE ) nuc1eotides. The internuc1eoside ( backbone ) 1inkages are phosphorothioate ( P : S ) throughout the oligonuc1eotide. A11 cytidine residues are 5 - methy1cytidines. ISIS 301012 is synthesized using methods described in US patent application Ser. No. 10 / 712 , 795 , Which is incorporated herein by reference in its entirety. [ 0247 ] Oligonuc1eotides. [ 0248 ] In the context of this inVention , the term “o1igonuc1eotide” refers to an oligomer or po1ymer of ribonuc1eic acid ( RNA ) or deoxyribonuc1eic acid ( DNA ) or mimetics thereof. Thus , this term inc1udes oligonuc1eotides composed of natura1ly - occurring nuc1eobases , sugars and coValent internuc1eoside ( backbone ) 1inkages ( RNA and DNA ) as We11 as oligonuc1eotides haVing non - natura11y - occurring portions Which ﬁinction similar1y ( oligonucleotide mimetics ) . Oligonuc1eotide mimetics are often preferred oVer natiVe forms because of desirab1e properties such as , for examp1e , enhanced ce11u1ar uptake , enhanced afﬁnity for nuc1eic acid target and increased stabi1ity in the presence of nuc1eases. As used herein , the term “modiﬁcation” inc1udes substitution and / or any change from a starting or natural oligonuc1eotide. [ 0249 ] As is knoWn in the art , a nuc1eoside is a base - sugar combination. The base portion of the nuc1eoside is norma11y a heterocyc1ic base. The tWo most common classes of such heterocyc1ic bases are the purines and the pyrimidines. Nucleotides are nucleo sides that ﬁ1rther include a phosphate group coVa1ent1y 1inked to the sugar portion of the nuc1eoside. For those nuc1eosides that inc1ude a pentofurano sy1 sugar , the phosphate group can be 1inked to the 2 ' , 3 ' or 5 ' hydroxy1 moiety of the sugar. In forming oligonuc1eotides , the phosphate groups coValently link adjacent nucleosides to one another to form a linear po1ymeric compound. Within the oligonuc1eotide structure , the phosphate groups are common1y referred to as forming the internuc1eoside backbone of the oligonuc1eotide. The norma1 1inkage or backbone of RNA and DNA is a 3 ' to 5 ' phosphodiester linkage. [ 0250 ] Oligonucleotides useﬁil in this inVention include oligonuc1eotides containing modiﬁed backbones or nonnatura1 internuc1eoside 1inkages. As used herein , an “o1igonuc1eotide mimetic” or “mimetic” refers to any compound of the inVention Which is modiﬁed from the natura11y occurring RNA or DNA nucleic acids. [ 0251 ] As deﬁned herein , oligonuc1eotides haVing modi - ﬁed backbones inc1ude those that retain a phosphorus atom in the backbone and those that do not haVe a phosphorus atom in the backbone. For the purposes of this speciﬁcation , and as sometimes referenced in the art , modiﬁed oligonuc1eotides that do not haVe a phosphorus atom in their internuc1eoside backbone can a1so be considered to be oligonuc1eosides. US 2012 / 0115926 A1. Modiﬁed oligonucleotide backbones include , for example , phosphorothioates. Phosphorothioate 1inkers proVide nuc1ease stabi1ity as We11 as p1asma protein binding characteristics to the oligonuc1eotide. Nuclease stability is useful for increasing the in ViVo 1ifetime of oligonuc1eotides , While p1asma protein binding decreases the rate of ﬁrst pass c1earance of oligonuc1eotide Via rena1 excretion. [ 0252 ] In other oligonuc1eotide mimetics , the sugar is modiﬁed or substituted With noVe1 groups. The base units are maintained for hybridization With an appropriate nuc1eic acid target compound. Sugar modiﬁcations may impart nuc1ease stability , binding aﬂinity or some other beneﬁcia1biologica1 property to the oligonuc1eotide. One such sugar modiﬁcation inc1udes 2 ' - methoxyethoxy ( 2 ' - O%IH2CH2OCH3 , a1so knoWn as 2 ' - O - ( 2 - methoxyethy1 ) or 2 ' - MOE ) ( Martin et a1. , He / v. Chim. Acta , 1995 , 78 , 486 - 504 ) i. e. , an a1koxya1koxy group. [ 0253 ] Oligonuc1eotide mimetics may a1so inc1ude nuc1eobase ( often referred to in the art simp1y as “base” ) modiﬁcations or substitutions. As used herein , “unmodiﬁed” or “natural” nuc1eobases inc1ude the purine bases adenine ( A ) and guanine ( G ) , and the pyrimidine bases thymine ( T ) , cytosine ( C ) and uraci1 ( U ) . Modiﬁed nuc1eobases inc1ude other synthetic and natura1 nuc1eobases such as 5 - methy1cytosine ( 5 - me - C ) . Certain nuc1eobase substitutions , inc1uding 5 - methy1cytosinse substitutions , are particu1ar1y usefu1 for increasing the binding afﬁnity of the oligonuc1eotides of the inVention. For examp1e , 5 - methy1cytosine substitutions haVe been shoWn to increase nuc1eic acid dup1ex stabi1ity by 0.6 - 1.20 C. ( SanghVi , Y. S. , Crooke , S. T. and Lebleu , B. , eds. , Antisense Research and Applicati0ns , CRC Press , Boca Raton , 1993 , pp. 276 - 278 ) and are present1y preferred base substitutions , eVen more particu1ar1y When combined With 2 ' - O - methoxyethy1 sugar modiﬁcations. [ 0254 ] It is not necessary for a1l positions in a giVen oligonuc1eotide or oligonuc1eotide mimetic to be uniformly modi - ﬁed , and in fact one or more of the aforementioned modiﬁ - cations may be incorporated in a sing1e oligonuc1eotide or eVen at a single nucleoside Within an oligonucleotide. [ 0255 ] Embodiments of the inVention a1so inc1ude oligonuc1eotides or mimetics Which are chimeric compounds. “Chimeric” oligonucleotides or “chimeras , ” in the context of this inVention , are compounds , particu1ar1y oligonuc1eotides , Which contain at 1east tWo chemica11y distinct regions , each made up of at 1east one monomer unit , i. e. , a nuc1eotide in the case of an oligonuc1eotide. These oligonucleotides typical1y contain at least one chemically distinct region Wherein the oligonuc1eotide is modiﬁed so as to confer upon the oligonuc1eotide increased resistance to nuc1ease degradation , increased ce11u1ar uptake , and / or increased binding afﬁnity for the target nucleic acid. An additional chemically distinct region of the oligonucleotide may serVe as a substrate for enzymes capab1e of c1eaVing RNA : DNA or RNA : DNA hybrids. By Way of examp1e , RNase H is a ce11u1ar endonu - c1ease Which cleaVes the RNA strand of an RNA : DNA dup1ex. Modiﬁcations Which actiVate , recruit or trigger RNase H and result in cleaVage of the RNA target thereby great1y enhance the efﬁciency of the oligonuc1eotide for inhibition of gene expression. Consequent1y , comparab1e resu1ts can often be obtained With shorter oligonucleotides When cbimeric oligonucleotides incorporating modiﬁcations Which faci1itate dup1ex c1eaVage are used , compared to phosphorothioate deoxyo1igonuc1eotides hybridizing to the same target region. C1eaVage of the RNA target can be routine1y. May 10 , 2012. detected by gel electrophoresis and , if necessary , associated nuc1eic acid hybridization techniques knoWn in the art. [ 0256 ] Chimeric oligonuc1eotides of the inVention may be formed as composite structures of tWo or more oligonucleotides , modiﬁed oligonuc1eotides , oligonuc1eosides and / or oligonuc1eotide mimetics as described aboVe. Chimeric oligonuc1eotides can be of seVera1 different types. These inc1ude a ﬁrst type Wherein the “gap” segment of 1inked nuc1eosides is positioned betWeen 5 ' and 3 ' “Wing” segments of linked nuc1eosides and a second “open end” type Wherein the “gap” segment is 10cated at either the 3 ' or the 5 ' terminus of the cbimeric oligonuc1eotide. Compounds of the ﬁrst type are a1so knoWn in the art as “gapmers” or gapped oligonuc1e - otides. Compounds of the second type are a1so knoWn in the art as “hemimers” or “Wingmers”. Such compounds haVe a1so been referred to in the art as hybrids. [ 0257 ] In a gapmer that is 20 nuc1eotides in 1ength , a gap or Wing canbe 1 , 2 , 3 , 4 , 5 , 6 , 7 , 8 , 9 , 10 , 11 , 12 , 13 , 14 , 15 , 16 , 17 or 18 nuc1eotides in 1ength. In one embodiment , a 20 - nucleotide gapmer is comprised of a gap 8 nucleotides in 1ength , ﬂanked on both the 5 ' and 3 ' sides by Wings 6 nuc1e - otides in 1ength. In another embodiment , a 20 - nuc1eotide gapmer is comprised of a gap 10 nuc1eotides in 1ength , ﬂanked on both the 5 ' and 3 ' sides by Wings 5 nuc1eotides in 1ength. In another embodiment , a 20 - nuc1eotide gapmer is comprised of a gap 12 nuc1eotides in 1ength ﬂanked on both the 5 ' and 3 ' sides by Wings 4 nuc1eotides in 1ength. In a further embodiment , a 20 - nuc1eotide gapmer is comprised of a gap 14 nuc1eotides in 1ength ﬂanked on both the 5 ' and 3 ' sides by Wings 3 nucleotides in 1ength. In another embodiment , a 20 - nuc1eotide gapmer is comprised of a gap 16 nuc1eotides in 1ength ﬂanked on both the 5 ' and 3 ' sides by Wings 2 nuc1e - otides in 1ength. In a further embodiment , a 20 - nuc1eotide gapmer is comprised of a gap 18 nuc1eotides in 1ength ﬂanked on both the 5 ' and 3 ' ends by Wings 1 nucleotide in length. A1ternatiVe1y , the Wings are of different 1engths , for examp1e , a 20 - nuc1eotide gapmer may be comprised of a gap 10 nuc1e - otides in 1ength , ﬂanked by a 6 - nuc1eotide Wing on one side ( 5 ' or 3 ' ) and a 4 - nuc1eotide Wing on the other side ( 5 ' or 3 ' ) . [ 0258 ] In a hemimer , an “open end” cbimeric oligonuc1e - otide haVing tWo chemically distinct regions , a ﬁrst chemi - ca11y distinct region , or the gap segment , in a compound 2O nuc1eotides in 1ength can be 10cated at the 5 ' terminus of the oligonuc1eotide and can be 1 , 2 , 3 , 4 , 5 , 6 , 7 , 8 , 9 , 10 , 11 , 12 , 13 , 14 , 15 , 16 , 17 , 18 or 19 nucleotides in 1ength. Furthermore , a second chemically distinct region in a compound 2O nuc1eotides in 1ength can be 10cated at the 3 ' terminus of the oligonuc1eotide and can be 1 , 2 , 3 , 4 , 5 , 6 , 7 , 8 , 9 , 10 , 11 , 12 , 13 , 14 , 15 , 16 , 17 , 18 or 19 nuc1eotides in 1ength. For examp1e , a 20 - nucleotide hemimer can haVe a ﬁrst chemical1y distinct region , or a gap segment , of 10 nucleotides at the 5 ' end and a second chemica11y distinct region of 10 nuc1eotides at the 3 ' end. [ 0259 ] RepresentatiVe United States patents that teach the preparation of such hybrid structures inc1ude , but are not 1imited to , US Pat. Nos. 5 , 013 , 830 ; 5 , 149 , 797 ; 5 , 220 , 007 ; 5 , 256 , 775 ; 5 , 366 , 878 ; 5 , 403 , 711 ; 5 , 491 , 133 ; 5 , 565 , 350 ; 5 , 623 , 065 ; 5 , 652 , 355 ; 5 , 652 , 356 ; and 5 , 700 , 922 , each of Which is herein incorporated by reference in its entirety. [ 0260 ] The oligonucleotides in accordance With this inVention comprise from about 14 to about 30 nuc1eobases ( i. e. from about 14 to about 30 linked nucleosides ) . One haVing ordinary ski11 in the art Wi11 appreciate that this embodies oligonuc1eotides haVing 14 , 15 , 16 , 17 , 18 , 19 , 20 , 21 , 22 , 23 , . US 2012 / 0115926 A1. 24 , 25 , 26 , 27 , 28 , 29 or 30 nucleobases. Embodiments of the inVention inc1ude oligonuc1eotides haVing 1 , 2 or 3 nuc1eobases added to or remoVed from either terminus of an oligonuc1eotide about 14 to 30 nucleobases in 1ength , Wherein the oligonuc1eotides do not 10se their therapeutic effectiVeness. [ 0261 ] In a ﬁirther embodiment , the oligonucleotides in accordance With this inVention comprise from about 2O to about 3O nuc1eobases. One haVing ordinary ski11 in the art Wi11 appreciate that this embodies oligonucleotides haVing 20 , 21 , 22 , 23 , 24 , 25 , 26 , 27 , 28 , 29 or 30 nuc1eobases. Embodiments of the inVention inc1ude oligonuc1eotides haVing 1 , 2 or 3 nuc1eobases added to or remoVed from either terminus of an oligonuc1eotide about 20 to 3O nuc1eobases in 1ength , Wherein the oligonucleotides do not 10se their therapeutic effectiVeness. [ 0262 ] The oligonuc1eotides used in accordance With this inVention may be conVenient1y and routine1y made through the We11 - knoWn technique of so1id phase synthesis. Equipment for such synthesis is so1d by seVera1 Vendors inc1uding , for examp1e , App1ied Biosystems ( Foster City , Ca1if. ) . Any other means for such synthesis knoWn in the art may additiona11y or a1ternatiVe1y be emp1oyed. It is We11 knoWn to use simi1ar techniques to prepare oligonuc1eotides such as the phosphorothioates and a1ky1ated deriVatiVes. [ 0263 ] The oligonucleotides described herein , particu1ar1y ISIS 301012 and ISIS 301012 re1ated oligonuc1eotides , encompass any pharmaceutica11y acceptab1e sa1ts , esters , or sa1ts of such esters , or any other compound Wbich , upon administration to a human , is capab1e of proViding ( direct1y or indirectly ) the biological1y actiVe metabolite or residue of the administered oligonuc1eotide. According1y , for example , the disc1osure is a1so draWn to prodrugs and pharmaceutica11y acceptab1e sa1ts of the oligonuc1eotides of the inVention , pharmaceutica11y acceptable sa1ts of such prodrugs , and other bioequiVa1ents. As used herein , “bioequiVa1ence” means the absence of a signiﬁcant difference in the rate and extent to Which the actiVe ingredient in pharmaceutica1 equiVa1ents becomes aVai1ab1e at the site of drug action When administered at the same mo1ar dose under simi1ar conditions. As used herein , “ISIS 301012 re1ated oligonuc1eotides” inc1ude oligonucleotides haVing the sequence of ISIS 301012 Which are truncated in 1 or 2 base increments from the 5 ' and / or 3 ' end. [ 0264 ] The term “prodrug” indicates a therapeutic agent that is prepared in an inactiVe form that is conVerted to an actiVe form ( i. e. , drug ) Within the body , or ce11s thereof , by the action of endogenous enzymes or other chemica1s and / or conditions. In particular , prodrug Versions of the oligonucleotides of the inVention are prepared as SATE [ ( S - acetyl - 2 - thioethy1 ) phosphate ] deriVatiVes according to the methods disc1osed in WO 93 / 24510 to Gosse1in et a1. , pub1ished Dec. 9 , 1993 or in WO 94 / 26764 and US Pat. No. 5 , 770 , 713 to Imbach et al. The term “pharmaceutica11y acceptable sa1ts” refers to physiologically and pharmaceutically acceptable sa1ts of the oligonuc1eotides of the inVention : i. e. , sa1ts that retain the desired bio1ogica1 actiVity of the parent compound and do not impart undesired toxico1ogica1 effects thereto. [ 0265 ] For oligonuc1eotides , preferred examp1es of pharmaceutica11y acceptab1e sa1ts inc1ude but are not 1imited to ( a ) sa1ts formed With cations such as sodium , potassium , ammonium , magnesium , calcium , po1yamines such as spermine and spermidine , etc. ; ( b ) acid addition sa1ts formed With inorganic acids , for examp1e hydroch1oric acid , hydrobromic acid , su1furic acid , phosphoric acid , nitric acid and the 1ike ; . May 10 , 2012. ( c ) salts formed With organic acids such as , for example , capric acid , acetic acid , oxa1ic acid , tartaric acid , succinic acid , ma1eic acid , fumaric acid , g1uconic acid , citric acid , ma1ic acid , ascorbic acid , benzoic acid , tannic acid , pa1mitic acid , a1ginic acid , po1yg1utamic acid , naphtha1enesu1fonic acid , methanesu1fonic acid , p - to1uenesu1fonic acid , naphtha - 1enedisu1fonic acid , po1yga1acturonic acid , and the 1ike ; and ( d ) sa1ts formed from e1ementa1 anions such as ch1orine , bromine , and iodine. C1inica1 Indications. [ 0266 ] The present inVention embodies methods of treating , preVenting or ameliorating conditions associated With e1eVated serum LDL - cho1estero1 , comprising administering to a human subject a therapeutica11y or prophy1atica11y effectiVe amount of an oligonuc1eotide that inhibits the expression of apolipoprotein B. One such compound is ISIS 301012. Such conditions inc1ude homozygous fami1ia1 hypercho1estero1emia , heterozygous fami1ia1hypercho1estero1emia , nonfami1ia1hypercho1estero1emia , fami1ia1 combined hypercho - 1estero1emia , and fami1ia1 defectiVe apolipoprotein B. As used herein , the term “therapeutica1ly effectiVe amount” means a dose that , When administered to a human , 10Wers one or more 1ipid parameters inc1uding serum LDL - cho1estero1 , serum apo1ipoprotein B , serum VLDL - cho1estero1 , serum tota1 cho - 1estero1 , serum 1ipoprotein ( a ) , serum trig1ycerides , serum tota1 cho1estero1 : HDL ratio , or serum LDL : HDL ratio. As used herein , the term “prophy1actica11y effectiVe amount” means a dose that , When administered to a human , preVents an e1eVation in one or more 1ipid parameters inc1uding serum LDL - cholestero1 , serum apo1ipoprotein B , serum VLDLcho1estero1 , serum tota1 cho1estero1 , serum 1ipoprotein ( a ) , . serum trig1ycerides , serum tota1 cholestero1 : HDL ratio , or serum LDL : HDL ratio. [ 0267 ] In a further embodiment , the methods of the present inVention encompass methods for treating , preVenting or ameliorating conditions associated With eleVated serum LDL - cho1estero1 in a human subject preVious1y unsuccess - fu11y treated by 1ipid - 1oWering agents. In one embodiment , the human subject Was preVious1y unsucces sfu11y treated by a statin. It understood that such subjects inc1ude homozygous familial hypercholesterolemic subjects , Who do not respond to a statin or exhibit a 1imited response to a statin , oWing to insufﬁcient LDL - receptor actiVity. Thus , homozygous fami1 - ia1 hypercho1estero1emic s , as We11 as the heterozygous hypercho1estero1emics , often do not achieVe clinical1y desirab1e lipid leVels of , for example , serum total cholesterol or serum LDL - cho1estero1. One haVing ski11 in the art Wi11 further understand that subjects preVious1y unsuccessfu11y treated by 1ipid - 1oWering therapeutic agents inc1ude those Who are into1 - erant to certain lipid - 1oWering agents. For example , those Who are experience seVere side effects folloWing treatment With a statin , e. g. rhabdomyo1ysis , are into1erant to a statin and consequent1y do not achieVe c1inica11y desirab1e 1ipid 1eVe1s With statin therapy. Additiona1 subjects inc1ude those Who experience adVerse effects fo11oWing administration of current lipid - loWering agents , for example , myopathy , fatigue or centra1 nerVous system effects ( e. g. insomnia ) fo11oWing treatment With a statin , and 1ikeWise do not achieVe c1inica11y desirab1e 1ipid leVels With statin therapy. In one embodiment , human subjects preVious1y unsuccessful1y treated by a statin are giVen doses of ISIS 301012 that proVide therapeutic ben - eﬁts , such as 10Wered serum apo1ipoprotein B , 10Wered serum LDL - cho1estero1 or 10Wered serum tota1 cho1estero1. US 2012 / 0115926 A1. [ 0268 ] As used herein , “preViously unsuccessfully treated by a statin” is understood to inc1ude human subjects Who is not achieVing c1inica11y desirab1e 1ipid 1eVe1s ( e. g. , serum LDL - cholestero1 , serum VLDL - cholestero1 , serum total cho - 1esterol ) due to one or more of the fo11oWing : insufﬁcient LDL - receptor actiVity ; into1erance to a statin ; adVerse effects fo11oWing treatment With a statin ; or poor adherence to c1ini - ca11y recommended statin therapy. [ 0269 ] As used herein , a human subject Who has “insufﬁ - cient LDL - receptor actiVity” is understood to inc1ude a subject Who meets one or more of the fo1loWing criteria : genetic testing conﬁrming 2 mutated LDL - receptor genes ; document history of untreated serum LDL - cho1estero1 greater than 500 mg / dL ; tendinous and / or cutaneous xanthoma prior to age 10 years ; or , both parents haVe documented e1eVated serum LDL - cho1estero1 prior to 1ipid - 1oWering therapy consistent With heterozygous fami1ia1 hypercho1estero1emia. In some embodiments , the subject has been diagnosed With homozygous or heterozygous fami1ial hypercholestero1emia. [ 0270 ] With respect to some aspects , the present inVention embodies methods for treating , preVenting or ameliorating apo1ipoprotein B - re1ated disorders. As used herein , “apo1ipoprotein B - re1ated disorder” indicates conditions or diseases that are associated With e1eVated serum apo1ipoprotein B , and include fami1ial hypercho1esterolemia , familial defectiVe apoB - 100 , fami1ia1 combined hypercho1estero1emia , nonfa - mi1ia1 ( or po1ygenic ) hypercho1estero1emia , hypertrig1yceridemia , metabo1ic syndrome , and Type 2 diabetes. [ 0271 ] With respect to some aspects , the present inVention embodies methods for treating human subjects exhibiting e1eVated1eVe1s of sma11 LDL partic1es , such subjects haVing more LDL - cho1estero1 carried in sma11 LDL partic1es as re1a - tiVe to 1arge LDL partic1es , comprising administering to a subject a therapeutica11y or prophy1atica11y effectiVe amount of an oligonuc1eotide that inhibits the expression of apo1ipoprotein B. One such compound is ISIS 301012. The tota1 1eVe1s of LDL - cho1estero1 in such subjects may or may not be e1eVated. [ 0272 ] Some embodiments of the present inVention relates to a method of using an oligonuc1eotide comprising the nuc1eobase sequence “GCCTCAGTCTGCTTCGCACC” ( SEQ ID NO : 2 ) in a treatment for reducing serum LDLcho1esterol in a human subject. The method comprises informing the human subject that the administration of said oligonuc1eotide results in a p1asma trough AUC of at 1east about 2 ug - br / mL , resu1ts in a p1asma trough concentration of at 1east about 5 ng / mL or resu1ts in an estimated liVer concentration of said oligonucleotide of at 1east about 10 ug / g. In some embodiments , the oligonucleotide comprises ISIS 301012. [ 0273 ] As used herein , “informing” refers to proViding information relating to the pharmacologic , pharmacokinetic and / or pharmacodynamic actiVities of an oligonuc1eotide. The act of informing can be performed , for examp1e , by proViding a Verba1 description or by proViding printed matter. In instances Where printed matter is used , the printed matter may proVide , for example , information relating to effects of the oligonuc1eotide on serum LDL - cho1estero1 , serum VLDL - cho1estero1 , serum tota1 cho1estero1 , serum sma11 LDL partic1es , serum total cho1esterol : HDL ratio or serum LDL : HDL ratio. The printed matter may ﬁirther proVide information re1ating to the pharmacokinetic proﬁ1e of an oligonucleotide , such as , for examp1e , p1asma trough AUC , p1asma trough concentrations , e1imination ha1f - 1ife , estimated tissue. May 10 , 2012. concentrations , or me. In one embodiment , the printed matter proVides information re1ating to the pharmacodynamic and pharmacokinetic effects of ISIS 301012. As used herein , “informing” does not require any more than the mere act of proViding the information. It is not required that intended recipients of the information accept , acknoW1edge receipt of or understand the information. [ 0274 ] As used herein , “1abe1” refers to printed matter that is associated With a container for ho1ding the oligonuc1eotides and / or pharmaceutica1 compositions that include the oligonuc1eotides described herein. By Way of non - 1imiting examp1e , the 1abe1 and container can be p1aced together in a box or shrink Wrap. A1ternatiVe1y , the 1abe1 can be attached directly to the container. In other embodiments , the labe1 need not be physically associated With or in physical proximity With the container , hoWeVer , the 1abe1 shou1d be proVided at the same time or at a time reasonab1y near to the time of proViding the container. Pharmaceutica1 Compositions. [ 0275 ] Pharmaceutica1 compositions comprising oligonuc1eotides ( e. g. the pharmaceutica1 composition comprising ISIS 301012 or ISIS 301012 re1ated olignuc1eotides ) , may be administered in a number of Ways , including parenteral1y. Parentera1 administration is understood to inc1ude intraVenous , intraarteria1 , subcutaneous , intraperitonea1 or intramus - cu1ar injection or infusion. In one aspect , administration of oligonuc1eotides such as ISIS 301012 to a human subject is performed by a hea1th professional In another aspect , administration of oligonuc1eotides is performed by a trained designee , such as , for examp1e , the subject. In one aspect , an oligonuc1eotide is administered subcutaneous1y as a sing1e injection into the abdomen or thigh. A1ternatiVe1y , the dose is diVided and administered as 2 or 3 non - contiguous injections into the abdomen or thigh. [ 0276 ] Compositions and formulations for parenteral administration may inc1ude steri1e aqueous so1utions , Which may a1so contain buffers , di1uents and other suitab1e additiVes such as , but not 1imited to , penetration enhancers , carrier compounds and other pharmaceutica11y acceptab1e carriers or excipients. Liquid pharmaceutical compositions of oligonuc1eotide can be prepared by combining the oligonuc1eotide With a suitab1e Vehic1e , for examp1e steri1e pyrogen free Water , or sa1ine so1ution. Steri1e pyrogen free Water is understood to inc1ude steri1e Water for injection. [ 0277 ] The pharmaceutica1 formu1ations of the present inVention , Wbich may conVenient1y be presented in unit dosage form , may be prepared according to conVentional techniques We1l knoWn in the pharmaceutical industry. Such techniques include the step of bringing into association the actiVe ingredients With the pharmaceutica1 carrier ( s ) or excipient ( s ) . In genera1 the formu1ations are prepared by bringing into association the actiVe ingredients With 1iquid carriers or ﬁne1y diVided solid carriers or both , and then , if necessary , shaping the product. [ 0278 ] The pharmaceutica1 compositions of the present inVention may also be formulated as suspensions in aqueous , non - aqueous or mixed media. The pharmaceutica1 compositions may inc1ude physio1ogica11y compatib1e buffers , inc1uding , for examp1e , phosphate - buffered sa1ine ( PBS ) . Aqueous suspensions may further contain substances Which increase the Viscosity of the suspension inc1uding , for examp1e , sodium carboxymethy1ce11u1ose , sorbito1 and / or dextran. The suspension may a1so contain stabi1izers. US 2012 / 0115926 A1. [ 0279 ] A “pharmaceutical carrier” or “excipient” is a pharmaceutica11y acceptable so1Vent , suspending agent or any other pharmaco1ogica11y inert Vehic1e for de1iVering one or more oligonuc1eotides to an animal The excipient may be liquid or solid and is selected , With the planned manner of administration in mind , so as to proVide for the desired bu1k , consistency , etc. , When combined With an oligonuc1eotide and any other components of a giVen pharmaceutica1 composition. Suitab1e pharmaceutica11y acceptable carriers inc1ude , but are not limited to , Water , sa1t so1utions , a1cohols , po1yeth - y1ene g1yco1s , ge1atin , 1actose , amy1ose , magnesium stearate , ta1c , si1icic acid , Viscous parafﬁn , hydroxymethy1ce11u1ose , po1yViny1pyrrolidone and the 1ike. [ 0280 ] The pharmaceutical compositions of the inVention encompass seVera1 actiVe drug products. In one aspect , an actiVe drug product is a steri1e oligonuc1eotide so1ution in Water for injection that may be administered as a subcutaneous injection or as an intraVenous infusion after dilution into sa1ine. The concentration of the actiVe drug ingredient is 250 mg / mL. This formu1ation comprises oligonuc1eotide in Water for injection adjusted to pH 7.0 - 9.0 With acid or base during preparation. The oligonuc1eotide in Water is packaged in a Type I , c1ear g1ass Via1 ( ammonium su1fate treated ) , stoppered With a TEFLON® - coated , bromobuty1 rubber c1osure and sea1ed With an a1uminum FLIP - OFF® oVersea1. In one embodiment , the steri1e oligonuc1eotide in Water for injection so1ution comprises ISIS 301012. [ 0281 ] In a further aspect , an actiVe drug product is steri1e 1yophi1ized oligonuc1eotide that is reconstituted With a suit - ab1e di1uent , e. g. , steri1e Water for injection. The reconstituted product is administered as a subcutaneous injection or as an intraVenous infusion after di1ution into sa1ine. The 1yophilized drug product consists of the oligonucleotide Which has been prepared in Water for injection , adjusted to pH 7.0 - 9.0 With acid or base during preparation , and then 1yophi1ized. The 1yophi1ized drug product may be 50 - 125 mg of the oligonucleotide. It is understood that this encompasses 50 , 75 , 100 and 125 mg of 1yophi1ized oligonuc1eotide. The 1yophi1ized drug product may be packaged in a 2 mL Type I , c1ear g1ass Via1 ( ammonium su1fate - treated ) , stoppered With a bromobuty1 rubber c1osure and sea1ed With an aluminum FLIPOFF® oVersea1. In one embodiment , the 1yophi1ized drug product comprises ISIS 301OI2. [ 0282 ] The compositions of the present inVention may additiona11y contain other adjunct components conVentionally found in pharmaceutical compositions , at their art - estab - 1ished usage 1eVe1s. Thus , for example , the compositions may contain additiona1 , compatib1e , pharmaceutica11y - actiVe materia1s such as , for examp1e , antipruritics , astringents , 10cal anesthetics or anti - inﬂammatory agents , or may contain additional materials useﬁil in physically formulating Various dosage forms of the compositions of the present inVention , such as dyes , ﬂaVoring agents , preserVatiVes , antioxidants , opaciﬁers , thickening agents and stabi1izers. HoWeVer , such materia1s , When added , should not undu1y interfere With the biological actiVities of the components of the compositions of the present inVention. The formu1ations can be steri1ized and , if desired , mixed With auxi1iary agents , e. g. , 1ubricants , preserVatiVes , stabi1izers , Wetting agents , emu1siﬁers , sa1ts for inﬂuencing osmotic pressure , buffers , co1orings , ﬂaVorings and / or aromatic sub stances and the 1ike Which do not de1eterious1y interact With the oligonuc1eotide ( s ) of the formu1a - tion. Dosing. [ 0283 ] As used herein , a “dose” refers to the amount of drug giVen to a human subject in one day ; e. g. by intraVenous or. May 10 , 2012. subcutaneous administration , in a single administration or diVided into mu1tip1e administrations. A preferred dose range for a typica1 7O kg subject is about 25 - 8OO mg. More preferred ranges include about 25 - 600 mg , about 25 - 400 mg , about 25 - 200 mg , about 50 - 600 mg , about 50 - 400 mg , or about 50 - 20O mg in a day. Additiona1 ranges inc1ude about 0.1 - 5 mg / kg , about O.5 - 3 mg / kg , about 0.5 - 8 mg / kg , about O.25 - 3 mg / kg , or about 0.25 - 2 mg / kg. As used herein , the amount of drug giVen as a dose ranges from 50 - 600 mg per Week. It is understood that doses of 50 , 100 , 150 , 200 , 250 , 300 , 350 , 400 , 450 , 500 , 550 and 600 mg per Week a11 fa11 Within the range of 50 - 600 mg / Week. As used herein , the terms “patient” and “subject” are interchangeab1e. [ 0284 ] Dosing regimens may inc1ude doses during a 10ading period and / or a maintenance period. During the loading period , Which usually or most often occurs at the initiation of therapy and Which 1asts approximate1y one Week ( a1though it cou1d be more or 1ess , e. g. 3 , 4 , 5 , 6 , 7 , 8 , 9 or 10 days ) , a sing1e administration may be giVen or mu1tip1e administrations may be giVen eVery day , eVery 2 days , eVery 3 days , eVery 4 days , eVery 5 days , eVery 6 days , or eVery Week. A1ternatiVe1y , the 10ading period may 1ast about 28 days , a1though it cou1d be moreor1ess , e. g. , 11 , 12 , 13 , 14 , 15 , 16 , 17 , 18 , 19 , 20 , 21 , 22 , 23 , 24 , 25 , 26 , 27 , 28 , 29 , 30 , 3l , 32 , 33 , 34 or 35 days , and a single administration may be giVen eVery day , eVery 2 days , eVery 3 days , eVery 4 days , eVery 5 days , eVery 6 days , or eVery 7 days. During a maintenance period , Which fo11oWs the 10ading period and may 1ast for a number of years or the duration of the 1ifetime of the subject , doses may be giVen at a frequency ranging from eVery day to eVery 3 months , Which is understood to inc1ude eVery day , eVery 2 days , eVery 3 days , eVery 4 days , eVery 5 days , eVery 6 days , eVery Week , eVery 2 Weeks , eVery 3 Weeks , eVery 4 Weeks , eVery month , eVery 2 months , or eVery 3 months. Maintenance period doses are typically , but not alWays , loWer than loading period doses , and may range from 10 - 5O mg / day. LoWered 1ipid1eVe1s , such as serum apo1ipoprotein B , serum tota1 cho1estero1 , serum LDL - cho1estero1 , serum VLDL - cho1estero1 , serum 1ipoprotein ( a ) , serum LDL : HDL ratio and / or serum cho1estero1 : HDL ratio can be maintained for at least 2 , 3 , 4 , 5 , 6 , 7 or 8 Weeks ( or 1 , 2 , 3 , or 4 months ) after a dose of the drug. [ 0285 ] An a1ternatiVe dosing regimen may inc1ude doses administered during a maintenance period , Without a preceding 10ading period. Doses may be giVen at a frequency ranging from eVery day to eVery tbree months , Which is understood to include eVery day , eVery 2 days , eVery 3 days , eVery 4 days , eVery 5 days , eVery 6 days , eVery Week , eVery 2 Weeks , eVery 3 Weeks , eVery 4 Weeks , eVery month , eVery 2 months , or eVery 3 months. [ 0286 ] The term “bioaVai1abi1ity” refers to a measurement of that portion of an administered drug Which reaches the circulatory system ( e. g. blood , especially blood plasma ) When a particu1ar mode of administration is used to de1iVer the drug. For examp1e , When a subcutaneous mode of administration is used to introduce the drug into a human subject , the bioaVai1ability for that mode of administration may be compared to a different mode of administration ( e. g. an intraVenous mode of administration ) and extrapo1ations made to faci1itate determination of the proper therapy. In genera1 , bioaVai1ability can be assessed by measuring the area under the curVe ( AUC ) or the maximum serum or p1asma concentration ( Cmm ) of the unchanged form of a drug fo1loWing administration of the drug to a human subject. AUC is a determination of the Area Under the CurVe p1otting the serum. US 2012 / 0115926 A1. or plasma concentration of a drug along the ordinate H - axis ) against time along the abscissa OI - axis ) . Genera1ly , the AUC for a particu1ar drug can be ca1cu1ated using methods knoWn to those of ordinary skill in the art and as described in G. S. Banker , Modem Pharmaceutics , Drugs and the Pharmaceuti - ca1 Sciences , 4”“ Ed , ( May 2002 ) . In some embodiments , the area under a drugs b1ood p1asma concentration curVe ( AUCSc ) after subcutaneous administration may be diVided by the area under the drugs p1asma concentration curVe after intraVenous administration ( AUCw ) to proVide a dimension - 1ess quotient ( re1atiVe bioaVailability , RB ) that represents fraction of drug absorbed Via the subcutaneous route as compared to the intraVenous route. [ 0287 ] As used herein , “AUC” or “AUCO_O , , ” indicates the area under the concentration - time curVe from time 0 ( at or prior to oligonuc1eotide administration ) to inﬁnity. “AUCO_ 48” refers to the area under the concentration - time curVe from time 0 ( at or prior to oligonuc1eotide administration ) to 48 hours fo11oWing oligonuc1eotide administration. In one embodiment , the oligonuc1eotide is ISIS 301012. [ 0288 ] A trough measurement is determined at a time after do sing When drug concentrations in p1asma are in equi1ibrium With drug concentrations in tissue , and When drug concentrations are no 10nger affected by absorption or c1earance functions , such as distribution of an injected dose to Various tissues. For examp1e , in the case of oligonuc1eotides such as ISIS 301012 , trough ca1cu1ations are made at 1east 3 days fo11oWing administration of the oligonuc1eotide to a human subject. As used herein , “C , , , 0 , , gh” or “p1asma trough concentration” refers to a minimum p1asma concentration When p1asma oligonuc1eotide concentrations are in equi1ibrium With tissue oligonuc1eotide concentrations. As used herein , “AUC , , . O , , gh” or “p1asma trough AUC” indicates the area under the concentration - time curVe at a time When p1asma oligonuc1eotide concentrations are in equi1ibrium With tissue oligonuc1eotide concentrations. In one embodiment , the oligonuc1eotide is ISIS 301012. The ha1f - 1ife of a drug can be ca1cu1ated using methods knoWn to those of ordinary ski11 in the art. Oligonucleotide half - life is determined during the distribution phase or e1imination phase fo11oWing admini stration of the oligonuc1eotide. The apparent distribution ha1f - 1ife is ca1cu1ated using 10g - 1inear regression of oligonuc1eotide concentrations in p1asma during the distribution phase. By Way of example , distribution phase for an oligonucleotide may 1ast for up to 3 days fo11oWing administration of the oligonuc1eotide to a human subject. As used herein , “termina1 e1imination ha1f - 1ife” or “e1imination ha1f - 1ife” represents the time at Which approximate1y 50% of the administered oligonucleotide is cleared from tissues , and is calculated using 10g - 1inear regression of oligonuc1eotide concentrations in p1asma during the termina1 e1imination phase of administration. [ 0289 ] One haVing ordinary ski11 in the art Wi11 understand that for oligonucleotides , plasma AUC , Cmax , Cmugh , and related parameters are measured in the plasma fraction of b1ood , rather than in the serum fraction , as the p1asma fraction measurement reﬂects the more c1inica11y re1eVant amount of oligonuc1eotide bound to and carried by p1asma proteins. Oligonucleotide concentrations in p1asma may be determined by methods routine in the art , for example , by hybridizationbased ELISA. It is 1ikeWise understood that 1ipid parameters , inc1uding apo1ipoprotein B , LDL - cho1estero1 , tota1 cho1es - . May 10 , 2012. terol , VLDL - cholesterol , lipoprotein ( a ) , HDL - cholesterol , or. triglycerides , are measured in the serum or plasma fraction of b1ood. [ 0290 ] In general , bioaVailabi1ity correlates With therapeutic efﬁcacy When a compounds therapeutic efﬁcacy is re1ated to the b1ood ( or p1asma ) concentration achieVed , eVen if the drugs u1timate site of action is intracellu1ar ( Van Berge - HenegouWen et al. , Gastr0enter0 / . , 1977 , 73 , 300 ) . Therapeutic eﬂicacy of ISIS 301012 is determined by comparing the p1asma concentration of ISIS 301012 to , for example , reductions in serum LDL - cho1estero1. [ 0291 ] Organ bioaVai1abi1ity refers to the concentration of an oligonucleotide in an organ. Organ bioaVailability may be measured in human subjects by a number of means , such as by Who1e - body radiography. Organ bioaVai1abi1ity may be modiﬁed , e. g. enhanced , by one or more modiﬁcations to an oligonuc1eotide , by use of one or more carrier compounds or excipients , etc. as discussed in more detai1 herein. In genera1 , an increase in bioaVai1abi1ity Wi11 result in an increase in organ bioaVai1abi1ity. Oligonuc1eotide p1asma trough concentrations , inc1uding ISIS 301012 p1asma trough concentrations , are in equi1ibrium With tissue drug concentrations and thus are used as a representation of liVer tissue concentrations. [ 0292 ] The effects of treatments With oligonuc1eotides such as ISIS 301012 can be assessed fo1loWing co11ection of tissues or ﬂuids from a human subject receiVing said treatments. It is knoWn in the art that a biopsy samp1e can be procured from certain tissues Without resu1ting in detrimenta1 effects to a subject. In certain embodiments , a tissue and its constituent ce11s comprise , but are not 1imited to , b1ood ( e. g. , hematopoietic ce11s , such as human hematopoietic progenitor ce11s , human hematopoietic stem ce11s , CD34 + ce11s CD4 + ce11s ) , 1ymphocytes and other blood 1ineage ce11s , bone marroW , breast , cerVix , colon , esophagus , lymph node , muscle , periphera1 b1ood , ora1 mucosa and skin. In other embodiments , a ﬂuid and its constituent ce11s comprise , but are not 1imited to , b1ood , urine , semen , synoVia1 ﬂuid , 1ymphatic ﬂuid and cerebro - spina1 ﬂuid. [ 0293 ] Tissues or ﬂuids from subjects can be eVa1uated for expression leVels of the target mRNA or protein. Addition - al1y , the mRNA or protein expression 1eVe1s of other genes knoWn or suspected to be associated With the speciﬁc disease state , condition or phenotype can be assessed. mRNA 1eVe1s can be measured or eVa1uated by rea1 - time PCR , Northern blot , in situ hybridization or DNA array analysis. Protein 1eVe1s can be measured or eVa1uated by ELISA , immunob1otting , quantitatiVe protein assays , protein actiVity assays ( for examp1e , caspase actiVity assays ) immunohistochemistry or immunocytochemistry. [ 0294 ] Furthermore , the effects of treatment can be assessed by measuring lipid parameters , as described herein ( cho1estero1 , 1ipoproteins and trig1ycerides , etc. ) , or biomarkers associated With the disease or condition in the aforementioned tissues and ﬂuids , col1ected from a patient or subject receiVing treatment , by routine c1inical methods knoWn in the art. These biomarkers include but are not limited to : glucose , free fatty acids and other markers of g1ucose and 1ipid metabo1ism ; 1iVer transaminases , bi1irubin , a1bumin , b1ood urea nitrogen , creatine and other markers of kidney and liVer ﬁinction ; inter1eukins , tumor necrosis factors , intracel1ular adhesion mo1ecu1es , C - reactiVe protein and other markers of inﬂammation ; testosterone , estrogen and other hormones ; tumor markers ; Vitamins , minera1s and e1ectro1ytes. US 2012 / 0115926 A1. [ 0295 ] In addition ; nuclear magnetic resonance ( NMR ) spectroscopy is used to determine the concentrations of b1ood 1ipoprotein partic1es , inc1uding VLDL partic1es ( tota1 , 1arge / chylomicron , medium and small ) , LDL particles ( total , large , small , medium - sma11 and Very small ) and HDL particles ( 1arge , medium and sma11 ) . Such measurements of 1ipoprotein partic1e size a11oW for the determination of LDL - cho1estero1 , VLDL - cho1esterol and HDL - cholesterol subc1asses , for examp1e the fraction of LDL - cho1estero1 that is carried in sma11 LDL partic1es Versus 1arge LDL partic1es. [ 0296 ] In situ measurements of 1ipid parameters in tissues and ﬂuids may a1so be performed using Who1e body imaging. techniques , including u1trasound , computed tomography ( CT ) scan , or magnetic resonance imaging. [ 0297 ] Whi1e the present inVention has been described With speciﬁcity in accordance With certain embodiments , the fo1 - 10Wing examp1es serVe on1y to i11ustrate the inVention and are not intended to 1imit the same. EXAMPLES Examp1e I. Antisense Inhibition of Human Apo1ipoprotein B Expression by a Chimeric Phosphorothioate Oligonuc1eotide HaVing 2 ' - MOE Wings and a Deoxy Gap ( ISIS 301012 ) . [ 0298 ] An oligonuc1eotide Was designed to target human apolipoprotein B RNA , using a published sequence ( GenBank accession number NM7OO0384. 1 , incorporated herein as SEQ ID NO : 1 ) and is referred to hereinafter as ISIS 301012 ( GCCTCAGTCTGCTTCGCACC ; SEQ ID NO : 2 ) . ISIS 301012 is a chimeric oligonuc1eotide synthesized using methods as described in WO 2004044181 , Which is incorporated herein by reference in its entirety. The chimeric ISIS 301012 oligonuc1eotide is a “gapmer” 2O nuc1eotides in 1ength , composed of a centra1 “gap” region consisting of ten 2 ' - deoxynuc1eotides , and ﬂanked on both sides ( 5 ' and 3 ' directions ) by ﬁVe - nucleotide “Wings”. The Wings are composed of 2 ' - O - methoxyethy1 ( 2 ' - MOE ) nuc1eotides. ISIS 301012 is shoWn in Tab1e 1 , Where , in the nuc1eotide sequence 2 ' - deoxynuc1eotides ( nuc1eobases 6 - 15 ) are indicated by p1ain type and 2 ' - MOE nuc1eotides ( nucleobases 1 - 5 and 16 - 20 ) are indicated by emboldened , underlined type. The internuc1eoside ( backbone ) 1inkages are phosphorothioate ( P : S ) throughout the oligonuc1eotide. A11 cytidine residues are 5 - methy1cytidines. [ 0299 ] ISIS 301012 reduced human apo1ipoprotein B in Vitro and in ViVo. In Tab1e 1 , “Target site” indicates the ﬁrst. ( 5 ' - most ) nucleotide number on the particular target sequence to Which the oligonuc1eotide binds. TAB LE 1. . ISIS 301012 Tarqet Site and Sequence. . TARGET SEQ SEQ ID TARGET ID ISIS # REGION NO SITE SEQUENCE NO. . 30lOl2 COding 2 Region. 3249 GQQIQAGTCTGCTTCGQAQQ 2. . May 10 , 2012. Example 2. Effects of Apo1ipoprotein B Antisense Inhibition in Cynomo1gus Monkeys. [ 0300 ] Cynomolgus monkeys ( male or fema1e ) Were used to eValuate antisense oligonucleotides for their potentia1 to 10Wer apo1ipoprotein B mRNA or protein 1eVe1s in ViVo , as We11 as to eVa1uate phenotypic endpoints associated With apo - 1ipoprotein B expression. As part of this examp1e , LDL - cho - 1estero1 and tota1 cho1estero1 1eVe1s of the treated monkeys Were determined. ISIS 301012 in Lean Cynomolgus Monkeys. [ 0301 ] The oligonuc1eotide ISIS 301012 Was inVestigated in a 10ng - term study for its effects on apo1ipoprotein B expression and serum 1ipid leVels in Cynomo1gus monkeys. [ 0302 ] Ma1e and fema1e Cynomo1gus monkeys Were treated With 2 , 4 or 12 mg / kg of ISIS 301012 intraVenous1y , or 2 or 20 mg / kg subcutaneous1y , at a frequency of eVery tWo days for the ﬁrst Week , and eVery 4 days thereafter , for 1 and 3 month treatment periods. Sa1ine - treated animals serVed as negatiVe contro1s. Each treatment group inc1uded 2 to 3 ani - ma1s of each sex. [ 0303 ] At a one month interVa1 and at the 3 month study termination , the animals Were sacriﬁced and eVa1uated for apo1ipoprotein B expression in 1iVer , 1ipid1eVe1s in serum and indicators of toxicity. RNA Was iso1ated from 1iVer tissue and apo1ipoprotein B mRNA expression Was measured by realtime PCR as described in US app1ication Ser. No. 10 / 712 , 795 , Which is herein incorporated by reference in its entirety. Serum 1ipids , inc1uding tota1 cho1estero1 , LDL - cho1estero1 , HDL - cho1estero1 and trig1ycerides , Were eVa1uated by routine clinica1 ana1ysis , e. g. , using an Olympus C1inica1 Ana1yzer ( O1ympus America Inc. , Me1Vi11e , N. Y. ) . Ratios of LDLcho1estero1 to HDL - cho1estero1 and tota1 cho1estero1 to HDLcho1estero1 Were also ca1cu1ated. Analyses of serum alanine aminotransferase ( ALT ) and serum asparate aminotransferase ( AST ) , inﬂammatory inﬁ1trates in tissue and basophi1ic granu1es in tissue proVided an assessment of toxicities re1ated to the treatment. Hepatic steato sis , or accumu1ation of 1ipids in the 1iVer , Was assessed by routine histo1ogica1 ana1y - sis With oi1 red O stain and measurement of 1iVer tissue trig - 1ycerides using a Trig1yceride GPO Assay ( Sigma - Aldrich , St. Louis , Mo. ) . [ 0304 ] The resu1ts from the one month interVal of the 10ng term treatment are shoWn in Tab1e 2 and Were norrnalized to saline - treated animals for mRNA and to untreated baseline Va1ues for 1ipid 1eVe1s. Tota1 cho1estero1 , LDL - cho1estero1 , HDL - cho1estero1 , LDL partic1e concentration and trig1yceride 1eVe1s in serum Were measured by nuc1ear magnetic resonance spectroscopy by Liposcience ( Ra1eigh , N. C. ) . Additiona1ly , the concentration of intact oligonucleotide in liVer Was measured by capillary gel electrophoresis and is presented as micrograms of oligonuc1eotide per gram of 1iVer tissue. Each resu1t represents the aVerage of data from 4 anima1s ( 2 ma1es and 2 females ) . Where present , “N. D.” indicates “not determined.”. US 2012 / 0115926 A1. TABLE 2. May 10 , 2012. . Effects of ISIS 301012 in lean Cynomolgus monkeys after 4 Weeks of treatment. . IntraVenous deliVerV. Saline 2 mg / kg 4 mg / kg 12 mg / kg. Subcutaneous iniection. 3.5 mg / kg 2O mg / kg. . apolipoprotein B expression —45 —76 —96 ( % change normalized to sa1ine ) antisense oligonuc1eotide 92 179 550. concentration in liVer ( ng / g ) . Lipid Parameters. ( % change norma1ized to untreated baseline Value ) . . Tota1 cho1estero1 + 1 — 6 —2 —2 LDL - cholesterol + 17 + 15 + 9 + 3 HDL - cholesterol — 1 1 —23 — 1 5 — 8 LDL / HDL + 62 + 94 + 3 8 + 44 Tota1 cholesterol / HDL + 30 + 44 + 22 + 21 Trig1yceride + 37 + 26 + 32 + 15 LDL Particle concentration + 15 + 8 + 8 —1 1. N. D. —94 N. D. 855 + 5 —5 —4 —16 + 13 + 5 —15 —19 —7 —10 + 1 —3 —14 —21. . [ 0305 ] These data shoW that ISIS 301012 inhibited apo1i - poprotein B expression in a dose - dependent manner in a primate species and concomitant1y 10Wered 1ipid 1eVe1s at higher doses of ISIS 301012. Furthermore , these resu1ts demonstrate that ISIS 301012 accumulated in the 1iVer in a dosedependent manner. [ 0306 ] Fo11oWing 13 Weeks of treatment With a 2 mg / kg intraVenous dose of ISIS 301012 or a 20 mg / kg subcutaneous dose of ISIS 301012 , tota1 cho1esterol , LDL - cho1estero1 , HDL - cho1estero1 , LDL partic1e concentration and trig1yceride 1eVe1s in serum Were measured by nuc1ear magnetic resonance spectroscopy by LipoScience , Inc. ( Raleigh , N. C. ) . These data are shoWn in Table 3 and are normalized to untreated base1ine Va1ues. Each resu1t represents the aVerage of data from 4 anima1s ( 2 ma1es and 2 fema1es ) . TABLE 3. . Eifects of ISIS 301012 in 1ean Cynomolgus monkeys after 13 Weeks of treatment. . Lipid parameters , % change normalized t0 untreated. . . baseline Value Saline 2 mg / kg 20 mg / kg Tota1 cholesterol + 1 1 + 7 + 1 1 LDL - cho1estero1 + 36 + 4 —3 HDL - cho1esterol —8 + 18 + 5 LDL / HDL + 64 —6 —20 Tota1 cho1estero1 / HDL + 30 + 5 —1 1 Trig1yceride + 36 + 5 + 10 LDL Partic1e concentration + 31 —3 —7. [ 03 07 ] These data i11ustrate signiﬁcant1y decreased LDL - . cho1esterol and total cholestero1 / HDL and LDL / HDL ratios fo11oWing 13 Weeks of treatment With ISIS 301012. Furthermore , HDL - cho1estero1 1eVe1s Were signiﬁcant1y increased. [ 0308 ] Hepatic steatosis , or accumu1ation of 1ipids in the 1iVer , Was not obserVed fo11oWing 4 Weeks of treatment With the doses indicated. Expected dose - related toxicities Were obserVed at the higher doses of 12 and 20 mg / kg , inc1uding a transient 1.2 - 1.3 fo1d increase in actiVated partial thrombo - p1astin time ( APTT ) during the ﬁrst 4 hours and basophi1ic granu1es in the 1iVer and kidney ( as assessed by routine his - . to1ogica1 examination of tissue samp1es ) . No functiona1 changes in kidney Were obserVed. [ 03 09 ] In a simi1ar experiment , ma1e and fema1e Cynomo1 - gus monkeys receiVed an intraVenous dose of ISIS 301012 at 4 mg / kg , eVery tWo days for the ﬁrst Week and eVery 4 days thereafter. Groups of anima1s Were sacriﬁced after the ﬁrst dose and the fourth dose , as Wel1 as 11 , 15 and 23 days fo11oWing the fourth and ﬁna1 dose. LiVer RNA Was iso1ated and apo1ipoprotein B mRNA 1eVe1s Were eVa1uated by rea1 - time PCR as described in US app1ication Ser. No. 10 / 712 , 795 , Which is herein incorporated by reference in its entirety. The resu1ts of this experiment demonstrated a 40% reduction in apolipoprotein B mRNA expression after a single intraVenous dose of 4 mg / kg ISIS 301012. Furthermore , after 4 doses of ISIS 301012 at 4 mg / kg , apo1ipoprotein B mRNA Was reduced by approximate1y 85% and a 50% reduction in apo - 1ipoprotein B mRNA Was sustained for up to 16 days fo11oWing the cessation of ISIS 301012 treatment. ISIS 326358 in High - Fat Fed Cynomo1gus Monkeys. [ 0310 ] In a further embodiment , the effects of antisense inhibition of apolipoprotein B in high - fat fed Cynomolgus monkeys Were eVa1uated. ISIS 326358 ( GCCTCAGTCTGCTTACACC ; SEQ ID NO : 3 ) is an oligonuc1eotide and the Cynomo1gus monkey equiVa1ent of ISIS 301012. The ISIS 326356 oligonucleotide differs from ISIS 301012 at 2 nucleobase positions. Like ISIS 301012 , ISIS 326358 is a gapmer , haVing a centra1 gap portion of 10 2 ' - deoxynuc1eotides , Which is ﬂanked on both sides ( 5 ' and 3 ' ) by Wing portions of 5 2 ' - MOE nuc1eotides. A11 internuc1eoside 1inkages are phosphorothioate , and a11 cytidine residues are 5 - methylcytidines. [ 0311 ] The pharmacologica1 actiVity of ISIS 326358 Was characterized in Cynomolgus monkeys fed a high - fat diet ( approximate1y 17% 1ard and approximate1y 25% cho1estero1 ) for 3 Weeks prior to treatment With ISIS 32635 8 , and throughout the study. ISIS 3263 58 Was administered subcutaneous1y at doses of 2.5 , 5 , or 17.5 mg / kg for 5 Weeks. Doses Were giVen on alternate days for the ﬁrst 3 doses ( loading doses ; 7.5 , 12.5 or 37.5 mg / kg / Week ) and tWice Week1y thereafter ( maintenance doses ; 5 , 10 or 35 mg / kg / Week ) . US 2012 / 0115926 A1. [ 0312 ] The high - fat diet increased serum cholesterol approximate1y 400 mg / dL , re1atiVe to the approximate1y 150 mg / dL 1eVe1 obserVed in monkeys receiVing a standard diet. Fol1oWing treatment With ISIS 326358 , LDL - cholestero1 , 1iVer apolipoprotein B ( mRNA and protein ) , and tota1 cho1estero1 Were signiﬁcant1y reduced as much as 70% , 50% and 50% , respectiVe1y. Reductions in LDL - cho1estero1 and tota1 cho1estero1 Were dose - and time - dependent. No statistica11y signiﬁcant changes in apolipoprotein B or 1ipoproteins Were noted in the sa1ine contro1 group , re1atiVe to pre - dosing Va1 - ues. No changes in 1iVer transaminases or 1iVer trig1yceride 1eVe1s Were noted in monkeys treated With ISIS 32 63 58. [ 0313 ] Together , these data demonstrate that antisense inhibition of apo1ipoprotein B using ISIS 326358 in primates receiVing a high - fat diet reduces liVer apo1ipoprotein B expression and signiﬁcant1y decreases serum tota1 cho1estero1 and LDL - cho1estero1. Examp1e 3. EVa1uation of ISIS 301012 in a Phase I C1inica1 Study. [ 0314 ] As described be1oW , ISIS 301012 Was tested in a doub1e b1ind , p1acebo - contro11ed , Phase I , dose - esca1ation study for the purpose of eVa1uating the safety and to1erabi1ity of sing1e and mu1tip1e doses of ISIS 301012 administered to humans intraVenous1y and subcutaneous1y. In addition , these studies eVa1uated the pharmacokinetic proﬁ1e of sing1e and multip1e doses of ISIS 301012 administered intraVenous1y and subcutaneous1y ; and a1so eValuated the pharmacodynamics of ISIS 301012 administered intraVenous1y and subcutaneously. [ 0315 ] For this Examp1e , a solution of ISIS 301012 ( 250 mg / mL , 0.5 mL ) in steri1e , unpreserVed , buffered sa1ine contained in 2 - mL stoppered g1ass Via1s Was proVided. The study drug Was stored secure1y at 20 C. to 80 C. and protected from light. The placebo Was O.9% sterile saline. Study Design. [ 0316 ] Subjects , 18 to 65 years of age With tota1 cho1estero1 betWeen 200 and 30O mg / dL after an oVernight fast and a body mass index ( BMI ) of 1ess than 30 kg / m2 , Were randomized into Cohorts to receiVe ISIS 301012 or p1acebo in a 3 : 1 ratio. The dosing cohorts Were as fo11oWs : Cohort A , 50 mg ISIS 301012 or p1acebo ; Cohort B , 100 mg ISIS 301012 or p1a - cebo ; Cohort C , 20O mg ISIS 301012 or p1acebo ; Cohort D , 4OO mg ISIS 301012 or placebo. [ 0317 ] The study consisted of a sing1e dose component ( SD ) fol1oWed by a multip1e dose component ( MD ) . In the sing1e dose component , each subject receiVed one subcutaneous dose of study drug , Which Was fo11oWed by a 4 Week obserVation period. Subjects Who comp1eted the single dose component and the obserVation period of the study Were continued in the multip1e dose component of the study. Additiona1 subjects Were recruited for the mu1tip1e dose component of the study on1y. The mu1tip1e dose period Was fo11oWing by a post - treatment eVa1uation period ( PD ) . [ 0318 ] During the mu1tip1e dose component , subjects from the sing1e dose component of the study continued to receiVe the study drug ( ISIS 301012 or p1acebo ) to Which they had preViously been randomized. During the ﬁrst Week of the multip1e dose treatment period , subjects receiVed three intraVenous doses at their respectiVe cohort dose 1eVe1s on a1ternate days fo11oWed by a sing1e Week1y subcutaneous dose for. May 10 , 2012. three Weeks. This dosing regimen resulted in estimated tissue concentrations that Were approximate1y 70 to 80% of steady state 1eVe1s. [ 0319 ] On Day SD1 ( day 1 of sing1e dose period ) , b1ood for a 1ipid pane1 ( tota1 cho1estero1 , LDL - cho1estero1 , HDL - cho - 1estero1 , VLDL - cho1estero1 , apo1ipoprotein B , trig1yceride , 1ipoprotein ( a ) and high - sensitiVity CRP ) Was collected fol - 10Wing an oVernight fast ( at 1east 12 hours ) . These measurements represent base1ine measurements. Study drug Was administered Via a subcutaneous injection ( s. c. ) With the end of the injection designated as Time 0 ( t=zero ) . Blood samp1es for pharmacokinetic ( PK ) ana1ysis Were col1ected at the fol - 10Wing timepoints : 0.5 , 1 , 1.5 , 2 , 3 , 4 , 6 , 8 , and 12 hrs after study drug administration. Urine samp1es for PK ana1ysis Were co11ected oVer a 24 hour period , beginning at Time 0 ( t=zero ) on Day SD1 and ending on Day SD2. On SD4 , b1ood samp1es Were collected for PK analysis and 1ipid panel ana1y - s1s. [ 0320 ] IndiVidual cohort treatments for the single dose administration period are summarized in Table 4. The subjects in the p1acebo group receiVe the same injection Vo1ume as in the Cohort to Which they Were assigned. TABLE 4. . Sing1e Dose Treatment Period. . . Tota1 A11 SQ injections at 250 mg / mL Dose # Subjects SD1 Placebo 7 According to cohort. 5O mg 8 1 injecti0n , 0.2 mL 10O mg 8 1 injection , 0.4 mL 200 mg 9 1 injection , 0.8 mL 4OO mg 4 2 injections , O.8 mL. . [ 0321 ] During the mu1tip1e dose component , study drug Was administered intraVenous1y as a 2 - hour infusion on Days MD1 , MD3 and MD5 of Week 1 and as a subcutaneous injection ( s ) of no more than 20O mg per injection on Days MD8 , MD15 and MD22. A11 subjects Were required to fast for at 1east 12 hours before the b1ood samp1ing for the 1ipid pane1 on MD1 , MD8 , MD15 , MD22 , MD25 , PD14 , PD30 , and , if app1icab1e , on Days PD44 , PD58 , PD72 , and PD86. [ 0322 ] On Day MD1 ( day 1 of mu1tip1e dose period ) , study drug Was administered Via a 2 - hour intraVenous ( i . V. ) infusion With the start of the infusion designated Time 0 ( t=zero ) . Blood samples for pharmacokinetic ( PK ) analysis Were col - 1ected 0.5 , 1 , 2 , 2.25 , 2.5 , 3 , 4 , 6 , and 8 hrs after start of study drug infusion. The 2 hour PK samp1ing Was co11ected just prior to the end of study drug infusion. In addition , a 24 - hour urine col1ection Was performed beginning at Time 0 ( t : zero ) for PK analysis. [ 0323 ] On Days MD3 and Day MD5 , study drug Was administered Via intraVenous inﬁision and blood samp1es for PK analysis Were collected 5 minutes prior to the start of study drug infusion and 2 hours after the start of study drug infusion. [ 0324 ] On Days MD2 , MD4 , MD6 , blood samples for PK Were co11ected 24 hours after the start of study drug infusion. [ 03 25 ] On Days MD8 , MD15 , study drug Was administered Via subcutaneous injection. B1ood samp1es for PK ana1ysis and urine samp1es for urina1ysis Were co11ected. [ 0326 ] On Day MD22 , study drug Was administered Via subcutaneous injection. B1ood samp1es for PK ana1ysis Were co11ected prior to and 0.5 , 1 , 1.5 , 2 , 3 , 4 , 6 , 8 , and 12 hours. US 2012 / 0115926 A1. 19. after study drug administration. A urine sample for urinalysis Was co11ected oVer a 24 hour period , beginning at time of dosing on Day MD22 and ending on Day MD23. [ 0327 ] On Day MD23 , b1ood samples for PK Were col - 1ected 24 hours after dosing of the study drug on Day MD22. [ 0328 ] On Day MD25 , 3 days after the ﬁna1 dose on Day MD22 , b1ood samp1es Were co11ected for PK ana1ysis. [ 03 29 ] ShoWn in Tab1e 5 is a summary of the do sing sched - u1e for the mu1tiple dose period. The 50 mg and 200 mg groups each had one less subject than during the sing1e dose period. The subjects in the p1acebo group receiVe the same injection Vo1ume as in the Cohort to Which they Were assigned. TABLE 5. May 10 , 2012. ( Tables 7 , 9 , 11 , 13 , 15 , 17 , and 21 ) . The mean represents the aVerage of data from 5 subjects in the p1acebo cohort , from 3 subjects in the 50 mg cohort , from 3 subjects in the 10O mg cohort , from 6 to 7 subjects in the 200 mg cohort and from 2 subjects in the 400 mg cohort. [ 0333 ] The base1ine Va1ue to Which the data Were norma1 - ized is indicated for each Tab1e. The base1ine Va1ues Were set at 100% , and Va1ues aboVe or be1oW 100% indicate an increase or decrease , respectiVe1y , in the 1ipid parameter measured. Data are presented for 1ipid parameter measurements made during the mu1tip1e dose periods , for examp1e , MD8 indicates a measurement made 8 days fo11oWing administration of the ﬁrst dose during the mu1tip1e dose periods. A1so. . Mu1tiple Dose Treatment Period. Loading Week + All 2 hour LV. 1Dﬁ1$1OHS. Once a Week Dosing + SQ Iniections at 25O mg / mL. . Dose # Subjects MD1 MD3 MD5 MD8 MD15 MD22 Placebo 7 N / A N / A N / A According to cohort 50 mg 7 50 mg 50 mg 50 mg 1inj , 1inj , 1inj , 0.2 mL 0.2 mL 0.2 mL 10O mg 8 100 mg 10O mg 100 mg 1 inj , 1 inj , 1 inj , 0.4 mL 0.4 mL 0.4 mL 200 mg 8 200 mg 200 mg 200 mg 1 inj , 1 inj , 1 inj , 0.8 mL 0.8 mL 0.8 mL 400 mg 2 400 mg 400 mg 400 mg 2 inj , 2 inj , 2 inj , 0.8 mL 0.8 mL 0.8 mL. . [ 0330 ] During the post - treatment eValuation period , on Days PD14 ( or PD39 , 39 days since MD1 ) , and PD30 ( or PD5 5 , 55 days since MD1 ) b1ood samp1es Were col1ected for 1ipid pane1 and PK analysis. A11 subjects Who had fasting tota1 serum cho1estero1 1eVe1s 1ess than or equa1 to 90% of their baseline Values on PD30 continued in an extended folloW - up period. Fasting 1ipid pane1 measurements Were made eVery 2 Weeks unti1 PD86 ( or PD111 , 111 days past MD1 ) or unti1 tota1 serum cho1estero1 1eVe1s returned to greater than 90% of base1ine. On Days PD44 , PD58 , PD72 , and PD 86 ( or PD69 , PD83 , PD97 and PD111 , respectiVely ) , blood samples Were co11ected for 1ipid pane1 and PK analysis. Pharmacodynamic Analysis. [ 0331 ] The pharmacodynamic effects of ISIS 301012 Were assessed by comparing 1ipid parameter 1eVe1s at the start of treatment to those fo11oWing mu1tip1e doses of ISIS 301012 ; these data are shoWn in the fo11oWing tables. Data are presented as mean percent change from baseline , Where the base1ine is either the respectiVe 1ipid parameter measurement made on the ﬁrst day of the ﬁrst dose of study drug administered , Which Was either the ﬁrst day of the sing1e dose treatment period ( SD1 ) or the ﬁrst day of the mu1tip1e dose treatment period ( MD1 ) . [ 0332 ] Total cholesterol , LDL - cholesterol , HDL - cholestero1 and trig1ycerides Were measured by routine c1inica1 procedures at MDS Pharma SerVices ( Be1fast , Ire1and ) . Apo1i - poprotein B and Lipoprotein ( a ) 1eVe1s Were measured by routine clinical 1aboratory procedures at MDS Pharma SerVices ( Be1fast , Ire1and ) . The data are presented in the Tab1es be1oW as the mean percent change re1atiVe to the base1ine Va1ues ofSD1 ( Tab1es 6 , 8 , 10 , 12 , 14 , 16 , 18 , and 19 ) or MDI. shoWn are data from 1ipid parameter measurements made during the post - treatment eVa1uation period , for examp1e , a measurement on day PD39 Was made on the 14m day of the post - treatment eVa1uation period , Which is equiVa1ent to 39 days fo11oWing the ﬁrst administration of the ﬁrst dose during the mu1tiple dose period. Where present , “ND” indicates that the particular measurement is “not determined”. Ana1yses of other serum biomarkers reVea1ed no clinica1 adVerse eVent trends , inc1uding no changes in White b1ood ce11 count , p1ate - 1et count or rena1 function. Furthermore , no toxicities Were obserVed fo11oWing administration of ISIS 301012. [ 0334 ] LDL - cho1esterol. Measurements of LDL - cho1esterol , shoWn in Tables 6 and 7 , reVealed reductions in this 1ipoprotein in the 100 mg , 200 mg and 4OO mg cohorts tbroughout the mu1tiple dose period. For examp1e , in Tab1e 6 , on MD25 , mean LDL - cho1estero1 1eVe1s Were 73% , 66% and 60% of baseline Values in the 100 mg , 200 mg and 400 mg cohorts , respectiVely. Effects Were seen in the 400 mg cohort , Where LDL - cho1estero1 1eVe1s Were reduced by as much as 39% ( 61% of MD1 base1ine on day MD22 ) or 45% ( 55% of SD1 baseline Va1ue on day MD15 ) . Furthermore , a reduction in LDL - cho1estero1 Was ob serVed out to day PD83 in the 100 mg cohort , approximately 2 months folloWing administration ofthe ﬁna1 dose of ISIS 301012. TABLE 6. . LDL - Cho1estero1 Mean Percent of Base1ine ( SD1 ) . . Placebo 50 mg 100 mg 200 mg 400 mg MD1 99 12O 89 83 91 MD8 99 99 75 83 79. US 2012 / 0115926 A1. TABLE 6 - continued. . LDL - Cho1estero1 Mean Percent of Baseline ( SD1 ) . . . . . . . Placebo 50 mg 10O mg 200 mg 400 mg MD15 100 106 63 68 61 MD22 94 109 69 65 55 MD25 92 108 73 66 60 PD39 87 ND 68 58 ND PD55 96 95 69 58 ND PD83 ND ND 78 ND ND. TABLE 7 LDL - Cholestero1 Mean Percent of Baseline ( MD1 ) . Placebo 50 mg 100 mg 200 mg 400 mg MD8 100 83 84 92 87 MD15 102 89 70 75 67 MD22 96 92 78 72 61 MD25 93 9O 82 73 66 PD39 88 ND 76 64 ND PD55 97 79 78 64 ND PD83 ND ND 87 ND ND. May 10 , 2012. TABLE 9. . Apolipoprotein B Mean Percent of Baseline ( MD1 ) . . . P1acebo 50 mg 100 mg 20O mg 400 mg MD8 102 77 89 96 83 MD15 98 90 74 67 61 MD22 92 81 89 64 48 MD25 88 81 100 45 57 PD3 9 104 81 89 58 52 PD5 5 94 77 89 53 57 PD69 ND 62 ND 62 57 PD83 ND 7O 100 70 61 PD97 ND 73 100 73 ND PD1 1 1 ND 80 100 80 ND. . [ 0336 ] Tota1 Cho1estero1. Ana1ysis of tota1 cho1estero1 reVea1ed a reduction in the mean percent change from base - 1ine , Whether the data Were norma1ized to SD1 ( Tab1e 10 ) or MD1 ( Tab1e 11 ) . For examp1e , on MD1 , MD8 , MD15 , MD22 and MD25 , mean tota1 cho1estero1 in the 200 mg cohort Was reduced to 97% , 89% , 74% , 71% and 76% of SD1 base1ine Values. Furthermore , these effects Were sustained fo1loWing cessation of dosing on MD 22. For examp1e , in the 2OO mg cohort , the mean tota1 cho1estero1 Was 88% of SD1 base1ine. Va1ues on PD111 , approximate1y 3 months fo11oWing administration of the ﬁna1 dose of ISIS 301012. TABLE 10. . [ 0335 ] Apo1ipoprotein B. Measurements of serum apo1ipoprotein B , shoWn in Tables 8 and 9 , reVealed a do se - dependent reduction in this apo1ipoprotein , particu1ar1y in the 10O mg , 2OO mg and 4OO mg cohorts. Reductions in serum apo1ipoprotein B Were maintained out to day PD111 in the 10O mg and 200 mg cohorts , approximate1y 3 months fo11oWing administration of the ﬁna1 dose of ISIS 301012. Reductions Were as great as 56% or 52% ( or 44% of SD1 base1ine Va1ue on day MD22 or 48% of MD1 base1ine Value on day MD22 , respectiVely ) in the 400 mg cohort ; a similar reduction in the mean percent re1atiVe to SD1 base1ine Was obserVed out to day PD83. Additiona11y , pro1onged effects Were a1so obserVed in the 10O mg and 200 mg cohorts , Where serum apo1ipoprotein B 1eVe1s Were 90% and 79% , respectiVe1y , of SD1 base1ine Va1ues on day PD 1 1 1 , approximate1y 3 months fo11oWing administration of the ﬁna1 dose of ISIS 301012. TABLE 8. . Apolipoprotein B Mean Percent of Baseline ( SD1 ) . . . Placebo 50 mg 10O mg 200 mg 400 mg MD1 111 111 90 99 92 MD8 113 86 80 94 76 MD15 109 10O 67 66 5 6 MD22 102 89 80 63 44 MD25 98 89 90 44 52 PD39 115 89 8O 58 48 PD55 104 86 80 53 52 PD69 ND ND ND 61 52 PD83 ND ND 90 69 56 PD97 ND ND 90 72 ND PD111 ND ND 90 79 ND. . . Tota1 Cho1estero1 Mean Percent of Base1ine ( SD1 ) . . . . Placebo 50 mg 10O mg 2OO mg 400 mg MD1 103 113 87 97 88 MD8 103 93 88 89 79 MD15 104 96 75 74 63 MD22 99 103 76 71 60 MD25 98 97 89 76 63 PD39 109 100 85 7O 61 PD55 114 105 90 74 68 PD69 ND ND 84 69 62 PD83 ND ND 95 78 ND PD97 ND ND 96 78 ND PD111 ND ND 105 88 ND TABLE 11. . Tota1 Cho1estero1 Mean Percent of Base1ine ( MD1 ) . . Placebo 50 mg 100 mg 200 mg 400 mg MD8 101 83 101 91 90 MD15 102 85 86 76 72 MD22 97 91 88 73 68 MD25 96 86 102 78 72 PD39 106 89 98 72 69 PD55 111 93 103 75 78 PD69 ND ND 97 71 70 PD83 ND ND 109 80 ND PD97 ND ND 110 80 ND PD111 ND ND 120 91 ND. . [ 0337 ] HDL - Cho1estero1. As shoWn in Tab1es 12 and 13 , these data reVeal some changes in HDL - cholestero1 in the 400 mg cohort , hoWeVer , in the 50 , 100 and 200 mg cohorts , HDL - cho1estero1 changes Were not marked1y changed. HDLcho1estero1 1eVe1s Were increased in the IO0 mg cohort , re1a - tiVe to base1ine day MD1. US 2012 / 0115926 A1. TABLE 12. . HDL - Cholesterol Mean Percent of Baseline ( SD1 ) . . . May 10 , 2012. 15% ( normalized to baseline SD1 or MD1 ) Were sustained out to day PD55 in the 100 mg and 200 mg cohorts , approximate1y one month fo11oWing administration of the ﬁna1 dose ofISIS 301012. . . . . . . . . P1acebo 50 mg 10O mg 200 mg 400 mg MD1 101 102 92 102 87 TABLE 16 MD8 94 78 102 91 71 EEE 33 SS 13 ; 13 : g Lipoprotein ( a ) Mean Percent of Baseline ( SD1 ) MD25 103 100 109 102 94 gggg 189 iii 13? iii 33 Placebo 50 mg 100 mg 20O mg 400 mg MD1 104 130 99 97 108 TABLE 13 MD8 93 99 107 109 71 MD15 100 103 84 89 93 HDL - Cho1estero1 Mean Percent of Base1ine ( MD1 ) MD22 104 95 75 82 76 Placebo 50 mg 100 mg 200 mg 40O mg MD25 111 109 90 84 78 MD8 93 76 110 89 82 PD39 140 ND 93 88 ND MD15 94 90 98 94 77 PD55 122 97 88 85 ND MD22 102 96 110 102 100 MD25 102 98 118 100 108 PD39 114 ND 108 99 ND PD55 98 96 109 104 ND TABLE 17. . [ 0338 ] Trig1yceride. Trig1yceride 1eVe1s , shoWn in Tab1es 14 and 15 , Were reduced by administration of ISIS 301012 in the 10O mg , 200 mg and 400 mg cohorts. As shoWn in Tab1e 14 , in the 100 mg and 200 mg cohorts , trig1yceride reduction Was achieVed by MD8 and MD15 , respectiVe1y , and Was maintained out to day PD55 , approximate1y 1 month fo1loWing administration of the ﬁna1 dose of ISIS 301012. TABLE 14. . Trig1Vceride Mean Percent of Baseline ( SD1 ) . . . . . . Placebo 50 mg 100 mg 200 mg 400 mg MD1 148 100 110 121 103 MD8 153 180 81 107 105 MD15 157 103 91 94 87 MD22 122 89 87 90 91 MD25 109 100 83 91 64 PD39 129 ND 70 83 ND PD55 96 115 92 66 ND. TABLE 15. Triglyceride Mean Percent of Baseline ( MD1 ) . P1acebo 50 mg 10O mg 200 mg 400 mg MD8 103 180 73 89 102 MD15 106 103 82 78 85 MD22 82 89 79 75 89 MD25 74 100 75 75 62 PD39 87 ND 64 69 ND PD55 65 115 83 55 ND. . [ 0339 ] Lipoprotein ( a ) . Lipoprotein ( a ) 1eVe1s in serum , shoWn in Tab1es 16 and 17 , Were reduced fo11oWing treatment With ISIS 301012. For example , in the 400 mg cohort , 1ipoprotein ( a ) Was reduced during the multip1e dose period , to 71% , 83% , 76% and 84% of SD1 baseline or 66% , 85% , 70% and 72% of MD1 base1ine on days MD8 , MD15 , MD22 and MD25 , respectiVe1y. Reductions of approximate1y 12% to. . Lipoprotein ( a ) Mean Percent of Base1ine ( MD1 ) . . . P1acebo 50 mg 100 mg 20O mg 400 mg MD8 89 76 108 112 66 MD15 96 79 84 91 85 MD22 100 74 75 84 70 MD25 106 84 91 86 72 PD39 134 ND 94 91 ND PD55 118 75 88 87 ND. . [ 0340 ] Tota1Cho1estero1 : HDL Ratio. As shoWn in Tab1e 18 , the ratios of tota1 cho1estero1 to HDL - cho1estero1 Were ca1cu - 1ated , reVea1ing an improVement in these ratios , Which is a clinica11y - desirab1e effect. A reduction in the ratios re1atiVe to base1ine Va1ues Was obserVed , for examp1e , in the 200 mg cohort , beginning on MD8 and persisting out to PD55. ImproVements in the ratio of total cholesterol to HDL - cho - 1estero1 Were a1so seen in the 10O mg and 4OO mg cohorts. TABLE 18. . Total Cholestero1 : HDL Ratio , Mean Percent of Baseline ( SD1 ) . . . Placebo 50 mg 100 mg 2OO mg 400 mg MD8 109 123 91 97 106 MD15 112 101 86 80 91 MD22 100 93 87 74 63 MD25 95 91 85 75 64 PD39 95 ND 91 69 ND PD55 108 97 90 68 ND. . [ 0341 ] LDL - cho1esterol Versus HDL - cho1estero1. As shoWn in Table 19 , the c1inically - desirable reduction in LDL : HDL ratio Was obserVed in the 100 mg , 200 mg and 400 mg cohorts during the multiple dose treatment period. These reductions persisted out to day PD55 in the IO0 mg and 20O mg cohorts , on Which day the ratios Were 68% and 55% , respectiVe1y , of SD1 base1ine Va1ues. . . . . . . . US 2012 / 0115926 A1 May 10 , 2012 22 TABLE 19 TABLE 21 - continued LDL : HDL Ratio , VLDL - Cholesterol Mean Percent of Baseline ( MD1 ) Mean Percent of Baseline ( SD1 ) P1acebo 50 mg 100 mg 20O mg 400 mg. Placebo 50 mg 10O mg 200 mg 400 mg PD39 88 ND 78 63 ND MD8 102 130 74 88 100 PD55 60 102 81 49 ND MD15 109 116 68 68 82 MD22 95 103 70 62 54 Pharmacodynamic Effects With Statistical Ana1ysis MD25 88 101 67 63 55 [ 0343 ] ShoWn in Tab1es 22 through 43 are summaries of the PD39 81 ND 69 55 ND lipid parameters eVa1uated in 7 subjects Who receiVed the PD55 93 97 68 55 ND placebo , and 8 , 8 , 9 , and 4 subjects Who receiVed 50 mg , 100. . [ 0342 ] VLDL - Cho1estero1. As shoWn in Tables 20 and 21 , VLDL - cho1esterol 1eVe1s Were shoWn to be reduced , in al1 cohorts re1atiVe to base1ine day MD1 and in the 100 mg , 200 mg and 4OO mg cohorts re1atiVe to base1ine day SD1. For examp1e , by day MD25 , VLDL - cho1estero1 1eVe1s in the 200 mg cohort Were reduced to 63% of base1ine MD1 , and these effects persisted out to study day PD55 , at Which time VLDLcho1estero1 1eVe1s Were 49% of base1ine day MD1. Sustained reductions in VLDL - cho1estero1 Were obserVed out to PD55 in the 100 and 200 mg cohorts , normalized to baseline days SD1 or MD1. TABLE 20. . VLDL - Cholesterol Mean Percent of Baseline ( SD1 ) . . . . P1acebo 50 mg 10O mg 200 mg 400 mg MD1 144 125 106 122 84 MD8 149 222 79 101 88 MD15 153 118 90 87 62 MD22 122 103 91 83 70 MD25 106 121 87 77 44 PD39 126 ND 83 77 ND PD55 87 127 86 60 ND TABLE 21. . VLDL - Cho1estero1 Mean Percent of Baseline ( MD1 ) . . . Placebo 50 mg 10O mg 200 mg 400 mg MD8 104 178 74 83 106 MD15 107 95 85 71 74 MD22 85 82 86 68 83 MD25 74 97 82 63 52. mg , 2OO mg and 4OO mg ISIS 301012 , respectiVe1y. Presented in the Summary tables are the mean 1eVe1s of each 1ipid parameter , e. g. mg / dL LDL - cholestero1 , per dose cohort. The second tab1e shoWn for each 1ipid parameter is the Percent Change tab1e , and represents the mean percent change from baseline for each cohort , e. g. mean percent change at MD25 re1atiVe to base1ine. “Study day” indicates the day of the study When the 11pid parameter , e. g. LDL - cho1estero1 , Was measured. The “base1ine” measurement is the 1eVe1 of the 1ipid parameter , e. g. LDL - cholesterol , prior to the initial dose of ISIS 301012 on study day SD1. If a measurement from SD1 Was not aVai1ab1e , a MD 1 measurement Was used in its p1ace. “MD” indicates a measurement taken during the mu1tip1e dose period , for example , MD15 is day 15 of the multip1e dose period. The mu1tip1e dose period Was 25 days in 1ength , thus the MD25 measurement is from a samp1e taken on the day of the ﬁna1 dose of study drug. “PD” is a measurement taken during the post - treatment eValuation period. For examp1e , PD39 is a measurement taken 14 days fo11oWing the ﬁna1 dose , Which is equiVa1ent to 39 days fo11oWing the ﬁrst dose of the mu1tip1e dose period. “N” indicates the number of samp1es used in ca1cu1ating the mean and median 1eVe1s ; N for measurements made during the MD or PD periods may be 1ess than N at baseline. “Std” is the standard deViation. P - Va1 - ues app1y to the difference betWeen means in dosing groups and means in the p1acebo group , and Were determined using the Wi1coxon Rank - sum test. “NC” indicates a 11pid parameter1eVe1 or P - Va1ue that Was not ca1cu1ated. [ 0344 ] LDL - Cholesterol. Table 22 contains the LDL - cho - 1estero11eVe1 summary , Where 1eVe1s are shoWn in mg / dL. The percent mean and median changes in LDL - cho1estero1 , re1a - tiVe to base1ine Va1ues , are presented in Tab1e 23. Pro1onged and dose - dependent reductions in serum LDL - cholesterol 1eVe1s Were obserVed. The maximum percent reduction of LDL - cho1estero1 Was approximate1y 35% for the 200 mg group and approximate1y 48% for the 40O mg group ( Tab1e 23 ) . LDL - cho1estero1 reduction persisted , remaining be1oW base1ine for 90 days in 50% of the subjects in the 200 mg. group. TABLE 22. . LDL - Cholesterol LeVel Summary , mg / dL. . Study Day Placebo 50 mg 100 mg 200 mg 400 mg. Baseline N 7 8 8 9 4 Mean 131 126 131 123 133 Median 123 118 136 121 130 Std 27 24 24 16 23 Min - Max 95 - 171 100 - 173 91 - 160 103 - 153 109 - 164 P - Value O.7789 1 0.6597 O.7879. MD8 N 7 7 8 8 2 Mean 126 118 119 105 105. Median 121 116 111 102 105. US 2012 / 0115926 A1. . . . . . . . 23 TABLE 22 - continued LDL - Cho1esterol LeVel Summary , mg / dL Study Day P1acebo 5O mg 100 mg 200 mg 400 mg Std 19 17 25 14 14 Min - Max 107 - 160 104 - 155 94 - 164 88 - 126 95 - 115 P - Value 0.197 0.414 0.0401 0.2222 MD15 N 7 8 8 8 2 Mean 132 124 101 85 82 Median 116 121 99 86 82 Std 29 20 29 14 21 Min - Max 109 - 175 99 - 166 59 - 151 67 - 107 67 - 96 P - Value 0.9302 0.0774 0.0003 0.0556 MD22 N 7 8 8 8 2 Mean 124 125 102 82 74 Median 112 125 98 85 74 Std 29 15 20 11 5 Min - Max 93 - 167 96 - 149 79 - 144 58 - 92 70 - 77 P - Value 0.4443 0.0881 0.0003 0.0556 MD25 N 7 8 8 8 2 Mean 122 128 105 83 80 Median 115 121 102 86 8O Std 32 16 16 13 6 Min - Max 76 - 170 117 - 163 84 - 139 54 - 95 76 - 84 P - Value 0.143 0.128 0.0126 0.1389 PD39 N 7 8 8 8 2 Mean 128 119 106 77 79 Median 118 115 98 81 79 Std 22 17 24 18 1 Min - Max 107 - 160 103 - 155 90 - 158 51 - 107 78 - 80 P - Value 0.4797 0.0362 0.0005 0.0556 PD55 N 7 8 8 8 2 Mean 127 117 103 79 85 Median 120 114 96 82 85 Std 25 16 25 17 13 Min - Max 103 - 179 100 - 151 72 - 154 59 - 114 76 - 94 P - Value 0.3357 0.0376 0.0009 0.0556 PD69 N 2 2 5 7 2 Mean 127 111 106 85 84 Median 127 111 105 87 84 Std 24 25 23 7 7 Min - Max 110 - 144 93 - 128 81 - 141 73 - 93 79 - 89 P - Value 0.6667 0.381 0.0278 0.3333 PD83 N 2 3 7 8 2 Mean 144 115 108 92 99 Median 144 111 106 92 99 Std 40 25 23 12 2 Min - Max 116 - 172 92 - 141 73 - 150 72 - 115 97 - 100 P - Value 0.4 0.2222 0.0444 0.3333 PD97 N 0 2 5 8 0 Mean NC 114 111 95 NC Median NC 114 116 95 NC Std NC 21 36 10 NC Min - Max NC 99 - 128 65 - 160 75 - 109 NC PD111 N 0 1 2 6 0 Mean NC 90 121 101 NC Median NC 90 121 100 NC Std NC NC 13 11 NC Min - Max NC 90 - 90 112 - 130 85 - 119 NC TABLE 23 LDL - Cholester0l LeVel Summary , % Change from Baseline Study Day Placebo 50 mg 100 mg 200 mg 400 mg MD8 N 7 7 8 8 2 Mean —2 —8 —8 —14 —27 Median 1 —8 —14 —14 —27 Std 16 7 15 10 5 Min - Max —20 - 27 —19 - 2 —23 - 20 —27 - 3 —30 - —23 P - Value 0.6200 0.3357 0.1893 0.0556. May 10 , 2012. . . . . US 2012 / 0115926 A1 May 10 , 2012 24 TABLE 23 - continued LDL - Cholester0l LeVel Summary , % Change from Baseline Study Day Placebo 50 mg 100 mg 200 mg 400 mg MD15 N 7 8 8 8 2 Mean 1 —0.2 —23 —29 —44 Median 4 —3 —24 —26 —44 Std 11 13 19 17 3 Min - Max —19 - 1 6 —14 - 29 —46 - 9 —50 - —7 —46 - —43 P - Va1ue 0.5358 0.0205 0.0022 0.0556 MD22 N 7 8 8 8 2 Mean —5 1 —21 —32 —48 Median —2 —2 —23 —28 —48 Std 12 15 12 15 7 Min - Max —31 - 7 —14 - 25 —33 - 0.0 —52 - —11 —53 - —44 P - Va1ue 0.8665 0.0289 0.0037 0.0556 MD25 N 7 8 8 8 2 Mean —6 3 —19 —31 —44 Median —4 1 —20 —26 —44 Std 19 16 11 16 7 Min - Max —43 - 21 —15 - 37 —32 - 2 —55 - —12 —49 - —39 P - Va1ue 0.6126 0.0939 0.0093 0.1111 PD39 N 7 8 8 8 2 Mean —1 —4 —19 —35 —44 Median —3 —8 —18 —35 —44 Std 13 16 14 19 10 Min - Max —19 - 20 —21 - 30 —36 - —1 —67 - —7 —51 - —37 P - Va1ue 0.6126 0.0721 0.0022 0.0556 PD55 N 7 8 8 8 2 Mean —1 —6 —20 —34 —41 Median 5 —7 —23 —37 —41 Std 15 8 17 19 3 Min - Max —18 - 21 —15 - 9 —40 - 10 —58 - —1 —43 - —39 P - Va1ue 0.8665 0.0939 0.0022 0.0556 PD69 N 2 2 5 7 2 Mean 4 —13 —18 —29 —41 Median 4 —13 —17 —24 —41 Std 18 14 9 12 7 Min - Max —8 - 17 —23 - —3 —33 - —11 —48 - —16 —46 - —36 P - Va1ue 0.6667 0.0952 0.0556 0.3333 PD83 N 2 3 7 8 2 Mean —1 —1 —19 —24 —30 Median —1 —4 —20 —1 8 —30 Std 3 16 8 15 12 Min - Max —3 - O.6 —15 - 17 —26 - —6 —45 - —6 —39 - —22 P - Va1ue 0.8000 0.0556 0.0444 0.3333 PD97 N 0 2 5 8 0 Mean NC 2 —15 —21 NC Median NC 2 —18 —1 6 NC Std NC 14 11 13 NC Min - Max NC —8 - 11 —29 - 0 —46 - —11 NC P - Va1ue 0 1 2 6 O PD111 N NC —17 7 —19 NC Mean NC —17 7 —19 NC Median NC 0 23 8 NC Std NC —17 - —17 —9 - 23 —30 - —6 NC Min - Max 7 7 8 8 2 P - Va1ue —2 —8 —8 —14 —27 [ 0345 ] Apo1ipoprotein B. ShoWn in Tab1es 24 and 25 are 90 days fo1loWing treatment in 75% of the 200 mg subjects. Due to the pro1onged effect of ISIS 301012 , the 1eVe1s of. the mean serum apo1ipoprotein B 1eVe1s per cohort and mean percent of base1ine per cohort , respectiVe1y. Administration of ISIS 301012 resu1ted in a dose - dependent , pro1onged reduction of serum apo1ipoprotein B 1eVels. The 200 mg dose group shoWed a maximum reduction of 50% , re1atiVe to base1ine ( Tab1e 25 ) , on MD25 , 72 hours fo11oWing the ﬁna1 dose. The reduced apo1ipoprotein B 1eVe1s remained be1oW base1ine for. serum apo1ipoprotein B Were measured at PD125 and PD139 for 2 subjects and 1 subject , respectiVe1y. At Day PD125 , the mean and median serum apo1ipoprotein B leVe1s for 2 subjects from the 200 mg cohort Was 9O mg / dL ( std : 28 ) , representing a —17% change re1atiVe to base1ine ( std=12 ) . At Day PD139 , tota1 serum apo1ipoprotein B in 1 subject Was 86 mg / dL , representing a —28% change re1atiVe to base1ine. US 2012 / 0115926 A1 May 10 , 2012. . . . 25 TABLE 24 Apolip0protein B LeVel Summary , mg / dL Study Day Placebo 50 mg 100 mg 200 mg 400 mg Base1ine N 7 8 8 9 4 Mean 102 101 105 101 113 Median 93 101 99 98 110 Std 22 20 22 17 27 Min - Max 84 - 147 77 - 142 68 - 141 76 - 133 86 - 145 P - Va1ue 0.9312 0.2671 0.4684 0.4939 MD8 N 7 8 8 8 2 Mean 107 86 95 93 90 Median 105 83 83 89 90 Std 18 24 24 15 21 Min - Max 86 - 132 56 - 136 75 - 142 76 - 117 75 - 105 P - Va1ue 0.058 0.1807 0.152 0.3889 MD15 N 7 8 8 8 3 Mean 103 94 78 67 70 Median 94 89 71 69 70 Std 28 20 21 13 16 Min - Max 68 - 143 72 - 138 57 - 122 47 - 84 54 - 86 P - Value 0.2939 0.0323 0.0034 0.0583 MD22 N 7 8 8 8 2 Mean 99 91 82 66 56 Median 93 89 77 70 56 Std 23 16 20 11 6 Min - Max 76 - 143 65 - 118 63 - 124 41 - 76 52 - 60 P - Va1ue 0.6943 0.113 0.0005 0.0556 MD25 N 7 8 8 8 2 Mean 94 87 87 50 66 Median 95 84 87 51 66 Std 22 10 18 16 6 Min - Max 67 - 123 74 - 106 61 - 122 21 - 73 61 - 70 P - Value 0.4634 0.5358 0.0012 0.1111 PD39 N 7 8 8 8 2 Mean 102 86 81 61 59 Median 101 82 79 62 59 Std 19 12 23 13 4 Min - Max 66 - 120 78 - 113 51 - 126 43 - 81 56 - 61 P - Value 0.0503 0.0774 0.002 0.0556 PD55 N 7 8 8 8 2 Mean 86 86 76 57 62 Median 95 81 72 58 62 Std 21 19 25 9 8 Min - Max 44 - 100 59 - 113 53 - 131 41 - 72 56 - 67 P - Va1ue 0.7573 0.2319 0.0166 0.2222 PD69 N 3 5 5 7 2 Mean 109 90 74 62 64 Median 112 86 75 61 64 Std 20 26 24 7 10 Min - Max 88 - 127 70 - 133 39 - 106 50 - 70 57 - 71 P - Va1ue 0.2857 0.0714 0.0083 0.2 PD83 N 2 4 7 8 2 Mean 120 96 72 67 70 Median 120 88 76 68 70 Std 28 25 28 11 10 Min - Max 100 - 139 76 - 131 30 - 104 47 - 85 63 - 77 P - Value 0.2667 0.1111 0.0444 0.3333 PD97 N 0 2 4 8 1 Mean NC 96 90 72 81 Median NC 96 88 74 81 Std NC 8 42 12 NC Min - Max NC 90 - 101 45 - 139 56 - 85 81 - 81 PD111 N 0 1 3 6 2 Mean NC 76 81 77 95 Median NC 76 87 74 95 Std NC NC 14 14 21. Min - Max NC 76 - 76 65 - 90 66 - 105 80 - 110. . . . . US 2012 / 0115926 A1 May 10 , 2012 26 TABLE 25 Apolip0protein B , % Change from Baseline Study Day P1acebo 50 mg 100 mg 200 mg 400 mg MD8 N 7 8 8 8 2 Mean 7 —14 —9 —8 —24 Median 11 —13 —11 —7 —24 Std 12 22 14 12 5 Min - Max —10 - 24 —46 - 17 —24 - 19 —27 - 10 —28 - —21 P - Va1ue 0.0721 0.0401 0.0401 0.0556 MD15 N 7 8 8 8 3 Mean 1 —6 —25 —32 —43 Median 1 —4 —28 —32 —43 Std 14 14 13 18 2 Min - Max —24 - 21 —27 - 14 —41 - —2 —61 - —14 —44 - —41 P - Va1ue 0.3969 0.0059 0.0022 0.0167 MD22 N 7 8 8 8 2 Mean —3 —9 —22 —34 —52 Median 0 —10 —20 —33 —52 Std 10 11 11 16 9 Min - Max —16 - 10 —23 - 7 —43 - —7 —56 - —11 —59 - —45 P - Value 0.1893 0.0037 0.0012 0.0556 MD25 N 7 8 8 8 2 Mean —7 —13 —16 —50 —44 Median —3 —11 —12 —50 —44 Std 16 12 13 17 11 Min - Max —28 - 14 —32 - 8 —37 - 3 —78 - —26 —52 - —36 P - Value 0.4634 0.281 0.0006 0.0556 PD39 N 7 8 8 8 2 Mean 2 —14 —22 —39 —50 Median 4 —16 —19 —37 —50 Std 21 9 15 18 12 Min - Max —26 - 37 —26 - 3 —57 - —10 —61 - —17 —58 - —41 P - Value 0.0939 0.0541 0.0059 0.0556 PD55 N 7 8 8 8 2 Mean —11 — 14 —28 —42 —47 Median 4 —16 —22 —45 —47 Std 29 13 15 14 9 Min - Max —70 - 12 —33 - 4 —49 - —7 —59 - —21 —54 - —41 P - Value 0.1893 0.0541 0.0205 0.2222 PD69 N 3 5 5 7 2 Mean 6 —16 —34 —38 —46 Median —1 —11 —34 —40 —46 Std 24 16 7 12 8 Min - Max —14 - 33 —33 - 4 —43 - —25 —55 - —20 —51 - —40 P - Value 0.3929 0.0357 0.0167 0.2 PD83 N 2 4 7 8 2 Mean 4 —12 —31 —33 —40 Median 4 —9 —21 —34 —40 Std 13 13 26 16 9 Min - Max —5 - 12 —30 - 0 —67 - —5 —52 - —8 —47 - —34 P - Va1ue 0.2667 0.1111 0.0444 0.3333 PD97 N 0 2 4 8 1 Mean NC 3 —19 —28 —15 Median NC 3 —20 —25 —15 Std NC 27 15 14 Min - Max NC —17 - 22 —34 - —1 —58 - —13 —15 - —15 PD111 N 0 1 3 6 2 Mean NC —30 —3 —23 —20 Median NC —30 —8 —25 —20 Std NC 33 16 6 Min - Max NC —30 - —30 —32 - 32 —48 - —3 —24 - —1 6. . [ 0346 ] Tota1 Cho1estero1. Tota1 cho1estero1 mean 1eVe1s and mean percent of base1ine are shoWn in Tables 26 and 27 , respectiVe1y. The maximum mean reductions obserVed Were 27% in the 200 mg group and 40% in the 400 mg group ( Tab1e 27 ) . Due to the pro1onged effects of ISIS 3OI012 , the 1eVe1s of serum tota1 cho1estero1 Were measured at Day PD125 for 2. subjects and Day PD139 for 1 subject. At Day PD125 , the mean and median serum total cholestero1 1eVe1 for 2 subjects from the 200 mg cohort Was 170 mg / dL ( std : 16 ) , representing a —17% change re1atiVe to baseline ( std : 6 ) . At Day PD139 , tota1 serum cho1estero1 in 1 subject Was 193 mg / dL , representing a —7% change re1atiVe to base1ine. . . . US 2012 / 0115926 A1 May 10 , 2012 27 TABLE 26 Total Cho1esterol LeVe1 Summary , mg / dL Study Day P1acebo 5O mg 100 mg 200 mg 400 mg Base1ine N 7 8 8 9 4 Mean 216 221 218 211 239 Median 213 217 220 201 240 Std 33 33 24 18 30 Min - Max 174 - 271 186 - 290 182 - 251 193 - 244 201 - 275 P - Va1ue 0.9324 0.8056 0.7378 0.2182 MD8 N 7 8 8 8 2 Mean 214 205 201 187 203 Median 209 195 199 182 203 Std 18 29 29 22 14 Min - Max 190 - 240 166 - 255 155 - 251 166 - 232 193 - 213 P - Va1ue 0.285 0.1961 0.0126 0.6389 MD15 N 7 8 8 8 2 Mean 220 212 177 160 174 Median 217 211 182 159 174 Std 24 35 33 27 16 Min - Max 193 - 259 170 - 282 135 - 240 120 - 197 162 - 186 P - Value 0.4848 0.0071 0.0006 0.0556 MD22 N 7 8 8 8 2 Mean 211 214 173 151 155 Median 201 219 172 153 155 Std 37 23 25 20 6 Min - Max 159 - 263 166 - 240 139 - 220 124 - 178 151 - 159 P - Va1ue 0.8005 0.0266 0.0022 0.0833 MD25 N 7 8 8 8 2 Mean 211 217 188 160 162 Median 209 209 191 157 162 Std 39 26 24 22 6 Min - Max 143 - 271 186 - 267 143 - 224 120 - 190 159 - 166 P - Value 0.8838 0.1125 0.0099 0.2222 PD39 N 7 8 8 8 2 Mean 230 218 190 153 157 Median 224 213 190 164 157 Std 27 28 25 27 14 Min - Max 197 - 263 186 - 275 162 - 244 104 - 178 147 - 166 P - Value 0.4127 0.0047 0.0002 0.0556 PD55 N 7 8 8 8 2 Mean 235 224 185 161 176 Median 228 220 186 168 176 Std 31 26 28 26 3 Min - Max 201 - 298 193 - 275 132 - 232 128 - 190 174 - 178 P - Va1ue 0.3804 0.0044 0.0003 0.0556 PD69 N 3 5 7 7 2 Mean 241 222 193 154 159 Median 248 209 186 155 159 Std 26 58 24 21 11 Min - Max 213 - 263 166 - 313 162 - 240 128 - 178 151 - 166 P - Va1ue 0.3929 0.025 0.0167 0.2 PD83 N 2 4 7 8 2 Mean 259 226 201 168 182 Median 259 219 201 172 182 Std 33 50 27 25 16 Min - Max 236 - 282 174 - 294 170 - 251 132 - 209 170 - 193 P - Value 0.5333 0.1111 0.0444 0.3333 PD97 N 0 2 5 8 1 Mean NC 205 201 166 190 Median NC 205 209 166 190 Std NC 27 49 20 NC Min - Max NC 186 - 224 155 - 271 143 - 201 190 - 190 PD111 N 0 1 3 6 2 Mean NC 162 209 186 203 Median NC 162 228 188 203 Std NC NC 34 10 14 Min - Max NC 162 - 162 170 - 228 170 - 197 193 - 213. . US 2012 / 0115926 A1. . . . . 28 TABLE 27 T0tal Cholesterol , % Change from Baseline Study Day P1acebo 50 mg 100 mg 200 mg 400 mg MD8 N 7 8 8 8 2 Mean 1 —7 —8 —11 —21 Median —6 —10 —11 —12 —21 Std 13 7 8 6 2 Min - Max —13 - 20 —16 - 5 —16 - 4 —21 - —2 —23 - —19 P - Value 0.281 0.127 0.0721 0.0556 MD15 N 7 8 8 8 2 Mean 3 —4 —19 —23 —32 Median 0 —2 —21 —22 —32 Std 11 7 12 15 0 Min - Max —9 - 19 —14 - 4 —35 - 0 —51 - —8 —32 - —32 P - Value 0.281 0.0061 0.0012 0.0556 MD22 N 7 8 8 8 2 Mean —2 —2 —21 —27 —40 Median 2 —2 —21 —26 —40 Std 12 11 9 12 8 Min - Max —26 - 11 —17 - 19 —34 - —6 —46 - —12 —45 - —34 P - Value 0.6943 0.014 0.0037 0.0556 MD25 N 7 8 8 8 2 Mean —2 —2 —14 —24 —37 Median 0 —1 —13 —23 —37 Std 17 7 8 12 8 Min - Max —33 - 18 —14 - 8 —29 - —2 —40 - —6 —42 - —31 P - Value 0.9554 0.0502 0.0132 0.0833 PD39 N 7 8 8 8 2 Mean 7 —1 —12 —27 —39 Median 9 0 —13 —28 —39 Std 10 9 8 14 11 Min - Max —7 - 20 —11 - 8 —24 - —2 —50 - —12 —41 - —31 P - Value 0.0721 0.0025 0.0003 0.0556 PD55 N 7 8 8 8 2 Mean 10 2 —15 —23 —31 Median 5 4 —13 —27 —31 Std 14 7 8 14 6 Min - Max —6 - 31 —11 - 9 —28 - —7 —39 - —4 —35 - —27 P - Value 0.4634 0.0003 0.0006 0.0556 PD69 N 3 5 7 7 2 Mean 1 —3 —12 —27 —38 Median 0 0 —12 —25 —38 Std 5 11 6 11 10 Min - Max —3 - 7 —20 - 8 —20 - —4 —39 - —10 —45 - —31 P - Value 0.8571 0.0167 0.0167 0.2 PD83 N 2 4 7 8 2 Mean 8 1 —8 —20 —29 Median 8 3 —7 —15 —29 Std 5 8 6 12 13 Min - Max 4 - 11 —10 - 7 —17 - 0 —35 - —6 —38 - —19 P - Value 0.2667 0.0556 0.0444 0.3333 PD97 N 0 2 5 8 1 Mean NC 3 —8 —20 —21 Median NC 3 —9 —17 —21 Std NC 10 10 11 Min - Max NC —4 - 9 —18 - 8 —41 - —4 —21 - —21 PD111 N 0 1 3 6 2 Mean NC —16 5 —13 —21 Median NC —16 0 —12 —21 Std NC 14 8 2 Min - Max NC —16 - —16 —6 - 20 —25 - —4 —23 - —19 [ 03 47 ] HDL - Cho1estero1. Presented in Tab1es 28 and 29 are. the mean HDL - cho1estero1 1eVe1s and mean percent change relatiVe to base1ine HDL - cholestero1 , respectiVe1y. No signiﬁ - cant changes in HDL - cho1estero1 1eVe1s Were obserVed , as Wou1d be expected since HDL does not inc1ude an apo1ipoprotein B component. Just as e1eVated LDL - cho1estero1 is a risk factor for cardioVascu1ar disease , reduced HDL - cho1estero1 is a1so a risk factor that is considered When determining Whether an indiVidual is in need of iipid - 1oWering therapy. Thus , that ISIS 301012 did not adVersely affect HDL - cho1es - . tero1 1eVels is a positiVe therapeutic outcome. May 10 , 2012. TABLE 28. . HDL - Cholesterol LeVel Summary , mg / dL. . . Study Day Placebo 50 mg 100 mg 200 mg 400 mg. Baseline N 7 8 8 9 4 Mean 51 59 49 53 59 Median 44 52 45 48 57. US 2012 / 0115926 A1 May 10 , 2012. . . . . . . . 29 TABLE 28 - continued TABLE 29 HDL - Cholesterol LeVel Summary , mg / dL HDL - Cholesterol , % Change from Base1ine Study Day Placebo 50 mg 100 mg 200 mg 400 mg Study Day P1acebo 50 mg 100 mg 200 mg 400 mg MD8 N 7 7 8 8 2 Std 19 18 11 13 17 Mean _2 _9 _5 _7 _2g Min - Max 29—83 44 - 98 39 - 72 33 - 70 41 - 81 M644 _5 _5 _5 _g _2g P - Va1ue 0.1893 0.7789 0.4869 0.6485 Std 19 16 10 11 2 MD8 N 7 7 8 8 2 Min - Max —31 - 22 —35 - 9 —19 - 11 —27 - 8 —29 - —27 Mean 48 49 47 47 44 P - Va1ue 0.7104 0.7789 0.7789 0.2222 Median 53 52 44 45 44 MD15 Em ; 2 S 2 33 SS 13 13 ' 0 10 21 Median —10 —7 —9 —6 —31 Mm - Max 29 - 68 28 - 68 36 - 64 35 - 62 29 - 59 Std 20 8 10 8 3 P - Va1ue 0.9015 0.7789 0.8665 1 Min - Max _22_24 _17_5 _22_3 —23 - 6 _33__29 MD15 N 7 8 8 8 2 P - Va1ue 0.6943 0.9551 0.9551 0.0556 Mean 48 56 45 48 42 MD22 N 7 8 8 8 2 Median 53 53 43 43 42 Mean 1 —2 —6 —1 —10 Std 15 18 8 13 18 Median - 7 - 5 - 6 3 - 10 Min - Max 29 - 67 36 - 94 36 - 64 35 - 68 29 - 54 iii Max 2119 : ” 1011 16 1227 9 1021 10 175 5 P ' Va ' m 0 ' 2358 0 ' 8429 0.7789 0 ' 2 P - Va1ue 0.8665 0.6126 0.7789 0.6667 MD22 N 7 8 8 8 2 MD25 N 7 8 8 8 2 Mean 51 57 46 52 54 Mean 2 3 0 0 _3 Median 52 52 42 48 54 Median _5 2 _2 2 _3 Std 18 14 11 15 21 Std 19 6 13 5 7 Min - Max 28—78 45 - 87 37 - 65 34 - 74 39 - 69 Min - MaX - 17 - 30 —4 - 11 - 22 - 15 —10 - 5 - 8 - 2 P - Va1ue 0_77g9 0.7542 1 0_8gg9 P - Value 0.1893 0.8665 0.3969 1.0000 MD25 N 7 8 8 8 2 PD39 N 7 8 8 8 2 Mean 52 60 49 52 58 MW 7 5 1 1 5 Median 55 55 46 46 58 Med ' an ‘2 6 ‘1 1 5 Std 17 15 11 14 23 SS 20 10 13 10 8 Min - Max 28 - 75 48 - 94 37—69 34—73 42—74 M ' n ' MaX ' 2 ' 42 ' 12"2 ' 17 ' 21 ' 12 ' 20 0 ' 11 P - Va1ue 0.6126 0.8665 0.9551 0.8889 P ' Va ' m 0 ' 4634 0.7789 0 ' 9551 0 ' 2000 PD55 N 7 8 8 8 2 PD39 N 7 8 8 8 2 Mean 10 11 1 7 25 Mean 55 62 50 53 63 Median 3 7 3 11 23 Median 56 58 49 52 63 Std 18 17 9 9 30 Std 19 17 11 14 25 Min - Max —11 - 40 —7 - 45 —13 - 15 —12 - 15 4 - 46 Min - Max 27 - 82 43 - 99 38 - 73 29 - 71 45 - 80 P - Value 0.8421 0.4448 0.9294 0.3056 P - Va1ue 0.5358 0.5358 1 0.6667 PD69 N 3 4 5 7 2 PD55 N 7 8 8 8 2 Mean 2 19 —2 —1 10 Mean 55 65 50 56 72 Median 2 19 —5 2 10 Median 56 63 49 54 72 Std 7 7 19 9 6 Std 18 19 11 16 17 Min - Max —5 - 9 12 - 28 —20 - 29 —15 - 13 5 - 14 Min - Max 33—86 41_100 38 - 74 33_g0 60_g4 P - Va1ue 0.0571 0.3929 O.5167 O.4000 P - Va1ue 0.3357 0.4634 0.9551 0.5 PD83 N 2 4 7 8 2 Mean 61 67 49 52 66 Med ' an 10 26 2 2 9 Median 73 65 46 54 66 iii Max 10 [ i0 1112 38 1522 28 1315 27 g 9 iii MaX 322679 1 : 7 83 1 : 5 68 1 : 0 73 2 : 7 85 PD97 P - Va1ue 0.1333 0.2222 0.1778 0.3333 P - Value 1 0.5714 0.3833 0.8 Em N8 1‘ ; 2 f ; PD83 N 2 4 7 8 2 Median NC 18 —2 0 8 Mean 56 65 49 53 66 Std NC 0 14 10 NC Median 56 63 44 54 66 PD111 Min - Max NC 18 - 18 —5 - 29 —9 - 17 8 - 8 Std 33 6 13 15 31 N 0 1 2 6 2 Min - Max 32 - 79 62 - 75 38 - 75 31 - 77 45 - 88 Mean NC 9 —1 3 8 P - Va1ue 1 1 0.8889 0.6667 Median NC 9 —1 —1 8 PD97 N 0 2 5 8 1 Std NC NC 1 15 5 mm NC 62 32 32 87 Min - Max NC 99 —2 - 0 —10 - 31 5 - 12 Median NC 62 53 54 87 iiimMaX ii : 9_64 136 , 77 1§2_71 87 : 87 [ 03 48 ] Trig1yceride. Trig1yceride 1eVe1 summaries and per - PD1 11 N 0 1 2 6 2 cent changes are presented in Tables 30 and 31 , respectiVe1y. Mean Nc 55 63 56 65 Dose - dependent reductions in trig1yceride 1eVe1s Were Median NC 55 63 61 65 obserVed , With maximum reductions of 27% in the 200 mg Std NC 11 13 27 group and 43% in the 4OO mg group ( Table 31 ) . EleVated. M ' “ ' MaX NC 2222 5 6 ' 71 31 ' 68 46 ' 84 serum trig1yceride 1eVe1s may be considered an independent. risk factor for coronary heart disease , thus a reduction in trig1yceride1eVe1s is a therapeutica11y desirab1e outcome. . US 2012 / 0115926 A1 May 10 , 2012. . . . 30 TABLE 30 Triglyceride LeVel Summary , mg / dl Study Day P1acebo 5O mg 100 mg 200 mg 400 mg Base1ine N 7 8 8 9 4 Mean 104 95 105 103 127 Median 76 94 88 88 108 Std 90 29 47 44 57 Min - Max 56 - 307 55 - 139 65 - 212 51 - 179 82 - 209 P - Va1ue 0.3512 0.0875 0.3652 0.0727 MD8 N 7 7 8 8 2 Mean 127 114 116 112 149 Median 99 69 112 88 149 Std 82 71 48 63 86 Min - Max 41 - 286 51 - 239 37 - 209 57 - 232 88 - 209 P - Va1ue 0.6200 0.8906 0.9551 0.6667 MD15 N 7 8 8 8 2 Mean 146 109 126 100 123 Median 108 98 117 84 123 Std 113 46 61 39 4 Min - Max 50 - 371 46 - 178 34 - 231 72 - 172 120 - 126 P - Value 0.6943 1.0000 0.6733 0.8889 MD22 N 7 8 8 8 2 Mean 118 104 122 99 129 Median 78 101 137 77 129 Std 84 20 48 51 28 Min - Max 56 - 291 80 - 133 56 - 204 50 - 199 109 - 149 P - Value 0.5142 0.6319 1.0000 0.6111 MD25 N 7 8 8 8 2 Mean 110 95 114 101 91 Median 90 86 108 97 91 Std 83 24 47 47 32 Min - Max 45 - 288 72 - 136 69 - 218 48 - 196 68 - 113 P - Value 1.0000 0.4634 0.7167 0.9444 PD39 N 7 8 8 8 2 Mean 113 116 114 91 83 Median 63 99 98 84 83 Std 89 46 61 36 26 Min - Max 56 - 297 75 - 207 45 - 240 49 - 138 64 - 101 P - Value 0.3201 0.5894 0.9336 0.8333 PD55 N 7 8 8 8 2 Mean 97 93 146 77 103 Median 59 81 115 77 103 Std 65 41 103 23 51 Min - Max 52 - 226 49 - 168 56 - 389 41 - 109 67 - 139 P - Value 0.8026 0.1520 0.8665 0.5000 PD69 N 3 4 5 7 2 Mean 219 110 197 103 106 Median 92 110 135 90 106 Std 248 36 146 57 6 Min - Max 61 - 505 67 - 152 98 - 451 41 - 222 101 - 110 P - Va1ue 0.8571 0.5714 0.8333 0.8000 PD83 N 2 4 7 8 2 Mean 237 94 131 134 148 Median 237 96 108 107 148 Std 199 36 72 74 59 Min - Max 96 - 378 47 - 135 38 - 243 55 - 262 106 - 190 P - Value 0.4667 0.6667 0.5333 1.0000 PD97 N 0 2 5 8 1 Mean NC 147 149 99 83 Median NC 147 128 85 83 Std NC 50 112 56 NC Min - Max NC 111 - 182 59 - 337 60 - 232 83 - 83 PD111 N 0 1 2 6 2 Mean NC 151 96 118 109 Median NC 151 96 80 109 Std NC NC 68 106 34. Min - Max NC 151 - 151 48 - 144 46 - 326 85 - 133. . US 2012 / 0115926 A1. . May 10 , 2012. . . . . . . 31 TABLE 31 Triglyceride Mean , % from Baseline. Study Day P1acebo 50 mg 100 mg 200 mg 400 mg MD8 N 7 7 8 8 2. Mean 32 8 17 —1 —5. Median 17 0 11 —4 —5. Std 53 44 49 27 7. Min - Max —27 - 108 —41 - 72 —54 - 117 —34 - 52 —9 - 0. P - Va1ue 0.3829 0.9551 0.3357 0.5 MD15 N 7 8 8 8 2. Mean 45 17 34 —6 —6. Median 21 25 8 0 —6. Std 64 37 97 20 51. Min - Max —24 - 166 —47 - 50 —58 - 255 —42 - 22 —43 - 30. P - Va1ue 0.9551 0.6126 0.0289 0.5 MD22 N 7 8 8 8 2. Mean 21 18 21 —8 —8. Median 0 13 8 —6 —8. Std 41 38 47 28 29. Min - Max —13 - 101 —35 - 91 —30 - 117 —64 - 30 —29 - 12. P - Va1ue 1 0.9551 0.1206 0.5 MD25 N 7 8 8 8 2. Mean 10 4 12 —7 —38. Median 17 4 1 —7 —38. Std 32 26 29 26 11. Min - Max —38 - 47 —34 - 35 —14 - 69 —46 - 28 —46 - —30. P - Va1ue 0.6943 1 0.281 0.1111 PD39 N 7 8 8 8 2. Mean 12 23 10 —15 —43. Median —3 16 4 —20 —43. Std 43 35 44 23 13. Min - Max —18 - 99 —13 - 92 —44 - 106 —44 - 30 —52 - —34. P - Va1ue 0.281 0.7789 0.152 0.0556 PD55 N 7 8 8 8 2. Mean 1 —1 37 —27 —32. Median —11 —6 20 —34 —32. Std 38 30 60 20 2. Min - Max —30 - 70 —52 - 56 —30 - 160 —43 - 18 —34 - —31. P - Va1ue 0.7789 0.2319 0.0541 0.0556 PD69 N 3 4 5 7 2. Mean 30 12 99 —9 —19. Median 17 17 14 —11 —19. Std 30 21 176 34 46. Min - Max 9 - 65 —16 - 29 —14 - 407 —54 - 45 —5 2 - 13. P - Va1ue 0.6286 1 0.1833 0.4 PD83 N 2 4 7 8 2. Mean 22 —2 31 17 23. Median 22 —1 21 22 23. Std 1 26 70 30 103. Min - Max 22 - 23 —32 - 25 —53 - 170 —25 - 71 —49 - 96. P - Va1ue 0.5333 0.8889 1 1 PD97 N 0 2 5 8 1. Mean NC 57 24 —9 —14. Median NC 57 6 —16 —14. Std NC 6 43 31 NC. Min - Max NC 53 - 61 —26 - 78 —39 - 52 —14 - —14 PD111 N 0 1 2 6 2. Mean NC 27 41 6 —24. Median NC 27 41 —16 —24. Std NC NC 114 57 17. Min - Max NC 27 - 27 —40 - 122 —45 - 113 —36 - —12 [ 0349 ] Lipoprotein ( a ) . Tab1es 32 and 33 shoW mean 1ipoprotein ( a ) leVels and mean lipoprotein ( a ) changes relatiVe to TABLE 32 baseline , respectiVely. Lipoprotein ( a ) has been linked With M O rOtemm ) LeVel Summ m / dL the deVelopment and progression of atherosc1erosis , thus its p p my g reduction can be a goa1 of iipid - 1oWering therapies. A maxi - Study Day Placeb0 50 mg 100 mg 200 mg 400 mg mal reduction of approximately 22% Was ob serVed Was in the Baseline N 7 8 8 9 4 2OO mg group at MD22 , hoWeVer , no other dose - dependent mm 12 16 10 24 6 statistica11y signiﬁcant reductions in 11poprotein ( a ) Were Median 4 7 7 11 5. obserVed. US 2012 / 0115926 A1 May 10 , 2012. . . . . . . . . . . 32 TABLE 32 - continued TABLE 32 - continued Lipoprotein ( a ) LeVe1 Summary , mg / dL Lipoprotein ( a ) Level Summary , mg / dL Study Day P1acebo 50 mg 100 mg 200 mg 400 mg Study Day P1acebo 50 mg 100 mg 200 mg 400 mg Std 16 24 11 27 4 Min - Max 1 - 38 1 - 80 1 - 21 2 - 70 1 - 6 Min - Max 1 - 45 1 - 71 1 - 29 3 - 73 1 - 10 P - Value 0.6876 0.5820 0.4434 0.5000 P - Value 0.6876 0.9549 0.2507 0.8242 PD55 N 7 8 8 8 2 MD8 N 7 7 8 8 2 Mean 13 14 8 21 1 Mean 12 6 11 25 4 Median 4 3 1 8 1 Median 6 3 6 10 4 Std 15 25 11 24 0 Std 15 7 13 29 4 Min - Max 1 - 42 1 - 74 1 - 28 4 - 60 1 - 1 Min - Max 1 - 43 1 - 21 1 - 32 4 - 84 1 - 7 P - Value 0.6061 0.2211 0.2810 0.1389 P - Value 0.5973 0.8291 0.2213 0.63 89 PD69 N 3 4 5 7 2 MD15 N 7 8 8 8 2 Mean 2 4 9 23 3 Mean 13 17 10 22 5 Median 1 3 6 13 3 Median 5 5 7 8 5 Std 2 3 11 25 2 Std 15 27 11 26 6 Min - Max 1 - 4 1 - 8 1 - 27 3 - 61 1 - 4 Min - Max 1 - 41 1 - 81 1—30 6 - 67 1 - 9 P - Value 0.5429 0.3214 0.0333 0.7000 P - Value 0.8379 0.7739 0.2681 0.63 89 PD83 N 2 4 7 8 2 MD22 N 7 8 8 8 2 Mean 3 3 9 21 4 Mean 13 15 8 21 4 Median 3 1 4 13 4 Median 3 3 3 8 4 Std 2 4 10 26 4 Std 16 26 11 26 4 Min - Max 1 - 4 1 - 9 1 - 23 1 - 65 1 - 7 Min - Max 1 - 44 1 - 75 1—31 3 - 63 1 - 7 P - Va1ue 1.0000 0.5000 0.4000 1.0000 P - Value 0.8632 0.6061 0.2674 0.63 89 PD97 N 0 2 5 8 1 MD25 N 7 8 8 8 2 Mean NC 1 14 22 1 Mean 14 17 10 22 4 Median NC 1 10 12 1 Median 5 6 4 9 4 Std NC 0 11 25 Std 18 30 12 26 5 Min - Max NC 1 - 1 1 - 27 1 - 66 1 - 1 Min - Max 1 - 50 1 - 89 1—31 2 - 65 1 - 7 PD111 N 0 1 2 6 2 P - Value 0.9549 0.7629 0.3340 0.7500 Mean NC 3 28 23 5 PD39 N 7 8 8 8 2 Median NC 3 28 10 5 Mean 14 14 8 23 3 Std NC 2 33 5 Median 9 3 4 11 3 Min - Max NC 3 - 3 27 - 30 4 - 90 1 - 9 Std 15 27 9 27 3 TABLE 33 Lipoprotein ( a ) , % Change from Baseline Study Day Placebo 50 mg 100 mg 200 mg 400 mg MD8 N 7 7 8 8 2 Mean 32 —12 —6 1 —17 Median 0 —21 0 —7 —17 Std 75 61 31 22 25 Min - Max —21 - 190 —82 - 1 10 —60 - 41 —24 - 40 —35 - 0 P - Va1ue 0.2063 0.8432 0.4448 0.4722 MD15 N 7 8 8 8 2 Mean 26 29 —5 —8 —5 Median 0 27 0 —15 —5 Std 56 77 20 34 6 Min - Max —9 - 150 —80 - 140 —41 - 28 —37 - 74 —9 - 0 P - Va1ue 1 0.3 893 0.0138 0.4444 MD22 N 7 8 8 8 2 Mean 25 6 —24 —22 —14 Median 0 —9 —20 —23 —14 Std 65 110 27 15 20 Min - Max —18 - 170 —89 - 250 —66 - 5 —49 - —3 —29 - 0 P - Va1ue 0.4625 0.0476 0.0034 0.3333 MD25 N 7 8 8 8 2 Mean 11 —9 —14 —20 —13 Median 9 —6 —6 —15 —13 Std 14 32 28 13 19 Min - Max 0 - 39 —50 - 38 —60 - 24 —41 - —4 —27 - 0 P - Va1ue 0.1377 0.0659 0.0003 0.1667 PD39 N 7 8 8 8 2 Mean 46 —31 —19 —15 —22 Median 7 —30 —17 —9 —22 Std 65 35 23 27 32 Min - Max —17 - 139 —78 - 13 —59 - 8 —75 - 9 —45 - 0. P - Va1ue 0.0176 0.0253 0.0499 0.2222. US 2012 / 0115926 A1. . . . . 3 3 TABLE 33 - continued Lipoprotein ( a ) , % Change from Base1ine. Study Day P1acebo 50 mg 100 mg 200 mg 400 mg PD55 N 7 8 8 8 2. Mean 41 —26 —30 —14 —45. Median 8 —4 —22 —1 6 —45. Std 65 41 33 28 64. Min - Max —7 - 140 —89 - 1 6 —91 - O —52 - 41 —90 - 0. P - Va1ue 0.039 0.0034 0.014 0.1389 PD69 N 3 4 5 7 2. Mean 3 —16 —12 —5 —29. Median 0 —20 —5 —10 —29. Std 4 66 20 38 41. Min - Max 0 - 8 —89 - 67 —48 - 0 —68 - 43 —57 - 0. P - Va1ue 0.6286 0.125 0.7833 0.6 PD83 N 2 4 7 8 2. Mean 4 —22 —28 —20 —18. Median 4 0 —20 —17 —18. Std 5 45 26 55 25. Min - Max 0 - 8 —89 - 2 —60 - 0 —91 - 81 —36 - 0. P - Va1ue 0.4667 0.1389 0.4 0.6667 PD97 N 0 2 5 8 1. Mean NC —45 —15 4 0. Median NC —45 —20 —13 0. Std NC 63 20 69. Min - Max NC —89 - 0 —3 8 - 12 —91 - 141 0.0 - 0.0 PD111 N 0 1 2 6 2. Mean NC —7O 8 24 —7. Median NC —70 8 5 —7. Std NC 23 80 11. Min - Max NC —70 - —70 —8 - 24 —63 - 156 —15 - 0 [ 0350 ] Tota1 Cho1estero1 Versus HDL - Cholestero1. ImproVements in 11poprotein 1eVe1s can be assessed by comparing the ratio of tota1 cho1estero1 to HDL - cho1estero1. A decrease in this ratio indicates an improVement in a iipoprotein proﬁ1e , and such a decrease can occur either through reduction in total cholesterol , increase in HDL - cholesterol , or a combination of changes in both parameters. As Wou1d be expected fol1oWing a decrease in tota1 cho1estero1 and no change in HDL - cholesterol , this ratio Was improVed folloWing ISIS 301012 treatment. For examp1e , in the 200 mg group , . a maxima1 reduction of approximate1y 29% Was obserVed at PD55 ( Tab1e 35 ) . TABLE 34. . Tota1 Cho1estero1HDL - Cho1esterol Ratio , Summary. . Study Day. Placebo. 50 mg. 10O mg. 20O mg. 400 mg. . Baseline. MD8. MD15. N. Mean Median Std Min - Max P - Value N. Mean Median Std Min - Max P - Value N. Mean Median Std Min - Max P - Va1ue. N435J1 - l. 3 - 9. NLMﬁ. 3 - 8. MLMﬁ. 3 - 9. H - b - boo. 2 - 5 0.8665. r— - |> - b - - .1. 3 - 6 0.8316. r— - |> - l>~. 2 - 5 0.6126. t— : - lb - - |> - oo. 2 - 6 0.9551. t— : - |‘—~ - - I> - oo. 3 - 7 O.6943. H434‘ : - . 3 - 6 0.3514. N - b - b - Jk. 3 - 7. NmUtNt - t. 3 - 7. NLLNH. 3 - 6 0.6667. May 10 , 2012. TABLE 34 - continued. . Tota1 Cho1estero1HDL - Cho1esterol Ratio , Summary. . . Study Day P1acebo 50 mg 100 mg 200 mg 40O mg MD22 N 7 8 8 8 2 Mean 5 4 4 3 3 Median 4 4 4 3 3 Std 2 1 1 1 1 Min - Max 3 - 9 2 - 5 3 - 6 2 - 4 2 - 4 P - Value O.843 0.8665 0.0939 O.5 MD25 N 7 8 8 8 2 Mean 5 4 4 3 3 Median 4 4 4 3 3 Std 2 1 1 1 1 Min - Max 3 - 10 3 - 5 3 - 6 2 - 4 2 - 4 P - Value O.7559 0.9312 0.0876 O.63 89 PD39 N 7 8 8 8 2 Mean 5 4 4 3 3 Median 4 4 4 3 3 Std 2 1 1 1 1 Min - Max 3 - 9 3 - 5 3 - 6 2 - 4 2 - 3 P - Va1ue O.2949 0.7169 0.0541 0.0556 PD55 N 7 8 8 8 2 Mean 5 4 4 3 2 Median 4 3 4 3 2 Std 2 1 1 1 1 Min - Max 3 - 8 3 - 5 3 - 6 2 - 4 2 - 3 P - Value 0.2438 O.4634 0.0225 0.1111 PD69 N 3 4 5 7 2 Mean 5 3 4 3 3 Median 3 3 4 3 3 Std 3 1 2 1 1 Min - Max 3 - 7 3 - 4 3 - 6 2 - 4 2 - 3 P - Value 0.4 O.7857 0.35 0.8 PD83 N 2 4 7 8 2 Mean 5 3 4 3 3 Median 5 3 4 3 3. US 2012 / 0115926 A1 May 10 , 2012. . . . . . . . . . . 34 TABLE 34 - continued TABLE 34 - continued Tota1 CholesterolHDL - Cholesterol Ratio , Summary Total CholesterolHDL - Cholesterol Ratio , Summary Study Day P1acebo 50 mg 100 mg 200 mg 400 mg Study Day Placebo 50 mg 100 mg 200 mg 400 mg Std 3 1 1 1 1 Min - Max 3 - 8 3 - 4 2 - 6 2 - 4 2 - 4 PD111 N 0 1 2 6 2 P - Value 0.5333 0.8889 0.4 0.6667 Mean NC 3 4 3 3 PD97 ﬁﬁ NC 3 i g 3 Median NC 3 4 3 3 Median NC 3 4 3 2 Std NC NC 1 1 1 Std NC 0 2 1 NC Min - Max NC 3 - 3 3 - 4 3 - 6 2 - 4 Min - Max NC 3 - 3 2 - 6 2 - 5 2 - 2 TABLE 35 Total Cholesterol : HDL Ratio , % Change from Base1ine Study Day P1acebo 50 mg 100 mg 200 mg 400 mg MD8 N 7 7 8 8 2 Mean 6 3 2 —2 6 Median 2 —3 —0.7 —7 6 Std 14 16 8 13 5 Min - Max —12 - 29 —10 - 35 —6 - 20 —14 - 23 3 - 10 P - Value 0.7104 0.6943 0.2319 0.6667 MD15 N 7 8 8 8 2 Mean 10 —1 —6 —18 —9 Median 11 —2 —6 —19 —9 Std 11 6 14 14 1 Min - Max —3 - 28 —9 - 9 —28 - 17 —37 - 1 —10 - —9 P - Value 0.0541 0.0721 0.0022 0.0556 MD22 N 7 8 8 8 2 Mean 0.5 —3 —8 —24 —34 Median —1 —3 —10 —25 —34 Std 12 7 8 11 13 Min - Max —14 - 21 —14 - 8 —18 - 5 —38 - —10 —43 - —25 P - Value 0.7789 0.1206 0.0012 0.0556 MD25 N 7 8 8 8 2 Mean —3 —6 —10 —24 —33 Median —2 —4 —10 —21 —33 Std 9 7 9 11 12 Min - Max —16 - 7 —15 - 7 —23 - 5 —39 - —11 —42 - —25 P - Value 0.5358 0.1206 0.0022 0.0556 PD39 N 7 8 8 8 2 Mean 0.8 —9 —10 —27 —43 Median 5 —8 —6 —26 —43 Std 10 14 12 14 17 Min - Max —15 - 11 —34 - 11 —35 - 3 —45 - —8 —55 - —31 P - Va1ue 0.1893 0.0939 0.0037 0.0556 PD55 N 7 8 8 8 2 Mean —1 —9 —11 —29 —45 Median —0.7 —12 —7 —28 —45 Std 6 18 15 12 17 Min - Max —10 - 6 —3 8 - 11 —44 - 7 —42 - —9 —57 - —33 P - Va1ue 0.5358 0.152 0.0006 0.0556 PD69 N 3 4 5 7 2 Mean —2 —27 —6 —26 —41 Median —0.7 —25 —0.4 —26 —41 Std 14.2 7.3 17.4 15.5 12 Min - Max —17 - 11 —38 - —22 —37 - 5 —53 - —6 —50 - —33 P - Va1ue 0.0571 1 0.0667 0.2 PD83 N 2 4 7 8 2 Mean —8 —26 —5 —20 —35 Median —8 —27 —5 —19 —35 Std 10 4 14 18 12 Min - Max —15 - —1 —29 - —20 —3 1 - 11 —54 - 2 —43 - —26 P - Va1ue 0.1333 0.6667 0.4 0.3333 PD97 N 0 2 5 8 1 Mean NC —15 —9 —17 —31 Median NC —15 —4 —13 —31 Std NC 6 17 18 0. Min - Max NC —19 - —11 —36 - 5 —56 - 2 —31 - —31. . . . . . . . . . . . . . . US 2012 / 0115926 A1 May 10 , 2012 35 TABLE 35 - continued Total Cholesterol : HDL Ratio , % Change from Baseline Study Day P1acebo 50 mg 100 mg 200 mg 400 mg PD111 N 0 1 2 6 2 Mean NC —22 15 —18 —32 Median NC —22 15 —13 —32 Std NC NC 16 15 10 Min - Max NC —22 - —22 4 - 26 —48 - —6 —39 - —25 [ 0351 ] LDL Cho1estero1 Versus HDL - cho1estero1. Lipid proﬁ1es Were further eVa1uated by comparing the LDL - cho - TABLE 36 - continued 1esterol leVel to the HDL - cho1esterol 1eVe1. A decrease in this . ratio is a positiVe outcome and indicates a reduction in LDL - LDL ' HDL mm Sm ' mm cho1estero1 , an e1eVation in HDL - cho1estero1 , or a combina - Study Day Placeb0 30 mg 100 mg 200 mg 400 mg tion of changes in both parameters. As Wou1d be expected With decreases in LDL - cho1estero1 and no change in HDL - SS 2 1 1 0 1 Cholestero1 fo11oWing treatment With ISIS 301012 , this ratio 111 : 1 ; 3 / 16“ 2 ' 6 0 22389 0 g ; 0 1522 0 22 Was loWered. For example , the mean ratio in the 200 mg group PD39 N 7 g ' g ' 8 ' 2 ' Was approximately 38% less than base1ine 1eVe1s at PD39. Mean 3 2 2 2 1 Median 2 2 2 2 1 Std 2 1 1 0 1 TABLE 36 Min - Max 2 - 6 1 - 3 1 - 4 1 - 2 1 - 2 LDL1HDL 11111111 Summm PD55 11 : 1 - va1ue 7 35542 111841 30135 32222 Study Day Placebo 50 mg 100 mg 200 mg 400 mg Mean 3 2 2 2 1 Med1an 2 2 2 1 1 . Std 1 1 1 1 1 BaSe ' me E g 3 g g j Min - Max 2 - 6 1 - 3 1 - 4 1 - 2 1 - 2 M : : ' 1 ' an 3 2 3 3 2 P - Value 0.3201 0.5358 0.0401 0.1111 Std 2 1 1 1 1 PD69 N 2 2 5 7 2 Min - Max 26 13 14 26 24 M631? 2 2 2 2 1 P - Value 0.4634 0.9315 0.5913 0.6848 Med1an 2 2 2 2 1 MD8 N 7 7 8 8 2 Std 0 0 1 1 1 Mean 3 3 3 2 3 Min - Max 2 - 2 2 - 2 1 - 4 1 - 3 12 Median 2 2 3 2 3 P - Value 1 0.5714 0.8889 1 Std 1 1 1 1 2 PD83 N 2 3 7 8 2 Min - Max 2 - 5 2 - 4 2 - 5 2 - 3 2 - 4 Mean 3 2 2 2 2 P - Value 0.8048 0.9551 0.5565 0.6667 Median 3 2 3 2 2 MD15 N 7 8 8 8 2 Std 3 0 1 1 1 WW 3 2 2 2 2 Min - Max 2 - 5 2 2 1 - 4 1 - 3 1 - 2 g1 : d13 - H 2 2 2 12 ) 2 P - Va1ue 1 0.8889 0.8889 0.6667 Min - Max 2 - 6 1 - 3 2 - 4 1 - 3 1 - 3 PD97 111111111 11112 2 2 3 0 NC P - Value 0.7789 0.3357 0.0401 0.6667 Median NC 2 2 2 NC MD22 N 7 8 8 8 2 Mean 3 2 2 2 2 Std NC 0 1 1 NC Median 2 2 2 2 2 Min - Max NC 2 2 1 - 4 1 - 3 NC Std 2 1 1 1 1 PD111 N 0 2 6 0 Min - Max 2 - 6 1 - 3 1 - 4 1 - 2 12 MW NC 2 2 2 NC P - Value 0.8019 0.9551 0.1284 0.5 Median NC 2 2 2 NC MD25 N 7 8 8 8 2 Std NC 1 1 NC Mean 3 2 2 2 2 Min - Max NC 2 2 2 - 2 1 4 NC Median 2 2 2 2 2 TABLE 37 LDL : HDL Ratio , % Change from Baseline Study Day Placebo 50 mg 100 mg 200 mg 400 mg MD8 N 7 7 8 8 2 Mean 2 3 —3 —5 1 Median 5 —3 —3 —6 1 Std 17 19 20 19 4 Min - Max —15 - 28 —12 - 44 —25 - 34 —30 - 28 —2 - 4 P - Va1ue 0 0.8048 0.5358 0.637 0.8889. . . . . US 2012 / 0115926 A1 May 10 , 2012 36 TABLE 37 - continued LDL : HDL Ratio , % Change from Baseline Study Day Placebo 50 mg 100 mg 200 mg 400 mg MD15 N 7 8 8 8 2 Mean 7 6 —16 —24 —19 Median 2 0 —18 —24 —19 Std 19 15 21 18 2 Min - Max —16 - 41 —8 - 33 —44 - 22 —50 - 0 —20 - —18 P - Value 0 0.8665 0.0289 0.0093 0.0556 MD22 N 7 8 8 8 2 Mean —4 3 —16 —31 —42 Median 1 2 —19 —28 —42 Std 19 16 14 16 12 Min - Max —27 - 27 —13 - 39 —36 - 11 —56 - —12 —51 - —34 P - Value 0 0.6126 0.3969 0.0103 0.0556 MD25 N 7 8 8 8 2 Mean —7 0.6 —18 —31 —42 Median 0 —4 —19 —26 —42 Std 15 18 13 15 12 Min - Max —32 - 4 —14 - 42 —35 - 6 —56 - —15 —50 - —34 P - Value 0 0.9551 0.2319 0.0205 0.0556 PD39 N 7 8 8 8 2 Mean —6 —9 —19 —36 —47 Median —8 —13 —23 —34 —47 Std 16 16 12 20 13 Min - Max —25 - 22 —28 - 28 —33 - 2 —62 - —8 —56 - —37 P - Value 0 0.8665 0.0721 0.0093 0.0556 PD55 N 7 8 8 8 2 Mean —10 —14 —21 —38 —51 Median —14 —17 —27 —35 —51 Std 8 12 17 16 14 Min - Max —18 - 2 —32 - 6 —42 - 6 —59 - —10 —61 - —41 P - Value 0 0.3969 0.1893 0.0037 0.0556 PD69 N 2 2 5 7 2 Mean 6 —26 —15 —28 —46 Median 6 —26 —15 —24 —46 Std 23 15 13 14 9 Min - Max —10 - 23 —37 - —16 —36 - —2 —50 - —10 —53 - —40 P - Value 0 0.3333 0.381 0.1111 0.3333 PD83 N 2 3 7 8 2 Mean —10 —24 —18 —24 —36 Median —10 —30 —23 —17 —36 Std 2 12 9 19 11 Min - Max —12 - —9 —30 - —10 —28 - —4 —52 - 5 —44 - —28 P - Value 0 0.4 0.5 0.2667 0.3333 PD97 N 0 2 5 8 0 Mean NC —14 —18 —21 NC Median NC —14 —16 —13 NC Std NC 12 18 18 NC Min - Max NC —22 - —6 —37 - 5 —54 - —3 NC N 0 1 2 6 0 Mean NC —24 7 —20 NC Median NC —24 7 —16 NC Std NC 0 24 14 NC Min - Max NC —24 - —24 —10 - 24 —46 - —7 NC [ 0352 ] VLDL - Cho1eStero1. Reducti0ns in VLDL - cho1es - . ter01 Were 0bSerVed , aS dem0nStrated in Tab1eS 38 and 39. Maxima1reducti0ns Were 30% in the 200 mg gr0up and 60% in the 400 mg group ( Table 39 ) . . . . TABLE 38 - c0ntinued. . Total VLDL Level Summary , mg / dL. . . Study TABLE 38 Day Placebo 50 mg 100 mg 200 mg 400 mg Total VLDL Level Summary , mg / dL Std 83 31 43 36 48 Study Min - Max 36 - 264 16 - 95 45 - 179 34 - 136 73 - 177 Day Placebo 50 mg 100 mg 200 mg 400 mg P - value 0.9807 0.1604 0.5177 0.0727 MD8 N 7 7 8 8 2 Base - N 7 8 8 9 4 Mean 91 83 89 75 118 line Mean 77 59 78 71 107 Median 56 54 81 56 118 Median 47 66 66 59 88 Std 75 68 42 48 81. US 2012 / 0115926 A1. TABLE 38 - continued. May 10 , 2012. TABLE 39 - continued. . Total VLDL Level Summary , mg / dL. . Total VLDL , % Change from Baseline. . Study. Study. . . . . . . . Day Placebo 50 mg 100 mg 200 mg 400 mg Day Placebo 50 mg 100 mg 200 mg 400 mg Min - Max 24 - 242 18 - 210 34 - 174 37 - 177 61 - 175 MD15 N 7 8 8 8 2 P - value 0.8048 0.6126 0.9551 0.5 Mean 47 39 45 —8 —32 MD15 N 7 8 8 8 2 Median 51 56 16 —15 —32 Mean 108 78 100 65 83 Std 72 48 106 29 24 Median 72 63 97 53 83 Min - Max —44 - 155 —36 - 88 —68 - 273 —47 - 50 —49 - —16 Std 104 48 58 25 10 P - value 0.9551 0.8665 0.152 0.2222 Min - Max 25 - 326 29 - 146 21 - 190 41 - 105 76 - 90 MD22 N 7 8 8 8 2 P - value 0.8665 0.7167 0.5913 0.8889 Mean 27 53 30 —6 —29 MD22 N 7 8 8 8 2 Median 11 40 15 3 —29 Mean 86 79 95 66 93 Std 59 68 54 32 6 Median 52 74 100 57 93 Min - Max —47 - 134 —30 - 171 —35 - 128 —70 - 35 —33 - —24 Std 75 40 43 31 35 P - value 0.6126 1 0.3969 0.2222 Min - Max 30 - 244 28 - 141 43 - 166 29 - 129 68—1 18 MD25 N 7 8 8 8 2 P - value 0.7789 0.3969 0.9551 0.5 Mean 14 25 23 —13 —60 MD25 N 7 8 8 8 2 Median 14 6 17 —7 —60 Mean 79 65 89 63 59 Std 60 57 33 34 16 Median 61 60 86 54 59 Min - Max —64 - 102 —37 - 125 —9 - 84 —57 - 34 —71 - —49 std 78 33 34 39 46 P - value 0.7789 0.8023 0.3969 0.2222 Min - Max 20 - 246 19 - 121 60 - 163 29 - 153 26 - 91 PD39 N 7 8 8 8 2 P - value 0.843 0.2303 0.8887 0.8611 Mean 16 61 25 —12 —51 PD39 N 7 8 8 8 2 Median —11 26 14 —15 —51 Mean 83 85 94 62 66 Std 55 75 41 36 3 Median 46 77 81 60 66 Min - Max —22 - 113 5 - 225 —9 - 120 —56 - 51 —53 - —49 std 76 43 49 28 34 P - value 0.0721 0.1206 0.4634 0.0556 Min - Max 28 - 239 24 - 157 50 - 195 23 - 97 42 - 90 PD55 N 7 8 8 8 2 P - value 0.5358 0.281 1 0.9444 Mean —1 5 33 —30 —55 PD55 N 7 8 8 8 2 Median —26 20 20 —44 —55 Mean 67 58 105 50 66 Std 50 34 45 31 17 Median 41 47 85 51 66 Min - Max —36 - 76 —57 - 38 —22 - 124 —51 - 42 —67 - —43 Std 58 35 74 21 50 P - value 0.6126 0.1206 0.0721 0.0556 Min - Max 23 - 191 22 - 115 42 - 279 18 - 77 30 - 101 PD69 N 3 4 5 7 2 P - value 1 0.0671 0.7789 1 Mean 4 35 83 —8 —35 PD69 N 3 4 5 7 2 Median —11 20 49 —4 —35 Mean 150 66 130 70 83 Std 30 55 124 39 12 Median 48 59 104 61 83 Min - Max —16—38 —15—114 —27—292 —69 - 39 —44——27 Std 184 27 73 43 23 P - value 0.6286 0.3929 0.8333 0.2 Min - Max 40 - 363 44 - 102 67 - 255 21 - 156 66 - 99 PD83 N 2 4 7 8 2 P - value 1 0.5714 1 0.8 Mean 24 —7 21 13 2 PD83 N 2 4 7 8 2 Median 24 —16 6 9 2 Mean 190 50 90 89 109 Std 3 52 63 36 88 Median 190 52 80 82 109 Min - Max 22 - 27 —60 - 64 —57 - 126 —31 - 62 —61 - 64 Std 187 25 54 54 55 P - value 0.5333 0.8889 0.7111 1 Min - Max 57 - 322 21 - 74 23 - 176 29 - 185 70 - 148 PD97 N 0 2 5 8 1 P - value 0.5333 0.6667 0.5333 1 Mean NC 14 35 —8 —52 PD97 N 0 2 5 g 1 Median NC 14 8 —10 —52 Mean NC 82 112 67 43 Std NC 25 62 37 Median NC 82 95 52 43 Min - Max NC —4 - 31 —18 - 138 —52 - 54 —52 - —52 std NC 45 87 46 NC PD111 N 0 1 2 6 2 Min - Max NC 50 - 114 42 - 260 34 - 176 43 - 43 M9311 NC 8 46 - 3 - 41 PD111 N 0 1 2 6 2 Median NC 8 46 —16 —41 Mean NC 94 76 78 82 Std NC 120 53 9 Median NC 94 76 48 82 Min - Max NC 8 - 8 —39 - 131 —44 - 97 —47 - —35 Std NC 7 60 77 48 Min - Max NC 94 - 94 33 - 118 19 - 225 48 - 116 [ 0353 ] LDL Partic1e Size. Evidence exists that high concentrations of sma11 , dense LDL partic1es can be re1iab1e TABLE 39 predictors of cardiovascu1ar risk. To eVa1uate the effects of ISIS 3010I2 on LDL partic1e siZe in study participants , tota1 T0talVLDL , % Chan9e fr0m Baseline LDL partic1e concentration , sma11 and 1arge LDL subc1ass Study partic1es , and mean LDL partic1e size Were determined by Day P1aCeb0 50 mg 100 mg 200 mg 400 mg NMR ( Liposcience , Ra1eigh , N. C. ) . As apo1ipoprotein B is a MD8 N 7 7 8 8 2 component ofLDL - cho1estero1 , p1asma ap01ipoproteinB1evMean 37 18 23 _2 _17 els provided an independent measure of LDL partic1e con - M : dia—n 18 0 12 - 10 - 17 centration. In addition to reductions in serum apo1ipoprotein iiin - Max _586_9149 _i75_121 37 - 1 35 —2191 - 55 _2322__1 B and LDL - cho1estero1 1n the 200 mg dose group , s1gn1ﬁcant P - va1ua 0.535 0.77g9 0.2319 0.3333 reductions in LDL partic1e number , predominant1y sma11 , . dense LDL partic1es Were observed. Reductions Were seen in. US 2012 / 0115926 A1 May 10 , 2012 38. the concentration of sma11 LDL partic1es ( Tab1es 40 and 41 ) , 301012. These resu1ts indicate that LDL - cho1estero1 reduc - as We11 as in the fraction of LDL - cho1estero1 that sma11 LDL - tion fo11oWing antisense inhibition of apo1ipoprotein B is in cho1estero1 ( Tab1es 42 and 43 ) . The duration of response Was part due to reduction in sma11 , dense , atherogenic LDL par - c0nsistent With the 10ng hepatic tissue ha1f - life 0f ISIS tic1es. TABLE 40. . Small LDL Particle Concentration , nmol / L. . Study Day Placebo 50 mg 100 mg 200 mg 400 mg Baseline N 7 8 8 9 4 Mean 913 401 848 821 869 Median 593 454 646 856 758 Std 859 306 583 277 511 Min - Max 409 - 2824 0 - 859 243 - 2134 446 - 1363 389 - 1569 P - value 0.152 0.6943 0.351 0.7879 MD8 N 7 7 8 8 2 Mean 1157 463 946 780 695 Median 989 484 828 687 695 Std 662 252 565 409 809 Min - Max 656 - 2582 8 - 775 416 - 2177 450 - 1709 123 - 1267 P - value 0.0023 0.3969 0.1206 0.8889 MD15 N 7 8 8 8 2 Mean 1181 465 825 582 390 Median 876 426 618 594 390 Std 844 391 545 212 465 Min - Max 245 - 2699 2 - 1107 397 - 2089 322 - 914 61 - 719 P - value 0.0939 0.281 0.0939 0.2222 MD22 N 7 8 8 8 2 Mean 979 449 816 520 265 Median 849 423 726 461 265 Std 693 367 607 246 375 Min - Max 93 - 2310 0 - 935 217 - 2134 236 - 1023 0 - 530 P - value 0.152 0.6126 0.1206 0.1111 MD25 N 7 8 8 8 2 Mean 993 434 862 514 272 Median 634 416 723 471 272 Std 861 273 597 210 343 Min - Max 327 - 2846 15 - 825 244 - 2193 308 - 900 29 - 514 P - va1ue 0.0721 0.7789 0.1893 0.1111 PD39 N 7 8 8 8 2 Mean 887 507 688 344 172 Median 646 487 644 344 172 Std 652 387 564 148 155 Min - Max 346 - 2226 19 - 1112 6 - 1948 98 - 571 62 - 281 P - value 0.281 0.5911 0.014 0.0556 PD55 N 7 8 8 8 2 Mean 876 479 791 289 280 Median 646 474 580 281 280 Std 668 361 540 231 339 Min - Max 124 - 2205 7 - 1032 458 - 2061 6 - 657 40 - 519 P - value 0.2319 0.6943 0.0401 0.2222 PD69 N 3 4 5 7 2 Mean 1096 345 881 589 232 Median 590 393 869 551 232 Std 897 234 576 281 242 Min - Max 566 - 2131 19 - 576 286 - 1809 352 - 1189 61 - 403 P - va1ue 0.1143 0.7857 0.1833 0.2 PD83 N 2 4 7 8 2 Mean 1478 522 919 509 196 Median 1478 636 912 422 196 Std 1600 358 621 292 277 Min - Max 346 - 2609 0 - 816 291 - 2185 100 - 1060 0 - 392 P - va1ue 0.8 0.8889 0.6889 0.6667 PD97 N 0 2 5 8 1 Mean NC 1051 879 592 0 Median NC 1051 685 455 0 Std NC 292 671 395 NC Min - Max NC 844 - 1257 301 - 1891 232 - 1376 0 - 0 PD111 N 0 1 2 6 2 Mean NC 320 448 694 386 Median NC 320 448 541 386 Std NC NC 54 470 506. Min - Max NC 320 - 320 409 - 486 382 - 1642 28 - 743. . US 2012 / 0115926 A1. . . . . 39 TABLE 41 Small LDL Particles , Mean % Change Study Day Placebo 50 mg 100 mg 200 mg 400 mg MD8 N 7 7 8 8 2 Mean 50 11 20 —9 —50 Median 60 —11 17 —21 —50 Std 42 49 29 39 43 Min - Max —9 - 115 —44 - 90 —22 - 71 —48 - 80 —80 - —19 P - value 0 0.1282 0.1893 0.0205 0.0556 MD15 N 7 7 8 8 2 Mean 48 28 8 —30 —72 Median 25 29 0.6 —22 —72 Std 78 41 43 26 26 Min - Max —40 - 161 —27 - 89 —34 - 100 —63 - 2 —90 - —54 P - value 0 0.9015 0.5358 0.0541 0.0556 MD22 N 7 7 8 8 2 Mean 18 5 —6 —39 —83 Median 25 9 —3 —45 —83 Std 55 35 18 24 24 Min - Max —77 - 79 —44 - 50 —45 - 13 —74 - 8 —100 - —66 P - value 0 0.62 0.3357 0.0401 0.1111 MD25 N 7 7 8 8 2 Mean 11 18 6 —40 —81 Median 13 6 2 —39 —81 Std 24 41 33 20 20 Min - Max —20 - 49 —24 - 77 —36 - 67 —66 - —5 —95 - —67 P - value 0 1 0.6126 0.0012 0.0556 PD39 N 7 7 8 8 2 Mean 9 40 —25 —58 —86 Median —15 12 —23 —60 —86 Std 48 45 38 22 6 Min - Max —27 - 99 —5 - 111 —98 - 17 —89 - —15 —90 - —82 P - value 0 0.1282 0.3357 0.0037 0.0556 PD55 N 7 7 8 8 2 Mean 2 16 3 —63 —80 Median 17 19 —13 —65 —80 Std 42 24 42 32 19 Min - Max —70 - 43 —22 - 55 —25 - 103 —99 - —2 —94 - —67 P - value 0 0.8048 0.7789 0.0093 0.1111 PD69 N 3 4 5 7 2 Mean 13 40 —5 —27 —82 Median 26 41 —8 —41 —82 Std 33 66 16 35 11 Min - Max —25 - 38 —35 - 111 —23 - 18 —62 - 25 —90 - —74 P - value 0 0.8571 0.5714 0.1167 0.2 PD83 N 2 4 7 8 2 Mean —17 7 9 —39 —88 Median —17 30 2 —49 —88 Std 13 74 26 33 18 Min - Max —26 - —8 —100 - 67 —22 - 59 —89 - 12 —100 - —75 P - value 0 0.5333 0.1111 0.5333 0.3333 PD97 N 0 2 5 8 1 Mean NC 131 —0.2 —33 —100 Median NC 131 2 —46 —100 Std NC 4 28 40 0 Min - Max NC 128 - 134 —41 - 34 —69 - 45 —100 - —100 PD111 N 0 1 2 6 2 Mean NC —40 32 —15 —74 Median NC —40 32 —38 —74 Std NC 0 51 48 30 Min - Max NC —40 - —40 —4 - 68 —48 - 73 —96 - —53 TABLE 42. May 10 , 2012. TABLE 42 - continued. . Small LDL Subclass of LDL - Cholesterol Summary , mg / dL. . Small LDL Subclass of LDL - Cholesterol Summary , mg / dL. . . . . Study Day Placebo 50 mg 100 mg 200 mg 400 mg Study Day Placebo 50 mg 100 mg 200 mg 400 mg. Baseline N 7 8 8 9 4 Std 51 18 35 17 31 Mean 54 24 51 50 52 Min - Max 23 - 168 0 - 52 15 - 127 27 - 83 24 - 94 Median 35 28 39 51 45 P - value 0.2319 0.7167 0.351 0.6485. US 2012 / 0115926 A1 May 10 , 2012. . . . . . . . . . . 40 TABLE 42 - continued TABLE 42 - continued Small LDL Subclass of LDL - Cholesterol Summary , mg / dL Small LDL Subclass of LDL - Cholesterol Summary , mg / dL Study Day Placebo 50 mg 100 mg 200 mg 400 mg Study Day P1acebo 50 mg 100 mg 200 mg 400 mg MD8 N 7 7 8 8 2 PD55 N 7 8 8 8 2 Mean 70 28 57 47 42 Mean 53 29 49 18 17 Median 60 30 51 41 42 Median 39 28 35 17 17 Std 40 15 34 25 50 Std 42 22 35 14 20 Min - Max 39 - 157 1 - 47 25 - 132 29 - 105 7 - 77 Min - Max 7 - 136 1 - 62 28 - 132 1 - 41 2 - 31 P - value 0.0023 0.3969 0.1206 0.8889 P - value 0.2319 0.6943 0.0541 0.2222 MD15 N 7 8 8 8 2 PD69 N 3 4 5 7 2 Mean 71 28 50 35 23 Mean 67 21 54 35 15 Median 53 26 37 36 23 Median 35 23 54 33 15 Std 52 23 32 13 28 Std 58 14 34 16 14 Min - Max 14 - 166 0 - 67 24 - 124 20 - 57 3 - 44 Min - Max 33 - 134 2 - 35 17 - 108 21 - 67 6 - 25 P - value 0.0939 0.281 0.1206 0.2222 P - value 0.2286 1 0.4167 0.2 MD22 N 7 8 8 8 2 PD83 N 2 4 7 8 2 Mean 59 27 49 31 16 Mean 92 32 56 31 12 Median 51 26 44 28 16 Median 92 39 56 25 12 Std 41 22 35 15 23 std 102 22 37 17 17 Min - MaX 6 - 136 0 - 57 12 - 122 14 - 62 0 - 32 Min - Max 20—164 0—51 18—131 6—63 0—24 MD25 N 7 8 8 8 2 PD97 N 0 2 5 ' 8 11 Mean 59 26 52 31 17 Median 38 24 44 30 17 Mei‘? NC 63 55 36 0 Std 52 17 35 13 21 Med1an NC 63 43 27 0 Min - Max 19 - 170 2 - 49 15—130 19 - 55 2 - 32 m NC 17 43 23 NC P - value 0 0.0721 0.9551 0.2319 0.3333 Mm ' MaX NC 51 ' 75 19 ' 121 14 ' 81 0 ' 0 PD39 N 7 8 8 8 2 PD111 N 0 1 2 6 2 Mean 54 31 42 21 10 Mean NC 19 28 42 24 Medmﬂ 38 30 3g 21 10 Median NC 19 28 33 24 Std 42 24 34 9 10 Std NC — 3 28 31 Min - Max 20 - 141 2 - 70 0 - 119 6 - 36 3 - 17 Min - Max NC 19 - 19 26 - 30 24 - 99 2 - 45 P - value 0.3357 0.7789 0.0154 0.0556 TABLE 43 Small LDL Subclass of LDL - Cholesterol , % of Baseline Study Day P1acebo 50 mg 100 mg 200 mg 400 mg MD8 N 7 7 8 8 2 Mean 54 13 21 —8 —50 Median 70 0 16 —21 —50 Std 43 51 27 41 45 Min - Max —7 - 117 —48 - 92 —16 - 70 —50 - 85 —82 - —18 P - value 0.1282 0.152 0.0205 0.0556 MD15 N 7 7 8 8 2 Mean 49 30 8 —30 —72 Median 27 30 —0.7 —22 —72 Std 78 43 42 27 26 Min - Max —40 - 160 —29 - 90 —31 - 97 —64 - 3 —91 - —54 P - va1ue 0.9015 0.4634 0.0541 0.0556 MD22 N 7 7 8 8 2 Mean 19 5 —7 —39 —83 Median 28 10 —4 —44 —83 Std 56 33 18 25 24 Min - Max —75 - 80 —40 - 51 —41 - 13 —74 - 10 —100 - —66 P - va1ue 0.62 0.351 0.0401 0.1111 MD25 N 7 7 8 8 2 Mean 11 19 6 —39 —81 Median 11 0.9 0 —38 —81 Std 22 43 34 20 21 Min - Max —14 - 48 —24 - 80 —36 - 68 —66 - —3 —96 - —66 P - value 1 0.7789 0.0012 0.0556 PD39 N 7 7 8 8 2 Mean 10 42 —22 —57 —86 Median —12 13 —19 —61 —86 Std 47 47 37 23 7 Min - Max —28 - 100 —5 - 110 —97 - 17 —89 - —12 —91 - —82 P - value 0.1282 0.2319 0.0037 0.0556 PD55 N 7 7 8 8 2. Mean 2 15 3 —62 —80. . . . US 2012 / 0115926 A1 May 10 , 2012 41 TABLE 43 - continued Small LDL Subclass of LDL - Cholesterol , % of Baseline Study Day Placebo 50 mg 100 mg 200 mg 400 mg Median 17 19 —12 —64 —80 Std 43 24 39 33 19 Min - Max —70 - 45 —20 - 56 —26 - 93 —99 - 1 —94 - —67 P - value 0.8048 0.9551 0.0093 0.1111 PD69 N 3 4 5 7 2 Mean 18 40 —4 —27 —79 Median 28 43 —2 —40 —79 Std 35 67 16 35 8 Min - Max —20 - 47 —37 - 1 10 —23 - 16 —64 - 18 —85 - —74 P - value 0.8571 0.3929 0.1167 0.2 PD83 N 2 4 7 8 2 Mean —15 6 11 —39 —87 Median —15 30 4 —48 —87 Std 18 73 26 33 18 Min - Max —28 - —3 —100 - 65 —21 - 62 —88 - 10 —100 - —74 P - value 0.5333 0.2222 0.4 0.3333 PD97 N 0 2 5 8 1 Mean NC 124 3 —33 —100 Median NC 124 2 —46 —100 Std NC 7 28 39 NC Min - Max 120 - 129 —38 - 36 —68 - 42 —100 - —100 PD111 N 0 1 2 6 2 Mean NC —42 35 —14 —74 Median NC —42 35 —37 —74 Std NC 0 53 48 31 Min - Max —42 - —42 —3 - 72 —47 - 75 —95 - —52. . Pharmacodynamic Summary. [ 0354 ] The data presented herein demonstrate that treatment With ISIS 301012 resu1ted in a dose - dependent reduc - ti0n in serum ap01ip0pr0tein B , LDL - ch01ester01 and t0ta1 - cho1estero1. The decreases in serum LDL - cho1estero1 , as sh0Wn in Tab1es 22 and 23 , Were observed throughout the treatment period , and at the end of the treatment period ranged fr0m appr0ximate1y 20% in the 100 mg gr0up t0 greater than 30% in the 200 mg and 400 mg groups. The reductions in serum apo1ipoprotein B , as shoWn in Tab1es 24 and 25 , Were a1so observed thr0ugh0ut the treatment period and ranged fr0m approximate1y 15% in the 50 mg gr0up t0 greater than 40% in the 200 mg and 400 mg groups at the end of the treatment period. Tota1 serum cho1estero1 1eve1s Were simi1ar1y reduced at the end of treatment , appr0ximate1y 15% in the IO0 mg group and greater than approximate1y 25% in the 200 mg and 400 mg groups. Individua1s With higher base1ine serum LDL - cho1estero1 and apo1ipoprotein B 1eve1s experienced greater percent reducti0ns in these 1ipidS , as compared to individua1s With 10Wer base1ine Serum LDLcho1estero1 and ap01ipoprotein B 1eve1s. Duration of Effect : 2 Weeks. [ 0355 ] The reductions in serum LDL - cho1estero1 , serum tota1 cho1estero1 , and serum apo1ipoprotein B 1eve1s Were sustained at PD39 , tWo Weeks fo11oWing MD25. Serum LDLcho1estero1 Was reduced approximate1y 20% , 35% and 45% in the 100 mg , 200 mg and 400 mg groups , respectiVe1y. Serum apo1ip0pr0tein B Was 10Wered by appr0ximate1y 20% , 35% and 50% in the 100 mg , 200 mg and 400 mg groups , respective1y. Tota1 serum cho1estero1 Was simi1ar1y decreased , by approximate1y 15% , 25% and 30% in the IO0 mg , 200 mg and 400 mg groups , respective1y. Duration of Effect : 30 Days. [ 0356 ] The duration of effect Was pro1onged , With signiﬁ - cant reductions in severa1 1ipid parameters 0bserved 30 days. fo11oWing MD25. A summary of these reductions is i11ustrated in Tab1e 44 , Where mean percent change from base1ine is shoWn for severa1 1ipid parameters. Data are expressed as mean percent change re1atiVe to base1ine. “Std” indicates standard deViation. N0 forma1 statistics Were done for 400 mg cohort due t0 sma11 samp1e size ( n : 2 ) . “N” indicates the number of subject eva1uated Within each cohort. . . . TABLE 44 Mean % Change at PD55. Lipid Parameter Placebo 50 mg 100 mg 200 mg 400 mg. N 7 8 8 8 2 LDL - Mean —1 —6 —20 —34 —41 Cholesterol Std 15 8 17 19 3. P - value 0.8665 0.0939 0.0022 0.0556 Apolipo - Mean —11 —14 —28 —42 —47 protein B Std 29 13 15 14 9. P - value 0.1893 0.0541 0.0205 0.2222 Total Mean 10 2 —15 —23 —31 Cholesterol Std 14 7 8 14 6. P - value 0.4634 0.0003 0.0006 0.0556 HDL - Mean 10 11 1 7 25 Cholesterol Std 18 17 9 9 30. P - value 0.8421 0.4448 0.9294 0.3056 Triglycerides Mean 1 —1 37 —27 —32. Std 38 30 60 20 2. P - value 0.7789 0.2319 0.0541 0.0556. . Duration of Effect : Three Months. [ 03 57 ] During the post - treatment eva1uati0n period , serum apo1ipoprotein B and LDL - cho1estero1 Were 20 - 25% be10W base1ine three months after MD25 in the 200 mg and 400 mg dose cohorts. These resu1ts are consistent With the 10ng tissue ha1f - 1ife of ISIS 301012 , Which Was estimated to be approxi - . US 2012 / 0115926 A1. mately 31 days in the 200 mg dose cohort. Serum triglycerides , VLDL - cholestero1 and lip0protein ( a ) a1so appear reduced. Serum HDL - cholestero1 Was not affected. Pharmacokinetic Ana1ysis. [ 0358 ] Non - c0mpartmental pharmacokinetic analysis of ISIS 301012 Was carried out on each indiVidua1 subject data set. P1asma concentrations of ISIS 301 01 2 Were measured by hybridization - based ELISA at PPD DeVe10pment ( Richmond , Va. ) The maximum 0bserVed drug concentration ( me ) and the time taken t0 reach me ( me ) Were 0btained direct1y from the concentration - time data. The p1asma disposition ha1f - life ( tlmZ ) associated With the apparent termina1 e1iminati0n phase Was calcu1ated from the equation , t 1 / 2M : 0. 693 / 7tZ , Where M is the termina1 rate c0nstant ass0ciated With the apparent termina1 elimination phase. The termina1 elimination rate constant is calculated using lo g - linear regression of the 1ast 3 or more concentration time points. The apparent distributi0n ha1f - life Was calcu1ated fr0m a similar equation , using the apparent distribution rate constant in p1ace of the terminal elimination rate c0nstant. The apparent distribution rate constant is calculated using log - linear regression of distribution phase time points. Fo1loWing sing1e dosing , an area under the p1asma concentration - time curVe fr0m zer0 time ( pre - d0se ) t0 inﬁnite time ( AUC00 ) Was ca1cu1ated using the 1inear trapezoidal rule and extrap01ation t0 inﬁnity by diViding the ﬁnal measurable concentration ( CIasr ) by KZ. FolloWing multiple dosing , the area under the plasma concentrationtime curVe during the time of each d0sing interVa1 ( tau , 1 : ) at steady - state ( AUC1 ) Was ca1cu1ated using the 1inear trapez0i - dal rule. Further , partial areas under the plasma concentration - time curVe fr0m zero time ( pre - dose ) to selected times ( t ) after the start of the intraVenous inﬁJsion or subcutaneous administration ( AUCT ) Was ca1cu1ated using the 1inear trap - ez0ida1 ru1e. P1asma c1earance ( CL ) Was ca1cu1ated fr0m CL : Actual D0se / AUCw. Steady - state Volume of distribution [ VSS : ( AUMC , v * Actual Dose ) / ( AUC , . V ) 2 ; Where AUMCw is the area under the ﬁrst moment curve f0110Wing intraVenous infusi0n ] Was a1so ca1cu1ated. Mean abs0rpti0n time f0110W - ing subcutaneous inj ecti0n Was ca1cu1ated by subtracting the plasma AUMCSC ( ﬁrst moment curVe for subcutaneous injection ) from AUMCm ( ﬁrst moment curVe for intraVenous infusion ) estimated f0r each subject , and refers to the extent to Which ISIS 301012 Was distributed thr0ugh0ut the b0dy at steady state concentrations. In addition , rati0s of subcutaneous oVer intraVenous plasma AUC Were used to estimate subcutaneous plasma bioaVailability ( F ) for each subject. [ 0359 ] The amount of ISIS 301012 and tota1 oligonucleotide excreted in the urine Was determined from the f0lloWing expression : . Aer‘ : Curin eX Vurin 9. Where Ae , is the am0unt excreted up to some ﬁxed timet ( i. e. , 24 hours ) , Cmne is the urine c0ncentrati0n of the ana1yte , and me is the t0ta1 urine V01ume. The percentage of the administered dose excreted in urine ( intact or as t0tal 01igonucle - 0tide ) Was then ca1cu1ated from the f0110Wing expression : . % Dose Excreted : ( Ae , / Administered dose ) ><100%. Pharmacokinetic Summary. [ 0360 ] The plasma pharmacokinetic pr0ﬁle of ISIS 301012 Was determined from b100d samp1ing fol1oWing the ﬁrst 2 - hr intraVen0us infusion ( MD1 ) , and is summarized in Tab1e 45. May 10 , 2012. Data are presented as mean : standard deViati0n for each dose group. me=maxima1 p1asma 00ncentrati0n ; me=time to reach me ; AUCO_48 , , , , : area under the p1asma concentrationtime curVe from time 0 to 48 hours after the start of dose administration ; CL=plasma c1earance ; VSS=steady - state VOlume of distribution. BioaVai1abi1ity fo11oWing an intraVenous administration is assumed to be 100%. TABLE 45. . ISIS 301012 Dosed IntraVenously : Plasma Pharmacokinetics. . . Dose Group 50 mg 100 mg 200 mg 400 mg Dose , mg / kg for 70 kg 0.7 : 0.1 1 : 0.1 2.7 : 0.5 5.9 : 1.2 N 8 8 8 3 Cmax ( ug / ml ) 5 : 1 9 : 1 22 : 4 38 : 5 TmM ( hr ) 2 : 0.1 2 : 0.1 2 : 0.2 2 : 0.2 AUC0_48 m ( ug * hrme ) 11 : 3 24 : 3 68 : 14 148 : 14 CL ( L / hr ) 5 : 1 4 : 0.6 3 : 0.7 3 : 0.3 V55 ( L ) 6 : 3 7 : 1 7 : 1 8 : 0.8 Apparent Distribution 0.7 : 0.1 0.8 : 0.1 1 : 0.2 1.7 : 0.4 t1 / 2 ( h1 ' ) . . [ 0361 ] D0se - dependent maximum p1asma concentrati0ns ( me ) f0lloWing 2 - h0ur intraVen0us infusi0ns Were seen at the end of inﬁ1sion folloWed by a biphasic decline. An initial , relatiVely fast distribution phase ( mean apparent distribution ha1f - life ranged 0.7 to l .7 hours ) dominated the p1asma c1earance and Was f0110Wed by a s10Wer apparent e1iminati0n phase. [ 0362 ] Plasma pharmac0kinetics determined fr0m b1o0d sampling folloWing the ﬁnal subcutaneous injection ( MD22 ) are summarized in Table 46. Data are presented as mean : standard deViation. me : maxima1p1asma 00ncentra - ti0n ; me=time to reach me ; AUC0_48 , , , .=area under the plasma c0ncentrati0n - time curVe from time 0 to 48 hours after the start of d0se administrati0n ; AUC0_O0a , SS : area under the plasma concentration - time curVe from time 0 to inﬁnity at steady - state ; % BAV : p1asma bi0aVai1abi1ity ( % ) fo11oWing subcutane0us administrati0n. TABLE 46. . ISIS 301012 Dosed Subcutaneously : Plasma Pharmacokinetics. . Dose Group 50 mg 100 mg 200 mg 400 mg Dose , mg / kg for 70 kg 0.7 : 0.1 1.3 : 0.1 2.7 : 0.5 5.9 : 1.2 N 7 8 8 2 Cmaxmng 1 : 03 2 : 1 3 : 1 7 maxW ) 4 : 2 4 : 2 3 : 2 7 AUC0 , 48 m ( ug * hr / mL ) 8 : 2 18 : 4 35 : 7 109 AUC0_OOn , SS ( ug * 19 : 9 28 : 5 63 : 13 160 hr / mL ) Apparent Distribution 4 : 1 5 : 3 7 : 3 8 t172 ( 11I ) Elimination tm ( hr ) 23 : 1 27 : 12 31 : 11 47 %BAV 69 : 9 76 : 18 54 : 11 78. . [ 03 63 ] The mean time to maximum plasma 00ncentrations ( me ) folloWing the ﬁnal subcutane0us injection ( MD22 ) of ISIS 301012 Was approximately 4 hours fo110Wing administrati0n of the 50 and 100 mg doses , and approximate1y 3 hours f0l10Wing administration of the 200 mg dose. P1asma c0ncentrations decreased more sloW1y from the maximum p1asma concentration ( me ) foll0Wing subcutane0us injection , When compared to intraVenous infusion , indicating continued absorpti0n of ISIS 30l0l2 after achieVement of me. Maxi - . US 2012 / 0115926 A1. mum plasma concentrations ( me ) ranged fr0m appr0ximate1y 1 t0 3 ug / mL ( 50 mg to 200 mg ) and Were d0sedependent over the studied subcutaneous dose range , but Were much loWer in comparison t0 equivalent intravenous infusion d0ses. me , me , plasma AUC fo1loWing the ﬁrst subcutaneous dose of ISIS 3010l2 Were simi1ar to those shoWn in Table 46 , fo1l0Wing the ﬁna1 subcutaneous dose. P1asma drug concentration Was decreased by at 1east 10 fo1d by 24 h0urs. The terminal e1iminati0n phase observed in p1asma provided a measure of tissue elimination rate , thus the e1imination ha1f - 1ife represents the time at Which approximate1y 50% of ISIS 301012 Was cleared from tissues. Characterizati0n of the termina1 e1iminati0n phase yie1ded an e1imination ha1f - 1ife 0f appr0ximately 23 ( : 1 ) to 31 ( : 11 ) days ( see Tab1e 46 ) . This resu1t is consistent With the Sl0W elimination of ISIS 301012 observed from monkey tissues , and thus appears to reflect an equi1ibrium 0f 01igonuc1eotide betWeen p1asma and tissue. Abs01ute p1asma bioavai1abi1ity ( BAV ) of ISIS 301012 f0l10Wing subcutane0us administration ranged from 54% to 78% , in comparison to intravenous infusion , and Was independent of dose. Plasma BAV may underestimate the u1timate comp1ete absorption of ISIS 301012 , as n0nhuman primate studies have sh0Wn that the entire d0se is ultimate1y distributed t0 tissues such that there is no difference betWeen intravenous and subcutaneous administration With regard to end organ drug concentrations. [ 03 64 ] Mean urinary excreti0n of t0ta1 01ig0nucle0tide Was less than 8% Within the ﬁrst 24 hours. Excreti0n of chain shortened metabolites Was evident. Urine excreti0n data indicate that ISIS 301012 is primari1y distributed t0 tissues. U1timate e1imination is a combinati0n 0f nuc1ease metab01ism and excretion in urine. Exp0sure - Resp0nse Re1ationships. [ 0365 ] The correlation betWeen ISIS 301012 plasma c0n - centrations , serum apolipoprotein B protein and LDL - cholesterol is shoWn in Table 47. Serum apolipoprotein B , LDLcho1ester01 and t0ta1 cho1ester01 are presented as percentage of base1ine. The numbers in parentheses f0110Wing ap01ipoprotein B percent baseline indicates the number 0f samples used to calculate the mean ; all other means Were calculated using the number 0f samp1es in the “N” co1umn. TABLE 47. . Exposure - Response Relationship : ISIS 301012 Plasma Level , apolipoprotein B protein and LDL - cholesterol in 200 mg treatment group. ISIS LDL - Total 301012 Apolipoprotein B Cholesterol Cholesterol Study Day N ng / mL % Baseline % Baseline % Baseline. . MD1 9 0.5 96 93 99 MD8 8 18 92 86 90 MD15 8 16 68 71 77 MD22 8 21 66 68 76 MD25 8 30 50 69 76 PD39 8 15 61 65 74 PD55 8 8.7 58 66 76 PD69 6 6.1 64 73 76 PD83 7 5.2 70 79 83 PD97 5 4.7 76 ( 7 ) 82 87 PD111 4 5.1 77 ( 6 ) 80 81. . [ 03 66 ] As sh0Wn in Tab1e 47 , t0ta1 tissue exposure , represented by ISIS 301012 plasma concentrations ( measured at 1east 72 hr after dosing during and f011oWing the mu1tip1e d0 se. May 10 , 2012. treatment period ) Was highly correlated With serum apolipo - pr0tein B pr0tein 1evels and LDL - ch01estero1 1evels , b0th of Which responded in simi1ar d0se - response manners. Increases in plasma AUC Were slightly greater than d0seproporti0na1. Signiﬁcant reducti0n in ap01ipopr0tein B protein ( p<0.02 ) from baseline for the 200 mg treatment gr0up Was achieved fr0m Day 15 ( MD 15 ) t0 Day 97 ( PD 72 , 0r 75 days after last dose ) , c0nsistent With the sloW elimination of ISIS 3010l2 in p1asma ( termina1 e1imination 11 / 2 of approximate1y 31 days ) . [ 0367 ] A comparison of serum reducti0ns versus p1asma troughAUC f0r 26 ISIS 301012 - treated subjects at the end 0f the multip1e dosing peri0d ( MD25 ) revea1ed a direct correlation betWeen tr0ugh AUC and the observed reductions in serum apo1ipoprotein B protein 1eve1s , LDL - cho1estero1 and tota1cho1ester01 ( r§0.67 , p§0.0002 ) ( FIG. 1 ) . Such a corre - 1ati0n is c0nsistent With the fact that trough AUC is a representation 0f liver concentrations , as result 0f the equilibrium reached betWeen drug concentrati0n in plasma and in liver. A correlation Was also observed betWeen plasma trough concentrations and serum reductions , When p1asma tr0ugh concentrations ( Cmugh ; mean tr0ugh c0ncentrati0n determined fr0m p1asma 1eve1s just pri0r t0 d0sing 0n days MD15 and MD22 ) Were compared t0 reductions in serum apolipoprotein B , serum LDL - cholesterol , and serum total cholesterol. Cmugh and trough AUC corre1ate With reductions in 1ipid parametes , dem0nstrating that as exposure t0 ISIS 301012 increased , serum apo1ip0pr0tein B , LDL - cho1ester0l and tota1 cholesterol decreased. [ 0368 ] The relationship betWeen serum apolip0protein B pr0tein levels and p1asma tr0ugh c0ncentrati0ns 0f ISIS 301012 is described With a sigm0ida1 inhibit0ry effect me model using the data collected 3 days post dosing. The estimated plasma EC50 and predicted liver concentrations based on pri0r n0nhuman primate studies Were 18 ( : 2 ) ng / mL and 60 ug / g , respective1y. P1asma trough c0ncentrati0ns increases folloWing multiple doses of ISIS 301012 , reflecting accumulation of ISIS 301012 in the liver ; increases Were 2 - fold fo11oWing the 10ading d0se of ISIS 301012 , and 5 - f01d f01 - 1oWing the ﬁna1 d0se 0f ISIS 301012. M0nkey and human plasma pharmac0kinetics f0r ISIS 301012 are essentially superimposable at mg / kg equivalent doses. Utilizing these knoWn PK simi1arities , measurement of drug concentrati0ns in the termina1 e1iminati0n phase in human clinica1 studies can be used to assess accumulation in liver. Such estimates are shoWn in Table 48. ISIS 301012 liver c0ncentrati0ns are estimated based 0n monkey data. M0nkey average p1asma concentrations represent an average fr0m 6 animals and Were measured 48 to 72 hours after the last dose ina 13 Week repeat dose t0xico10gy study ( e. g. the study described in Examp1e 2 ) . Human p1asma tr0ugh concentration data Was obtained 72 hours after the last intravenous loading dose ; the number of study subjects is indicated in parentheses. Monkey liver concentrations represent an average of 4 - 6 animals and Were measured in tissues 0011ected 48 h0urs after the 1ast dose in a l3 Week repeat dose toxico1ogy study. TABLE 48. . ISIS 301012 : Monkey and Human Plasma Pharmacokinetics. . . Dose / Route Plasma C www Monkey ( ng / mL ) Actual Liver Conc. ( ug / g ) 3.5 mg / kg / Week / i. v. 28 100 : 59. 7 mg / kg / Week / i. v. 107 293 : 105. US 2012 / 0115926 A1. TABLE 48 - c0ntinued. . ISIS 301012 : Monkey and Human Plasma Pharmacokinetics. . 21 mg / kg / Week / iv 292 35 mg / kg / Week / s. c. 570. 584 : 129 1129 : 242. . Plasma Cmth. . Human ( ng / mL ) Estimated Liver Conc. ( ug / g ) 50 mg / Week / i. v. / s. c. 24 ( n = 5 ) 10. 100 mg / Weekfi. v. / s. c. 8 ( n = 3 ) 28. 200 mg / Weekfi. v. / s. c. 18 ( n = 6 ) 60. 400 mg / Week / i. v. / s. c. 40 ( n = 2 ) 150. . [ 0369 ] Plasma trough AUC for the 50 mg , 50 mg , lO0 mg , 200 mg and 400 mg d0se groups Was found t0 be 3 , 5 , 12 and 18 ug - hr / mL , respective1y , on MD25 ( three days f011oWing the ﬁnal dose during the multiple d0sing period ) . [ 03 70 ] Reducing the levels 0f LDL - ch01ester01 in a human pr0vides a means f0r treating , preventing and / or ameliorating coronary heart disease. As described above , the 01igonucleotide ISIS 3010l 2 produced substantia1 , sustained reductions serum ap01ip0protein B and LDL - ch01estero1 , as We11 as in other 1ipid parameters , and is thus an agent usefu1 for the treatment 0f hypercho1ester0lemia. Examp1e 4 L0ading and Maintenance Treatments. [ 0371 ] In order to treat subjects suffering from diseases related to production 0f apolipoprotein B or LDL - cholesterol , a series of different loading and maintenance regimens are ana1yzed f0r their therapeutic efﬁcacy. Subjects are treated With ISIS 301012 as described be1oW : . [ 0372 ] Group A receives a s10W 10ading phase , during Which 4 doses of 200 mg ISIS 301012 are administered over 11 days. This sloW loading phase is folloWed by an 11 Week maintenance phase , during Which a 200 mg dose of ISIS 301012 is administered every other Week. [ 0373 ] Group B receives a s10W 10ading phase , during Which 4 doses of 200 mg ISIS 301012 are administered over 11 days. This sloW loading phase is folloWed by an 11 Week maintenance phase , during Which a 10O mg dose of ISIS 30l0l2 is administered every other Week. [ 0374 ] Group C receives a s10W 10ading phase , during Which 3 doses of 200 mg ISIS 301012 are administered Weekly for three Weeks. This Sl0W 10ading phase is fo11oWed by a 3 month maintenance phase , during Which a 200 mg d0 se of ISIS 301012 is administered 0nce per month. [ 03 75 ] Group D receives a fast 10ading phase , during Which 3 d0ses of 200 mg ISIS 301012 are administered 0ver 7 days. This fast loading phase is f01loWed by an 11 Week mainte - . nance phase , during Which a 200 mg dose of ISIS 301012 is administered every other Week. [ 03 76 ] Group E receives a fast 10ading phase , during Which 3 doses of 200 mg ISIS 30l 012 are administered 0ver 7 days. This fast 10ading phase is fo110Wed by a 3 m0nth maintenance. phase , during Which a 200 mg dose of ISIS 301012 is administered 0nce per month. [ 0377 ] Group F receives a maintenance phase only , during Which a 20O mg d0se of ISIS 301012 is administered once Week1y for 13 Weeks. May 10 , 2012. [ 03 78 ] Gr0up G receives a maintenance phase on1y , during Which a 200 mg d0se of ISIS 30l012 is administered once every other Week f0r 13 Weeks. [ 03 79 ] It is disc0vered that treating subjects in Gr0ups A , B , C , D , E , F , and G With ISIS 301012 provides therapeutic beneﬁts. The therapeutic beneﬁts inc1ude reducti0n in serum LDL - cholestero1 , serum apo1ipoprotein B , trig1ycerides , tota1 cho1ester01 , n0n - HDL cholester01 , VLDL - cho1esterol , lipo - pr0tein ( a ) , the LDL : HDL rati0 and apolip0pr0tein B : apo1i - popr0tein A - 1 ratio re1ative to baseline. It is f0und that there is no change in the levels of HDL - cholesterol. The differences in onset and degree of therapeutic beneﬁts are used to eva1uate the therapeutic efﬁcacy of each do sing regimen. Example 5 H0mozygous Fami1ia1 Hyperch0lesterolemia. [ 0380 ] Fami1ia1hyperch0lestero1emia ( FH ) is an aut0s0ma1 d0minant metabolic disorder characterized by marked1y elevated LDL - cholesterol and premature onset of atherosclerosis. C1inica1 symptoms result from the development of LDL - ch01estero1 dep0sits in the skin , tendons ( xanthoma ) and arterial p1aques ( ather0mata ) . The primary genetic defect in FH is a mutation in the LDL - receptor ( LDL - R ) gene. The LDL - R facilitates the uptake of LDL - cholesterol into liver ce11s , Where it is metabolized , resu1ting in the re1ease of ch01ester01 f0r metab01ic use. Defects in the LDL - R resu1t in inefﬁcient uptake 0f LDL - ch01ester0l , Which in turn1eads t0 delayed plasma clearance 0f LDL - cholesterol. The longer residence of LDL - cholester0l in plasma alloWs f0r its uptake by scavenger and other ce11s , Which dep0sit the extrane0us LDL - ch01estero1 and produce xanth0ma and ather0mata. [ 0381 ] The prevalence of homozyg0us individuals WorldWide is 1 : 1 , 000 , 000 ; appr0ximate1y 300 h0m0zyg0us FH subjects reside in the United States. Due to f0under effects , certain c0untries have a higher preva1ence rate , for examp1e , French Canada , SouthAfrica , Fin1and and Iceland. Nearly all subjects With homozygous FH Will develop xanthomata by 5 years of age and atherosc1er0sis bef0re adu1tho0d. Despite treatment With existing ch01estero1 - 1oWering therapies , feW homozygous FH subjects achieve treatment goa1s. Thus , homozygous FH subjects are in need of alternative therapeutic options. [ 0382 ] ISIS 301012 is provided to adult FH subjects as a 200 mg / mL solution in 1 mL total volume and is administered subcutaneously as a single injection into the abdomen or thigh. In some individua1s , the dose is divided and administered as 2 0r 3 n0n - contigu0us inj ecti0ns int0 the abdomen 0r thigh. [ 0383 ] A t0tal of 12 d0ses of ISIS 3010l2 are administered subcutane0us1y 0r intravenous1y. The ﬁrst dose is administered on Day 1 0f the study , Whi1e the remaining 11 doses are administered beginning 0n Day 8 and Weekly thereafter , at Which times subjects receive a 20O mg dose of ISIS 3010l2. [ 03 84 ] A group of pediatric FH subjects ( ages 8 through 17 ) are als0 treated Wherein the do sing is based up0n body Weight at time 0f screening. Pediatric subjects Who are at least 25 kg but 1ess than 37.5 kg receive a ﬁrst dose 0f50 mg ISIS 3010l2 , f0l1oWed by 100 mg d0se 0f ISIS 301012 for the remainder 0f the study. Subjects Wh0 are at 1east 37.5 kg but less than 50 kg receive a ﬁrst d0se 0f 100 mg , fo1l0Wed by Week1y 150 mg doses for the remainder of the study. Pediatric subjects Who are greater than 50 kg receive the adu1t dose described ab0ve. US 2012 / 0115926 A1. [ 0385 ] FolloWing the treatment regime , each subject is found to have therapeutical1y relevant reduced levels of LDLcho1ester01 , re1ative t0 base1ine ( pre - treatment ) LDL - ch01estero1. The subjects are also found to have reduced serum apolipoprotein B pr0tein , triglyceride , VLDL - cholesterol , 1ipoprotein ( a ) and t0tal ch01estero1 1eve1s in c0mparis0n to base1ine. According1y , ISIS 301012 pr0vides a therapeutic beneﬁt to the individua1s treated With this compound. Examp1e 6 Heterozygous Familia1Hypercho1estero1emia. [ 0386 ] The preva1ence of individua1s that are heterozygous for Fami1ial hypercholester01emia is approximate1y l : 500 , With appr0ximate1y 500 , 000 heterozyg0us FH subjects residing in the United States. Whereas hom0zyg0us FH subjects have tWo copies of a mutated LDL - recept0r allele , heterozygous FH subjects have one mutated LDL - receptor a11e1e. Heterozyg0us FH subjects usua11y deve10p xanthomata in the 3M decade 0f life and atherosc1er0sis by the 4th decade. Approximately 30% of subjects diagnosed With FH already have a hist0ry of cardiovascular disease. Despite maximal therapy , approximate1y 20% of these subjects are unable to achieve treatment g0a1s. Therefore , heter0zyg0us FH subjects are c0nsidered a p0pu1ati0n in need 0f a1ternative cho - 1ester0l - l0Wering treatments. F0r this reas0n , heter0zygous FH subjects are ch0sen for treatment With ISIS 301012. [ 0387 ] Doses of ISIS 3010l2 are administered as a subcutaneous inj ection in the abd0men 0r thigh 0nce a Week f0r 12 Weeks. The ﬁrst d0se 0f ISIS 301012 is administered as a 100 mg dose. Provided that the subjects tolerate the study drug during the ﬁrst Week , all subsequent doses of ISIS 301012 are 200 mg ( Weeks 2 through l2 doses ) . ISIS 301012 is supp1ied as a 1 mL 0f a 200 mg / mL so1uti0n and 100 and 200 mg d0ses of ISIS 301012 are administered in v01umes 0f 0.5 and 1.0 mL , respectively. [ 0388 ] FolloWing the treatment regime , each subject is f0und to have therapeutica11y re1evant reduced 1eve1s 0f LDLcho1ester01 , re1ative t0 base1ine ( pre - treatment ) LDL - cho1ester01. The subjects are a1s0 f0und t0 have reduced serum apolipoprotein B pr0tein , triglyceride , VLDL - cholesterol , lipoprotein ( a ) and total ch0lesterol levels in comparison to base1ine. Acc0rding1y , ISIS 301012 pr0vides a therapeutic beneﬁt t0 the individua1s treated With this comp0und. Example 7 Targeted Minimum P1asma C0ncentration. [ 0389 ] A human subject suffering fr0m high cholester0l levels is treated With the oligonucleotide ISIS 301012 tar - . May 10 , 2012. geted t0 apolipoprotein B. The subject is ﬁrst given loading d0ses of ISIS 301012 , Which are ca1culated t0 result in a p1asma tr0ugh c0ncentration 0f at 1east 5 ng / mL. In this case , the subject receives a sloW loading phase , during Which 4 d0ses of 200 mg ISIS 301012 are administered 0ver 11 days. F0110Wing the s1oW 10ading phase , the subject is treated With maintenance d0ses 0f ISIS 301012 , Which are calcu1ated to result in a plasma tr0ugh concentrati0n of at least 5 ng / m1. In this case , the subject is treated by Week1y 200 mg maintenance doses of ISIS 301012. Plasma concentrations are determined by pharmac0kinetic ana1ysis 0f bl00d samples c01 - 1ected during and after the d0sing peri0ds. After severa1 months of treatment , the subject on1y receives monthly or quarterly treatments With appr0priate c0ncentrati0ns 0f ISIS 3010l2 in order t0 maintain a p1asma trough concentration of at least 5 ng / ml. [ 0390 ] Additi0na1 subjects receive d0 ses a fast 10ading phase , Which are calcu1ated to resu1t in a plasma trough concentration 0f at 1east 5 ng / mL. In this case , the subject receives 3 doses 0f 200 mg ISIS 301012 that are administered over 7 days. FolloWing the fast loading phase , the subject is treated With maintenance d0ses of ISIS 301012 , Which are ca1cu1ated to resu1t in a p1asma tr0ugh 00ncentrati0n of at 1east 5 ng / mL. In this case , the subject is treated by Weekly 200 mg maintenance doses 0f ISIS 301012. P1asma 00ncentrati0ns are determined by pharmacokinetic ana1ysis 0f b100d samp1es 001 - lected during and after the d0sing peri0ds. After several m0nths 0f treatment , the subject on1y receives m0nthly or quarter1y treatments With appropriate c0ncentrations 0f ISIS 301012 in order t0 maintain a plasma trough concentration of at 1east 5 ng / ml. It is disc0vered that treating the subject t0 have a minimum p1asma concentration of 5 ng / m1 resu1ts in a greater than 10% reduction in serum apolipoprotein B , serum LDL - cholesterol , serum triglyceride , and serum total cholester01 1eve1s. [ 0391 ] While the above detailed description has shoWn , described , and pointed 0ut n0ve1 features of the invention as app1ied to vari0us embodiments , it Wi11 be understo0d that various 0missions , substitutions , and changes in the f0rm and detai1s 0f the c0mpositi0ns 0r pr0cesses i11ustrated may be made by th0se skil1ed in the art With0ut departing from the spirit of the invention. As Wi11 be rec0gnized , the present inventi0n may be emb0died Within a f0rm that does not pr0 - vide all 0f the features and beneﬁts set f0rth herein , as some features may be used or practiced separately from others. . SEQUENCE LISTING. <l60> NUMBER OF SEQ ID NOS : 3. <2l0> SEQ ID NO 1. <2ll> LENGTH : l4l2l. <2l2> TYPE : DNA. <2l3> ORGANISM : H. sapiens. <400> SEQUENCE : l. attcccaccg ggacctgcgg ggctgagtgc ccttctcggt tgctgccgct gaggagcccg 60. cccagccagc cagggccgcg aggccgaggc caggccgcag cccaggagcc gccccaccgc lZ0. US 2012 / 0115926 A1. 46. May 10 , 2012. . —continued agctggcgat ggacccgccg aggcccgcgc tgctggcgct gctggcgctg cctgcgctgc lB0 tgctgctgct gctggcgggc gccagggccg aagaggaaat gctggaaaat gtcagcctgg 240 tctgtccaaa agatgcgacc cgattcaagc acctccggaa gtacacatac aactatgagg 300 ctgagagttc cagtggagtc cctgggactg ctgattcaag aagtgccacc aggatcaact 360 gcaaggttga gctggaggtt ccccagctct gCagcttcat cctgaagacc agccagtgca 420 ccctgaaaga ggtgtatggc ttcaaccctg agggcaaagc cttgctgaag aaaaccaaga 480 actctgagga gtttgctgca gccatgtcca ggtatgagct caagctggcc attccagaag 540 ggaagcaggt tttcctttac ccggagaaag atgaacctac ttacatcctg aacatcaaga 600 ggggcatcat ttctgccctc ctggttcccc cagagacaga agaagccaag caagtgttgt 660 ttctggatac cgtgtatgga aactgctcca ctcactttac cgtcaagacg aggaagggca 720 atgtggcaac agaaatatcc actgaaagag acctggggca gtgtgatcgc ttcaagccca 780 tccgcacagg catcagccca cttgctctca tcaaaggcat gacccgcccc ttgtcaactc 840 tgatcagcag cagccagtcc tgtcagtaca cactggacgc taagaggaag catgtggcag 900 aagccatctg caaggagcaa cacctcttcc tgcctttctc ctacaacaat aagtatggga 960 tggtagcaca agtgacacag actttgaaac ttgaagacac accaaagatc aacagccgct lO20 tctttggtga aggtactaag aagatgggcc tcgcatttga gagcaccaaa tccacatcac lO80 ctccaaagca ggccgaagct gttttgaaga ctctccagga actgaaaaaa ctaaccatct ll40 ctgagcaaaa tatccagaga gctaatctct tcaataagct ggttactgag ctgagaggcc lZ00 tcagtgatga agcagtcaca tctctcttgc cacagctgat tgaggtgtcc agccccatca l260 ctttacaagc cttggttcag tgtggacagc ctcagtgctc cactcacatc ctccagtggc l320 tgaaacgtgt gcatgccaac ccccttctga tagatgtggt cacctacctg gtggccctga l380 tccccgagcc ctcagcacag cagctgcgag agatcttcaa catggcgagg gatcagcgca l440 gccgagccac cttgtatgcg ctgagccacg cggtcaacaa ctatcataag acaaacccta lS00 cagggaccca ggagctgctg gacattgcta attacctgat ggaacagatt caagatgact lS60 gcactgggga tgaagattac acctatttga ttctgcgggt cattggaaat atgggccaaa l620 ccatggagca gttaactcca gaactcaagt cttcaatcct caaatgtgtc caaagtacaa l680 agccatcact gatgatccag aaagctgcca tccaggctct gcggaaaatg gagcctaaag l740 acaaggacca ggaggttctt cttcagactt tccttgatga tgcttctccg ggagataagc lS00 gactggctgc ctatcttatg ttgatgagga gtccttcaca ggcagatatt aacaaaattg lS60 tccaaattct accatgggaa cagaatgagc aagtgaagaa ctttgtggct tcccatattg lQ20 ccaatatctt gaactcagaa gaattggata thaagatct gaaaaagtta gtgaaagaag lQ80 ctctgaaaga atctcaactt ccaactgtca tggacttcag aaaattctct cggaactatc 2040 aactctacaa atctgtttct cttccatcac ttgacccagc ctcagccaaa atagaaggga 210O atcttatatt tgatccaaat aactaccttc ctaaagaaag catgctgaaa actaccctca 2l60 ctgcctttgg atttgcttca gctgacctca tcgagattgg cttggaagga aaaggctttg 2220 agccaacatt ggaagctctt tttgggaagc aaggattttt cccagacagt gtcaacaaag 228O ctttgtactg ggttaatggt caagttcctg atggtgtctc taaggtctta gtggaccact 2340 ttggctatac caaagatgat aaacatgagc aggatatggt aaatggaata atgctcagtg 2400. US 2012 / 0115926 A1. 47. . —continued ttgagaagct gattaaagat ttgaaatcca aagaagtccc ggaagccaga gcctacctcc 2460 gcatcttggg agaggagctt ggttttgcca gtctccatga cctccagctc ctgggaaagc 2520 tgcttctgat gggtgcccgc actctgcagg ggatccccca gatgattgga gaggtcatca 258O ggaagggctc aaagaatgac ttttttcttc actacatctt catggagaat gcctttgaac 2640 tccccactgg agctggatta cagttgcaaa tatcttcatc tggagtcatt gctcccggag 2700 ccaaggctgg agtaaaactg gaagtagcca acatgcaggc tgaactggtg gcaaaaccct 2760 ccgtgtctgt ggagtttgtg acaaatatgg gcatcatcat tccggacttc gctaggagtg 282O gggtccagat gaacaccaac ttcttccacg agtcgggtct ggaggctcat gttgccctaa 2880 aagctgggaa gctgaagttt atcattcctt ccccaaagag accagtcaag ctgctcagtg 2940 gaggcaacac attacatttg gtctctacca ccaaaacgga ggtgatccca cctctcattg 3000 agaacaggca gtcctggtca gtttgcaagc aagtctttcc tggcctgaat tactgcacct 3060 caggcgctta ctccaacgcc agctccacag actccgcctc ctactatccg ctgaccgggg 3120 acaccagatt agagctggaa ctgaggccta caggagagat tgagcagtat tctgtcagcg 3l80 caacctatga gctccagaga gaggacagag ccttggtgga taccctgaag tttgtaactc 3240 aagcagaagg tgcgaagcag actgaggcta ccatgacatt caaatataat cggcagagta 3300 tgaccttgtc cagtgaagtc caaattccgg attttgatgt tgacctcgga acaatcctca 3360 gagttaatga tgaatctact gagggcaaaa cgtcttacag actcaccctg gacattcaga 3420 acaagaaaat tactgaggtc gccctcatgg gccacctaag ttgtgacaca aaggaagaaa 3480 gaaaaatcaa gggtgttatt tccatacccc gtttgcaagc agaagccaga agtgagatcc 3540 tcgcccactg gtcgcctgcc aaactgcttc tccaaatgga ctcatctgct acagcttatg 3600 gctccacagt ttccaagagg gtggcatggc attatgatga agagaagatt gaatttgaat 3660 ggaacacagg caccaatgta gataccaaaa aaatgacttc caatttccct gtggatctct 3720 ccgattatcc taagagcttg catatgtatg ctaatagact cctggatcac agagtccctg 3780 aaacagacat gactttccgg cacgtgggtt ccaaattaat agttgcaatg agctcatggc 3840 ttcagaaggc atctgggagt cttccttata cccagacttt gcaagaccac ctcaatagcc 3900 tgaaggagtt caacctccag aacatgggat tgccagactt ccacatccca gaaaacctct 3960 tcttaaaaag cgatggccgg gtcaaatata ccttgaacaa gaacagtttg aaaattgaga 4020 ttcctttgcc ttttggtggc aaatcctcca gagatctaaa gatgttagag actgttagga 4080 caccagccct ccacttcaag tctgtgggat tccatctgcc atctcgagag ttccaagtcc 4l40 ctacttttac cattcccaag ttgtatcaac tgcaagtgcc tctcctgggt gttctagacc 4200 tctccacgaa tgtctacagc aacttgtaca aCtggtccgc ctcctacagt ggtggcaaca 4260 ccagcacaga ccatttcagc cttcgggctc gttaccacat gaaggctgac tctgtggttg 4320 acctgctttc ctacaatgtg caaggatctg gagaaacaac atatgaccac aagaatacgt 438O tcacactatc atgtgatggg tctctacgcc acaaatttct agattcgaat atcaaattca 4440 gtcatgtaga aaaacttgga aacaacccag tctcaaaagg tttactaata ttcgatgcat 4500 ctagttcctg gggaccacag atgtctgctt cagttcattt ggactccaaa aagaaacagc 456O atttgtttgt caaagaagtc aagattgatg ggcagttcag agtctcttcg ttctatgcta 4620 aaggcacata tggcctgtct tgtcagaggg atcctaacac tggccggctc aatggagagt 4680. May 10 , 2012. US 2012 / 0115926 A1. 48. May 10 , 2012. . —continued ccaacctgag gtttaactcc tcctacctcc aaggcaccaa ccagataaca ggaagatatg 4740 aagatggaac cctctccctc acctccacct ctgatctgca aagtggcatc attaaaaata 4800 ctgcttccct aaagtatgag aactacgagc tgactttaaa atctgacacc aatgggaagt 486O ataagaactt tgccacttct aacaagatgg atatgacctt ctctaagcaa aatgcactgc 4920 tgcgttctga atatcaggct gattacgagt cattgaggtt cttcagcctg ctttctggat 4980 cactaaattc ccatggtctt gagttaaatg ctgacatctt aggcactgac aaaattaata 5040 gtggtgctca caaggcgaca ctaaggattg gccaagatgg aatatctacc agtgcaacga 5100 ccaacttgaa gtgtagtctc ctggtgctgg agaatgagct gaatgcagag cttggcctct 5160 ctggggcatc tatgaaatta acaacaaatg gccgcttcag ggaacacaat gcaaaattca 5220 gtctggatgg gaaagccgcc ctcacagagc tatcactggg aagtgcttat caggccatga 5280 ttctgggtgt cgacagcaaa aacattttca acttcaaggt cagtcaagaa ggacttaagc 5340 tctcaaatga catgatgggc tcatatgctg aaatgaaatt tgaccacaca aacagtctga 5400 acattgcagg cttatcactg gacttctctt caaaacttga caacatttac agctctgaca 5460 agttttataa gcaaactgtt aatttacagc tacagcccta ttctctggta actactttaa 5520 acagtgacct gaaatacaat gctctggatc tcaccaacaa tgggaaacta cggctagaac 5580 ccctgaagct gcatgtggct ggtaacctaa aaggagccta ccaaaataat gaaataaaac 5640 acatctatgc catctcttct gctgccttat cagcaagcta taaagcagac actgttgcta 5700 aggttcaggg tgtggagttt agccatcggc tcaacacaga catcgctggg ctggcttcag 5760 ccattgacat gagcacaaac tataattcag actcactgca tttcagcaat gtcttccgtt 5820 ctgtaatggc cccgtttacc atgaccatcg atgcacatac aaatggcaat gggaaactcg 5880 ctctctgggg agaacatact gggcagctgt atagcaaatt cctgttgaaa gcagaacctc 5940 tggcatttac tttctctcat gattacaaag gctccacaag tcatcatctc gtgtctagga 6000 aaagcatcag tgcagctctt gaacacaaag tcagtgccct gcttactcca gctgagcaga 6060 caggcacctg gaaactcaag acccaattta acaacaatga atacagccag gacttggatg 6120 cttacaacac taaagataaa attggcgtgg agcttactgg acgaactctg gctgacctaa 6180 ctctactaga ctccccaatt aaagtgccac ttttactcag tgagcccatc aatatcattg 6240 atgctttaga gatgagagat gccgttgaga agccccaaga atttacaatt gttgcttttg 6300 taaagtatga taaaaaccaa gatgttcact ccattaacct cccatttttt gagaccttgc 6360 aagaatattt tgagaggaat cgacaaacca ttatagttgt agtggaaaac gtacagagaa 6420 acctgaagca catcaatatt gatcaatttg taagaaaata cagagcagcc ctgggaaaac 6480 tcccacagca agctaatgat tatctgaatt cattcaattg ggagagacaa gtttcacatg 6540 ccaaggagaa actgactgct ctcacaaaaa agtatagaat tacagaaaat gatatacaaa 6600 ttgcattaga tgatgccaaa atcaacttta atgaaaaact atctcaactg cagacatata 6660 tgatacaatt tgatcagtat attaaagata gttatgattt acatgatttg aaaatagcta 6720 ttgctaatat tattgatgaa atcattgaaa aattaaaaag tcttgatgag cactatcata 6780 tccgtgtaaa tttagtaaaa acaatccatg atctacattt gtttattgaa aatattgatt 6840 ttaacaaaag tggaagtagt actgcatcct ggattcaaaa tgtggatact aagtaccaaa 6900 tcagaatcca gatacaagaa aaactgcagc agcttaagag acacatacag aatatagaca 6960. US 2012 / 0115926 A1. 49. May 10 , 2012. . —continued tccagcacct agctggaaag ttaaaacaac acattgaggc tattgatgtt agagtgcttt 7020 tagatcaatt gggaactaca atttcatttg aaagaataaa tgatgttctt gagcatgtca 7080 aacactttgt tataaatctt attggggatt ttgaagtagc tgagaaaatc aatgccttca 7140 gagccaaagt ccatgagtta atcgagaggt atgaagtaga ccaacaaatc caggttttaa 7200 tggataaatt agtagagttg acccaccaat acaagttgaa ggagactatt cagaagctaa 7260 gcaatgtcct acaacaagtt aagataaaag attactttga gaaattggtt ggatttattg 7320 atgatgctgt gaagaagctt aatgaattat cttttaaaac attcattgaa gatgttaaca 7380 aattccttga catgttgata aagaaattaa agtcatttga ttaccaccag tttgtagatg 7440 aaaccaatga caaaatccgt gaggtgactc agagactcaa tggtgaaatt caggctctgg 7500 aactaccaca aaaagctgaa gcattaaaac tgtttttaga ggaaaccaag gccacagttg 7560 cagtgtatct ggaaagccta caggacacca aaataacctt aatcatcaat tggttacagg 7620 aggctttaag ttcagcatct ttggctcaca tgaaggccaa attccgagag actctagaag 7680 atacacgaga ccgaatgtat caaatggaca ttcagcagga acttcaacga tacctgtctc 7740 tggtaggcca ggtttatagc acacttgtca cctacatttc tgattggtgg actcttgctg 7800 ctaagaacct tactgacttt gcagagcaat attctatcca agattgggct aaacgtatga 7860 aagcattggt agagcaaggg ttcactgttc ctgaaatcaa gaccatcctt gggaccatgc 7920 ctgcctttga agtcagtctt caggctcttc agaaagctac cttccagaca cctgatttta 7980 tagtccccct aacagatttg aggattccat cagttcagat aaacttcaaa gacttaaaaa 8040 atataaaaat cccatccagg ttttccacac cagaatttac catccttaac accttccaca 8100 ttccttcctt tacaattgac tttgtcgaaa tgaaagtaaa gatcatcaga accattgacc 8160 agatgcagaa cagtgagctg cagtggcccg ttccagatat atatctcagg gatctgaagg 8220 tggaggacat tcctctagcg agaatcaccc tgccagactt ccgtttacca gaaatcgcaa 8280 ttccagaatt cataatccca actctcaacc ttaatgattt tcaagttcct gaccttcaca 8340 taccagaatt ccagcttccc cacatctcac acacaattga agtacctact tttggcaagc 8400 tatacagtat tctgaaaatc caatctcctc ttttcacatt agatgcaaat gctgacatag 8460 ggaatggaac cacctcagca aacgaagcag gtatcgcagc ttccatcact gccaaaggag 8520 agtccaaatt agaagttctc aattttgatt ttcaagcaaa tgcacaactc tcaaacccta 8580 agattaatcc gctggctctg aaggagtcag tgaagttctc cagcaagtac ctgagaacgg 8640 agcatgggag tgaaatgctg ttttttggaa atgctattga gggaaaatca aacacagtgg 8700 caagtttaca cacagaaaaa aatacactgg agcttagtaa tggagtgatt gtcaagataa 8760 acaatcagct taccctggat agcaacacta aatacttcca caaattgaac atccccaaac 8820 tggacttctc tagtcaggct gacctgcgca acgagatcaa gacactgttg aaagctggcc 8880 acatagcatg gacttcttct ggaaaagggt catggaaatg ggcctgcccc agattctcag 8940 atgagggaac acatgaatca caaattagtt tcaccataga aggacccctc acttcctttg 9000 gactgtccaa taagatcaat agcaaacacc taagagtaaa ccaaaacttg gtttatgaat 9060 ctggctccct caacttttct aaacttgaaa ttcaatcaca agtcgattcc cagcatgtgg 9120 gccacagtgt tctaactgct aaaggcatgg cactgtttgg agaagggaag gcagagttta 9180 ctgggaggca tgatgctcat ttaaatggaa aggttattgg aactttgaaa aattctcttt 9240. US 2012 / 0115926 A1. 50. May 10 , 2012. . —continued tcttttcagc ccagccattt gagatcacgg catccacaaa caatgaaggg aatttgaaag 9300 ttcgttttcc attaaggtta acagggaaga tagacttcct gaataactat gcactgtttc 9360 tgagtcccag tgcccagcaa gcaagttggc aagtaagtgc taggttcaat cagtataagt 9420 acaaccaaaa tttctctgct ggaaacaacg agaacattat ggaggcccat gtaggaataa 9480 atggagaagc aaatctggat ttcttaaaca ttcctttaac aattcctgaa atgcgtctac 9540 cttacacaat aatcacaact cctccactga aagatttctc tctatgggaa aaaacaggct 9600 tgaaggaatt cttgaaaacg acaaagcaat catttgattt aagtgtaaaa gctcagtata 9660 agaaaaacaa acacaggcat tccatcacaa atcctttggc tgtgctttgt gagtttatca 9720 gtcagagcat caaatccttt gacaggcatt ttgaaaaaaa cagaaacaat gcattagatt 9780 ttgtcaccaa atcctataat gaaacaaaaa ttaagtttga taagtacaaa gctgaaaaat 9840 ctcacgacga gctccccagg acctttcaaa ttcctggata cactgttcca gttgtcaatg 9900 ttgaagtgtc tccattcacc atagagatgt cggcattcgg ctatgtgttc ccaaaagcag 9960 tcagcatgcc tagtttctcc atcctaggtt ctgacgtccg tgtgccttca tacacattaa 10020 tcctgccatc attagagctg ccagtccttc atgtccctag aaatctcaag ctttctcttc 10080 cacatttcaa ggaattgtgt accataagcc atatttttat tcctgccatg ggcaatatta 10140 cctatgattt ctcctttaaa tcaagtgtca tcacactgaa taccaatgct gaacttttta 10200 accagtcaga tattgttgct catctccttt cttcatcttc atctgtcatt gatgcactgc 10260 agtacaaatt agagggcacc acaagattga caagaaaaag gggattgaag ttagccacag 10320 ctctgtctct gagcaacaaa tttgtggagg gtagtcataa cagtactgtg agcttaacca 10380 cgaaaaatat ggaagtgtca gtggcaaaaa ccacaaaagc cgaaattcca attttgagaa 10440 tgaatttcaa gcaagaactt aatggaaata ccaagtcaaa acctactgtc tcttcctcca 10500 tggaatttaa gtatgatttc aattcttcaa tgctgtactc taccgctaaa ggagcagttg 10560 accacaagct tagcttggaa agcctcacct cttacttttc cattgagtca tctaccaaag 10620 gagatgtcaa gggttcggtt ctttctcggg aatattcagg aactattgct agtgaggcca 10680 acacttactt gaattccaag agcacacggt cttcagtgaa gctgcagggc acttccaaaa 10740 ttgatgatat ctggaacctt gaagtaaaag aaaattttgc tggagaagcc acactccaac 10800 gcatatattc cctctgggag cacagtacga aaaaccactt acagctagag ggcctctttt 10860 tcaccaacgg agaacataca agcaaagcca ccctggaact ctctccatgg caaatgtcag 10920 ctcttgttca ggtccatgca agtcagccca gttccttcca tgatttccct gaccttggcc 10980 aggaagtggc cctgaatgct aacactaaga accagaagat cagatggaaa aatgaagtcc 11040 ggattcattc tgggtctttc cagagccagg thagctttc caatgaccaa gaaaaggcac 11100 accttgacat tgcaggatcc ttagaaggac acctaaggtt cctcaaaaat atcatcctac 11160 cagtctatga caagagctta tgggatttcc taaagctgga tgtaaccacc agcattggta 11220 ggagacagca tcttcgtgtt tcaactgcct ttgtgtacac caaaaacccc aatggctatt 11280 cattctccat ccctgtaaaa gttttggctg ataaattcat tactcctggg ctgaaactaa 11340 atgatctaaa ttcagttctt gtcatgccta cgttccatgt cccatttaca gatcttcagg 11400 ttccatcgtg caaacttgac ttcagagaaa tacaaatcta taagaagctg agaacttcat ll460 catttgccct caacctacca acactccccg aggtaaaatt ccctgaagtt gatgtgttaa 11520. US 2012 / 0115926 A1. 51. May 10 , 2012. . —continued caaaatattc tcaaccagaa gactccttga ttcccttttt tgagataacc gtgcctgaat 11580 ctcagttaac tgtgtcccag ttcacgcttc caaaaagtgt ttcagatggc attgctgctt 11640 tggatctaaa tgcagtagcc aacaagatcg cagactttga gttgcccacc atcatcgtgc 11700 ctgagcagac cattgagatt ccctccatta agttctctgt acctgctgga attgtcattc ll760 cttcctttca agcactgact gcacgctttg aggtagactc tcccgtgtat aatgccactt 11820 ggagtgccag tttgaaaaac aaagcagatt atgttgaaac agtcctggat tccacatgca 11880 gctcaaccgt acagttccta gaatatgaac taaatgtttt gggaacacac aaaatcgaag 11940 atggtacgtt agcctctaag actaaaggaa cacttgcaca ccgtgacttc agtgcagaat 12000 atgaagaaga tggcaaattt gaaggacttc aggaatggga aggaaaagcg cacctcaata 12060 tcaaaagccc agcgttcacc gatctccatc tgcgctacca gaaagacaag aaaggcatct 12120 ccacctcagc agcctcccca gccgtaggca ccgtgggcat ggatatggat gaagatgacg 12180 acttttctaa atggaacttc tactacagcc ctcagtcctc tccagataaa aaactcacca 12240 tattcaaaac tgagttgagg gtccgggaat ctgatgagga aactcagatc aaagttaatt 12300 gggaagaaga ggcagcttct ggcttgctaa cctctctgaa agacaacgtg cccaaggcca 12360 caggggtcct ttatgattat gtcaacaagt accactggga acacacaggg ctcaccctga 12420 gagaagtgtc ttcaaagctg agaagaaatc tgcagaacaa tgctgagtgg gtttatcaag 12480 gggccattag gcaaattgat gatatcgacg tgaggttcca gaaagcagcc agtggcacca 12540 ctgggaccta ccaagagtgg aaggacaagg cccagaatct gtaccaggaa ctgttgactc 12600 aggaaggcca agccagtttc cagggactca aggataacgt gtttgatggc ttggtacgag 12660 ttactcaaaa attccatatg aaagtcaagc atctgattga ctcactcatt gattttctga 12720 acttccccag attccagttt ccggggaaac ctgggatata cactagggag gaactttgca 12780 ctatgttcat aagggaggta gggacggtac tgtcccaggt atattcgaaa gtccataatg 12840 gttcagaaat actgttttcc tatttccaag acctagtgat tacacttcct ttcgagttaa 12900 ggaaacataa actaatagat gtaatctcga tgtataggga actgttgaaa gatttatcaa 12960 aagaagccca agaggtattt aaagccattc agtctctcaa gaccacagag gtgctacgta 13020 atcttcagga ccttttacaa ttcattttcc aactaataga agataacatt aaacagctga 13080 aagagatgaa atttacttat cttattaatt atatccaaga tgagatcaac acaatcttca 13140 atgattatat cccatatgtt tttaaattgt tgaaagaaaa cctatgcctt aatcttcata 13200 agttcaatga atttattcaa aacgagcttc aggaagcttc tcaagagtta cagcagatcc 13260 atcaatacat tatggccctt cgtgaagaat attttgatcc aagtatagtt ggctggacag 13320 tgaaatatta tgaacttgaa gaaaagatag tCagtctgat caagaacctg ttagttgctc 13380 ttaaggactt ccattctgaa tatattgtca gtgcctctaa ctttacttcc caactctcaa 13440 gtcaagttga gcaatttctg cacagaaata ttcaggaata tcttagcatc cttaccgatc 13500 cagatggaaa agggaaagag aagattgcag agctttctgc cactgctcag gaaataatta 13560 aaagccaggc cattgcgacg aagaaaataa tttctgatta ccaccagcag tttagatata 13620 aactgcaaga tttttcagac caactctctg attactatga aaaatttatt gctgaatcca 13680 aaagattgat tgacctgtcc attcaaaact accacacatt tctgatatac atcacggagt 13740 tactgaaaaa gctgcaatca accacagtca tgaaccccta catgaagctt gctccaggag 13800. US 2012 / O115926 A1 52. —continued. May 10 , 2012. . aacttactat catcctctaa ttttttaaaa gaaatcttca tttattcttc ttttccaatt gaactttcac atagcacaga aaaaattcaa actgcctata ttgataaaac catacagtga gccagccttg cagtaggcag tagactataa gcagaagcac atatgaactg gacctgcacc aaagctggca ccagggctcg gaaggtctct gaactcagaa ggatggcatt ttttgcaagt. taaagaaaat caggatctga gttattttgc taaacttggg ggaggaggaa caaataaatg. l386O. l3920. l398O. l404O. l4l00. gagtctttat tgtgtatcat a. <210> SEQ ID NO 2. <2ll> LENGTH : 20. <2l2> TYPE : DNA. <213> ORGANISM : Artificia1 Sequence <220> FEATURE : . <223> OTHER INFORMATION : Oligonucleotide. <400> SEQUENCE : 2. gcctcagtct gcttcgcacc. <2lO> SEQ ID NO 3. <2ll> LENGTH : 20. <2l2> TYPE : DNA. <213> ORGANISM : Artificial Sequence <220> FEATURE : . <223> OTHER INFORMATION : Oligonucleotide. <400> SEQUENCE : 3. gcctcagtct gctttacacc. l4l2l. 20. 20. . 1. - 216. ( cance1ed ) . 217. A meth0d 0f reducing serum ch01ester01 1eve1s in a human subject , comprising administering t0 a human subject a p1ura1ity of doses of an olig0nuc1e0tide 20 nuc1e0bases in length comprising the nucle0base sequence GCCTCAGTCTGCTTCGCACC” ( SEQ ID NO : 2 ) , Wherein said administering resu1ts in a p1asma tr0ugh area under the curve ( AUC ) fr0m about 10 ug°hr / mL to about 20 ug°hr / mL f0r the 01igonuc1eotide in said human subject and thereby reducing said serum cholesterol levels in said human subject , Wherein said oligonucleotide comprises 5 - methylcytosine at nucleobases 2 , 3 , 5 , 9 , 12 , 15 , 17 , 19 , and 20 , and Wherein every internuc1eo side 1inkage is a ph0sphor0thi0ate1inkage , nuc1eotides 1 - 5 and 16 - 20 are 2 ' - O - methoxyethy1nuc1eotides , and nucleotides 6 - 15 are 2‘ - deoxynucle0tides. 218. The method of claim 217 , Wherein the p1asma trough AUC is measured 3 days after a dose. 219. The meth0d of c1aim 218 , Wherein the d0 se is the ﬁna1 dose. 220. The meth0d of claim 217 , Wherein said administering resu1ts in a p1asma tr0ugh AUC fr0m about 12 ug - hr / mL t0 about 20 ug - hr / mL. 221. The meth0d 0f claim 217 , Wherein said administering results in a p1asma tr0ugh AUC fr0m about 12 ug ' hr / mL to about 16 ug - hr / mL. 222. The meth0d of claim 217 , Wherein said administering results in a p1asma tr0ugh AUC of ab0ut 15 ug - hr / mL. 223. The method of any of claims 217 to 222 , Wherein said p1asma tr0ugh AUC is achieved from about 3 to about 33 days subsequent to the administration 0f a d0 se of said p1ura1ity of doses 0f the oligonuc1e0tide. 224. The meth0d 0f c1aim 217 , Wherein said serum ch01ester0l levels are reduced in said human subject by at least ab0ut ten percent. 225. The meth0d 0f c1aim 217 , Wherein said serum cho1esterol levels are reduced in said human subject by at least about thirty percent. 226. The meth0d 0f claim 217 , Wherein said serum cholesterol levels are serum loW density lipopr0tein ( LDL ) cholester01 levels. 227. The meth0d 0f claim 217 , Wherein said serum cholesterol levels are serum very loW density lipopr0tein ( V LDL ) cho1ester01 1eve1s. 228. The method of claim 217 , Wherein at least 0ne d0se of said plurality of doses is administered about once a Week. 229. The method of claim 217 , Wherein at least 0ne d0se of said plurality of doses is administered ab0ut once a m0nth. 230. The method of c1aim 217 , Wherein said human subject suffers fr0m hyperch0lesterolemia. 231. The method of claim 217 , Wherein each d0se of said p1ura1ity of doses comprises from about 200 mg to about 400 mg of the oligonucle0tide. 232. The method of claim 217 , Wherein each d0se 0f said p1ura1ity of doses comprises about 200 mg of the oligonucleotide. 233. The method of claim 217 , Wherein said administering results in a p1asma AUC from about 10 ug - hr / mL to about 20 ug°hr / mL When measured at 1east three days after the ﬁna1 dose of the p1ura1ity of doses. 234. A method of reducing serum cholesterol leve1s in a human subject , comprising administering to said subject a p1ura1ity of doses of an olig0nuc1eotide 20 nuc1eobases in. US 2012 / 0115926 A1. length comprising the nucle0base sequence GCCTCAGTCTGCTTCGCACC ( SEQ ID NO : 2 ) , Wherein said administering resu1ts in a p1asma tr0ugh concentrati0n from ab0ut 18 ng / mL t0 ab0ut 40 ng / mL in said human subject and thereby reducing said serum ch0lestero1 levels in the human subject , Wherein said oligonuc1eotide comprises 5 - methy1cytosine at nuc1eobases 2 , 3 , 5 , 9 , 12 , 15 , 17 , 19 , and 20 , and Wherein every internucle0side linkage is a phosph0rothi0ate linkage , nuc1e0tides 1 - 5 and 16 - 20 are 2 ' - O - meth0xyethyl nucleotides , and nucleotides 6 - 15 are 2 ' - de0xynuc1eotides. 235. The method of c1aim 234 , Wherein the p1asma trough concentrati0n as is measured 3 days after a dose. 236. The meth0d of c1aim 235 , Wherein the d0 se is the ﬁna1 dose. 237. The method of claim 234 , Wherein said administering results in a plasma trough concentration from about 1 8 ng / mL to ab0ut 30 ng / mL. 238. The meth0d of claim 234 or 237 , Wherein said p1asma tr0ugh concentrati0n is achieved ab0ut 7 days subsequent t0 the administration of a dose of said plura1ity 0f d0ses of the oligonucleotide. 239. The method of claim 234 , Wherein said serum cho1ester01 1eve1s are reduced in said human subject by at 1east ab0ut ten percent. 240. The meth0d of claim 234 , Wherein said serum cholesterol levels are reduced in said human subject by at least ab0ut thirty percent. 241. The meth0d 0f claim 234 , Wherein said serum cho1estero1 1evels are LDL ch0lestero1 levels. 242. The meth0d of claim 234 , Wherein said serum cholesterol levels are VLDL cholesterol levels. 243. The meth0d of c1aim 234 , Wherein at 1east one d0se of said p1ura1ity of d0ses is administered ab0ut once a Week. 244. The meth0d of claim 234 , Wherein at least one d0se of said plurality of doses is administered about once a month. 245. The method 0f claim 234 , Wherein said human subject suffers fr0m hyperch01estero1emia. 246. The meth0d 0f c1aim 234 , Wherein each dose 0f said p1ura1ity 0f doses comprises fr0m about 200 mg to ab0ut 400 mg of the oligonucleotide. 247. The method of claim 234 , Wherein each dose of said p1ura1ity 0f d0ses comprises about 200 mg of the 01ig0nuc1e - otide. 248. The meth0d 0f c1aim 217 , Wherein each dose of said plurality 0f doses comprises about 300 mg of the 01igonucleotide. 249. The meth0d 0f claim 217 , Wherein said serum cho1ester01 1eve1s are reduced in said human subject by at 1east ab0ut ﬁfty percent. 250. The meth0d 0f claim 234 , Wherein each dose of said p1ura1ity 0f doses comprises about 300 mg of the 01igonucleotide. May 10 , 2012. 251. The meth0d 0f claim 234 , Wherein said serum cholester01 1eve1s are reduced in said human subject by at 1east ab0ut ﬁfty percent. 252. The method of claim 234 , Wherein said administering results in a p1asma AUC from about 10 ug - hr / mL to ab0ut 20 ug°hr / mL When measured at 1east three days after the ﬁna1 dose of the p1ura1ity of doses. 253. A method of reducing serum cho1esterol 1eve1s in a human subject , c0mprising administering to said subject a p1ura1ity 0f d0ses of an olig0nuc1eotide 20 nuc1e0bases in 1ength comprising the nuc1eobase sequence GCCTCAGTCTGCTTCGCACC ( SEQ ID NO : 2 ) , Wherein each dose of said p1ura1ity of d0ses c0mprises fr0m ab0ut 200 mg to about 400 mg 0f the 01igonucleotide , thereby reducing said serum cho - 1estero1 levels in the human subject , and Wherein said oligonucleotide comprises 5 - methylcytosine at nucleobases 2 , 3 , 5 , 9 , 12 , lS , 17 , 19 , and 20 , and Wherein every internuc1eoside 1inkage is a ph0 sph0r0thi0ate 1inkage , nuc1eotides 1 - 5 and 16 - 20 are 2 ' - O - methoxyethyl nuc1e0tides , and nuc1eotides 6 - 15 are 2 ' - deoxynuc1e0tides. 254. The method of claim 253 , Wherein each dose of said p1ura1ity of doses comprises about 20O mg of the oligonuc1e - 0tide. 255. The method of claim 253 , Wherein each d0se 0f said plurality of doses comprises about 300 mg of the 01igonucleotide. 256. The method of claim 253 , Wherein each dose of said p1ura1ity 0f d0ses c0mprises about 400 mg 0f the 01ig0nuc1e - 0tide. 257. The method 0f claim 253 , Wherein said serum cholesterol levels are reduced in said human subject by at least about ten percent. 258. The meth0d 0f c1aim 253 , Wherein said serum ch01ester01 1eve1s are reduced in said human subject by at 1east ab0ut thirty percent. 259. The method 0f claim 253 , Wherein said serum cholester01 1eve1s are serum LDL cho1ester01 1eve1s. 260. The meth0d 0f c1aim 253 , Wherein said serum ch01ester01 levels are serum VLDL cho1ester01 levels. 261. The method of claim 253 , Wherein at least one d0se of said plurality of doses is administered about once a Week. 262. The meth0d 0f c1aim 253 , Wherein at 1east 0ne d0se 0f said p1ura1ity of doses is administered ab0ut 0nce a m0nth. 263. The method 0f c1aim 253 , Wherein said human subject suffers fr0m hyperch0lesterolemia. 264. The meth0d 0f c1aim 253 , Wherein said serum ch01ester0l levels are reduced in said human subject by at least ab0ut ﬁfty percent. 2 65. The method of c1aim 253 , Wherein the oligonuc1e0tide is an antisense oligonucleotide. $ $ $ $ $